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9ABSTRACT
This thesis is set against the context of China’s economic transition period and in
particular the policy environment of national Medical Reform for 2009. The
national policy acknowledged the growing aging population that has boosted
market demand and growth. Indeed, from 2009 to 2014, a series of policies were
promulgated by both central and provincial governments. Here, these are shown
to influence strategy formulation and implementation within small and
medium-sized pharmaceutical companies (SMPCs).
Given this business environment, the research reported here finds that the “pure
form” of Porter’s strategy theories do not work completely for China’s
pharmaceutical industry. In particular, two non-market factors of government
policies and guanxi are deemed critical and yet absent within one of his models.
Here, Porter’s Five Forces model is extended to include the two forces of guanxi
and government policies. The subsequent “seven forces” model arises from
examining SMPCs’ strategy application in two comparative case studies, and in
light of changing government policies.
The two case studies were identified as being typical and representative of the
industry. One is a chemical medicine producer and the other is a Traditional
Chinese Medicine producer. The two case studies share the characteristics of
being private medium-sized companies and having prescription drug
manufacturing capability. A critical realist approach was adopted with a
semi-structured interview technique to collect primary data from nine
interviewees, four of whom provided a second follow up interview to explore
guanxi giving a total of 13 interviews.
The two main conclusions drawn from the analysis of the rich interview accounts
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are: guanxi is a force in terms of Porter’s theoretical scheme. It offers
competitive advantage to facilitate achieving organizational strategy goals and is
embedded in the business practices of SMPCs and seemingly runs through the
whole process of their strategy formulation and implementation. The second
conclusion is that national and provincial government policy influences market
entry, market coverage rates, product pricing, costs and profitability. Notably,
guanxi was conceptualised as one underlying causal mechanism influencing
government policy formulation at provincial level. The contribution of this thesis
is to show that guanxi and government policy do interact in complex ways to
influence SMPCs’ strategy; these forces also connect and influence the other
Porter’s Five Forces.
The theoretical implications are that the “pure form” of Porter’s strategy theories
do not work completely in this context but do help as a “scheme” for
practitioners in the industry. Given the Chinese context, guanxi and government
policy interact and have an influence on Porter’s Five Forces model, hence, they
add two key forces to Porter’s theoretical model. Turning to the practical
implications, the thesis’ findings will/can assist strategy makers’ understanding
of the interaction of guanxi and government policy associated with the process of
strategy formulation and implementation and thus may facilitate the achievement
of strategy goals.
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CHAPTER ONE: INTRODUCTION
The author has been interested in the application of Porter’s strategy to China’s
pharmaceutical industry since starting her Masters degree in 2004. Subsequently,
she combined Porter’s focus strategy and differentiation strategy to formulate her
own company strategy and develop her business. From her DBA research, the
practicability of Porter’s strategy has been further developed given the emergent
importance of government policy changes and guanxi. This research has been
undertaken in two small and medium-sized pharmaceutical companies (SMPCs)
and shows the ongoing management from a stable to dynamic environmental
context.
This introductory chapter briefly explains the author’s previous research, which
represents a research context for this thesis. This is followed by a description of
the outcomes of this thesis through summarizing the chapters that follow.
1.1 Previous Research
The author embarked on her research into Generic Strategy and Five Forces
Strategy (Porter, 1980, 1985) in Document One. Next, within the context of the
pharmaceutical industry in China, Document Two reviewed the existing literature
and two significant factors emerged: an apparent neglect of guanxi and
government policies. This literature review led to a conceptual framework
showing the factors of policy, guanxi, product, entrepreneurship and e-commerce
that small and medium-sized pharmaceutical companies (SMPCs) should take
into account when formulating and implementing strategy. The research findings
of Document Three – from semi-structured interviews conducted with an elite
cross-section of the Chinese pharmaceutical industry – supported the view that
these factors were significant. The author’s own company was used as one case
study to explore the feasibility of the application of Porter’s generic strategy.
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Thirty-six interviewees were selected from different categories of pharmaceutical
companies including medicine producers, agents, distributors and drugs logistic
companies with the purpose of determining what factors should be taken into
account and what barriers exist when SMPCs apply Porter’s model. At that stage,
the senior managers who were interviewed for Document Three still considered
strategy as very important but had different understandings from each other.
Furthermore, and of interest, the interviewees emphasized that companies should
have competence in possessing, acquiring and monitoring guanxi-based
resources. The interviewees also gave important clues to market-orientation
including existing competition and current policies – both national and provincial.
E-commerce was also considered in Document Three, but as e-commerce is
restricted by governmental policy, most SMPCs did not consider e-commerce in
formulating and applying their strategies. Therefore, e-commerce was not
continued in Document Four. One overall finding was that Porter’s strategy
theories were applicable to the SMPCs, yet other key aspects were missing.
Research for the development of Document Four showed that there was an
extensive competitive environment in existence. Based on the findings of
Document Three, the research for Document Four adopted a structured
questionnaire using six hypotheses which were presented to measure the
reliability and practicability of the application of Porter’s theories. The goal of
Document Four was to identify the critical influencing factors for strategy
formulation and implementation. 220 completed questionnaires were received
and 190 valid questionnaires were confirmed. One key finding was that Porter’s
generic strategy seemed no longer applicable because of policy changes and a
complex environment. The critical policies included medical reform, drug
licensing certification (e.g. good manufacturing practice (GMP)), medical
insurance schemes and drug pricing, and drug regulatory systems. These central
policies strongly influenced SMPCs’ strategy formulation and implementation in
the Chinese pharmaceutical industry. For products with competitive elements, it
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emerged that policies resulting from central government could influence product
development. Furthermore, guanxi with relevant government agencies was
established as still being an important resource in both strategy formulation and
implementation.
Given the findings of qualitative research in Document Three and quantitative
research in Document Four, an understanding of Porter’s strategy has become
more complex during the period of three years. Given the influence of
government policies, one question was how and why, but also, its absence within
Porter’s framework was noted. Guanxi, which arose in Documents Three and
Four, was also emerging as an essential resource that needed to be taken into
account. The literature supports this when considering any business in China
(Pablos, 2005；Gibb, 2006；Ying, 2007; Zhao, 2009; Cao, Liu and Porter, 2010;
Yen, Barnes and Wang, 2011; Gao, Knight and Ballantyne, 2012; Arribas, 2013;
Cao, Baker and Schniederjans, 2014). Based on a literature review, but also the
author’s practical experience, guanxi is shown to exist in all primary activities
and supports achievement in China. Yet this factor too is not captured as a force
in any of Porter’s original theories. As the research reported here shows, guanxi,
as a competitive advantage, has been influential in SMPCs’ development. So the
overall guiding/emergent questions were, can guanxi as a force influence
policy-making in the Chinese pharmaceutical industry? What is the relationship
between policy and guanxi? These issues are explored in this thesis.
1.2 Research Context
China’s economy stands in a transition period (Yuan, 2014). During “the
transition from an industrial to post-industrial economy” (Zhang, 2015, p. 59),
China’s pharmaceutical industry is also developing rapidly. The industry is a
massive and growing area (BMI, 2014) (See Appendix 1). China is seeing big
changes in healthcare policies in relation to provincial policy making, medicine
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producers’ certification and production, medicine logistics, and medication use in
hospitals. The background to the issuing of these policies is China’s Medical
Reform, which is formulated by the Chinese central government. China’s
Medical Reform (See Appendix 2) imposes public health, and sustaining it, as a
national long-term goal. The most relevant national policy to this research is
Medical Reform for 2009 (See Appendix 3). It aims to boost the market demand
and capacity of the pharmaceutical market. This provides numerous opportunities
for SMPCs.
However, “resource misallocation” is also a problem which weakens China’s
economic growth (Zhang, 2015). The pharmaceutical industry also faces this
same problem. Public hospitals mainly undertake medical education, medical
diagnosis and treatment for the public. They account for 54% of the total number
of hospitals, have 49% of registered doctors (Statistical Yearbook of China
Health and Family Planning, 2014), and share 90% of the medical market (Jiang,
Lv and Zhao, 2014) in China. Without doubt, public hospitals (See Appendix 4)
own the main medical resources and dominate the market share of the
pharmaceutical industry. Not surprisingly, therefore, a common strategy for
medicine producers is to develop business with public hospitals.
More specifically, small and medium enterprises (SMEs) provide major
economic contributions for a country (Sharma, 2011): In China, SMEs are much
more numerous than the stated-owned enterprises, and therefore, research into
SMPCs is arguably important given the potential greater policy influence of
SMPCs. Indeed, analysing SMPCs’ strategy formulation and implementation
given the changing national and provincial policies has become an important area
to research. This thesis begins that effect and aims to offer insights into the role
and influence of policy and guanxi as forces within SMEs’ efforts to apply,
especially medicine producers in this sector.
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1.3 Definitions of SMPCs
Initial references to the definition of the SMEs and their characteristics,
developments and obstacles were undertaken in Documents Two and Three. In
this thesis, the earlier review of SMEs classification has followed the European
Commission Standard, which was converted from Euro to Renminbi (for further
explanation see Appendix 5). SMPCs are defined as being located in Mainland
China. While it is impossible to summarize all types of Chinese pharmaceutical
enterprises strategy developments in this thesis, given the author’s context and
knowledge, chemical and Traditional Chinese Medicines (TCMs) producers are
one classification and were accessible for the collection of data. The research
subjects, then, are drawn from the chemical drugs and the TCM sectors.
Previously, in Documents Three and Four, the research subjects included
pharmaceutical producers, agents, distributors and logistic companies. Based on
this previous research work, the drugs tender bidding process was identified as
the main issue in the drug business operations. Whatever drugs producers,
distributors or logistic companies do, they have to follow, coordinate with, and
implement producers’ strategy or market operations. Hence, pharmaceutical
producers are central to the whole pharmaceutical industry and the corresponding
value chain. Pharmaceutical producers stay at the head of the industrial chain.
This is especially the case for all drugs tendering and bidding. Pharmaceutical
producers are, then, the bidding subjects and the decision-makers for drug
pricing. Given this, pharmaceutical producers were chosen as the context of
research focus for this thesis.
1.4 Research Period: from 2009 to 2014
The central government launched the Medical Reform policies for improving and
upgrading the pharmaceutical industry. Subsequently, a series of health laws,
policies, government opinions, directives, and regulations were promulgated by
the Chinese central government from 2009 to the present. The State requires the
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industry to be up-to-date, with professional standards of the pharmaceutical
industry and medical services aiming to implement policies such as the new
Good Manufacturing Practice (GMP) (See Appendix 6) and Good Supply
Practice (GSP) policies. The requirements of the Medical Reform for 2009 are
reflected in the various policies and regulations (for more details see Appendix 3)
and some of these directly influence product structure, the business model and
the company strategy of pharmaceutical enterprises, indeed, even the survival of
SMPCs ( for example, the policy of Drug Centralized Procurement Bidding
(DCPB)- see Appendix 7). At the same time, the DCPB policy showed that price
was going to be reduced year by year. Clearly, this situation directly influences
SMPCs’ operations.
1.5 Research Questions and Aims
The two research questions were established as:
(a) How do guanxi and government policies influence SMPCs’ strategy
formulation and implementation?
(b) To what degree does Porter’s Five Forces theory influence SMPCs’ strategy
in the Chinese pharmaceutical industry?
Furthermore, given the literature review and documents Three and Four research,
an interest in exploring the role of guanxi was retained too. Although there are
many negative aspects of guanxi as the literature indicates, in this thesis, the
author focuses on guanxi’s critical role to influence other forces under the
context of government policies, such as New GMP, medical insurance scheme,
and drugs tender bidding. Given the research context, the author sought
specifically to examine (1) the relationship between government policy, guanxi
and the Five Forces; (2) exploring the effects of government policy and guanxi
on strategy practice in particular in China’s pharmaceutical industry, here, in two
SMPCs.
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1.6 Case Study
The author chose two case studies from SMPCs: both were known to the author .
They are a chemical producer, named Company A, located in Shengzheng,
Guangdong, with the second being a Traditional Chinese Medicine (TCM)
producer, named Company B, located in Guizhou province. The two case study
companies share the characteristics of being private, medium-sized producers
and have prescription drug systems including at least one product listed in the
two most important Government insurance schemes. The interviewees were
senior managers and decision-makers within the companies.
A critical realist approach was adopted which informed the data collection and
analysis. Thirteen semi-structured interviews were conducted to collect primary
data from the nine interviewees working in five departments. The data collection
included two phases of interview. Seven questions were adopted for the first
phase and six questions were adopted for the follow-up interviews in order to
collect further data. Both phases of face-to-face interviews followed the same
steps. The four interviewees chosen for follow-up interviews had also been
chosen for the first interview phase. After completing data collection, data
management included transcribing the records into Chinese, making notes and
generating themes in Chinese first and then accurately translating it all into
English. Given the Chinese context, the main findings are:
(1) Guanxi offers a competitive advantage which facilitates achieving strategic
goals. It was conceptualized as one underlying influencing force in government
policy formulation at provincial level, and a critical force which is not the
determining factor but plays a tactical role in strategy formulation. Guanxi is
shown to have the dominant functions of “catalyst, lubricant, and multiplier” in
strategy implementation.
(2) National and provincial policy are intense forces that directly influence
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SMPCs’ entry barriers, market coverage rates, product pricing, costs and
profitability.
(3) Guanxi and government policy interact and this uniquely influences strategy.
Notably, the findings suggest that the “pure form” of Porter’s strategy theories
does not work completely but helps initially to begin to understand the industry.
Guanxi and government policy, then, are seen as two forces in terms of Porter’s
theoretical themes and they need to be added to Porter’s Five Forces model in
this national/cultural context. A modified model, with “seven forces” is suggested
as offering a more insightful guide for SMPCs to cope with complex policy,
economic and social environments.
The contribution of this thesis is that guanxi and government policy do interact in
complex ways to influence SMPCs’ strategy; these forces also connect and
influence Porter’s other Five Forces. It is suggested that the “seven forces” model
assists strategy makers understand the interaction of guanxi and government
policy associated with the process of strategy formulation and implementation
and develops strategies in the pharmaceutical sector which can be applied within
the current dynamic environment.
1.7 The Structure of the Thesis
The thesis is arranged as follows. In the next chapter, the literature review
focuses on the three elements of strategy, guanxi and policy. In particular,
Porter’s generic strategy and Five Forces theory are reviewed and updated. The
definition and implications of guanxi and its functions are explored too. At the
same time, the operations of guanxi are investigated at the two levels of the
individual and the organization and the links between the two are reviewed. Then,
the interrelationship between guanxi, government policy, and strategy would be
explored. Guanxi as underlying causal mechanism is explained too. Based on the
literature, the conceptual framework is generated and this guided the data
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analysis. In Chapter Three, the research design, methodological approach, data
collection, and data management are outlined. In Chapter Four, the analyses and
a discussion of the key theme findings are explored critically. Finally, the
conclusions are drawn and include highlighting both the theoretical contributions
to Porter’s strategy theories as well as contributions to the author’s practice too.
Future studies are also presented, alongside a consideration of limitations which,
together, close the thesis.
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CHAPTER TWO: LITERATURE REVIEW
The focuses of this thesis are strategy, policy and guanxi. Strategy definitions
were explored in previous research and are presented as selective summaries here.
The review of the implications of guanxi is updated based on previous research.
Guanxi operations at the two levels of individual and organizational level are
extended too. The role of government, the medical administration system, the
structure of the government medical regulatory system and their impact on
business will be outlined next, as some pharmaceutical industry policies are
perplexing and contradictory (BMI, 2014). The interrelationship between guanxi
and government policy and strategy are also extended too. Finally, the conceptual
framework is outlined.
2.1 Understanding of Strategy
In this section, the term “strategy” and strategy formulation and implementation
will be explored and updated from literature.
2.1.1 Review of the Implications of Strategy
The term “strategy” is widely applied in military and economic fields (. In China,
it has been in use since the Spring and Autumn Period (BC 722-481). But what
exactly is strategy? Regarding the different definitions of strategy and scholars’
understanding of the term, it cannot be defined in a few brief sentences or
paragraphs (Mintzberg, 1994, Dandira, 2012). Strategy has long been used
implicitly (Mintzberg, 1987), and developed since the 1960s (Feurer and
Chaharbaghi, 1997). Some scholars consider that strategy is a plan or planning.
Mintzberg (1987), for example, defines strategy as plan, ploy, pattern, position,
and perspective and explores their interrelationship. Mintzberg’s definition
provides valuable directions for companies on how to achieve competitive
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advantage in the five dimensions. In contrast, Kay (1993) argues that strategy is
no longer planning or visioning. More recently, Mintzberg, Ahlstrand and
Lampel (2005) elucidate that strategy is also needed to focus efforts instead on
promoting coordination of activities.
Davies (2000, p. 25) explores strategy’s nature and purpose and considers that it
could be viewed as one element of a troika of policy-strategy-resources. He
explains that “In government, policy is the product of a legislature that delineates
the goals, objectives and priorities of the state. In business, the term ‘policy’ is
used to define a company’s principal goals and objectives and to prescribe the
company’s operational domain.” Based on the interdependence of the three
elements, the purpose of formulating and implementing strategy is to make
corporate policy succeed in the competitive environment. Without resources,
strategy cannot be achieved. He highlights that strategy-making must be
implementable and flexible. Davies (2000) combines government policy,
corporate strategy and resources together to facilitate strategy formulation and
implementation. The author considers that guanxi can be regarded as a resource
in China; a unique resource that can be seen as a competitive advantage. Johnson
and Scholes (2004, p. 9) define strategy as relevant to the long-term development
and unique resources so as to adjust resource allocation to achieve competitive
advantages. Porter (1980, 1985) considers that strategy is to achieve competitive
advantages in the industry. Porter (2008, p. 53) improves on this further that
“strategy is the creation of a unique and valuable position, involving a different
set of activities”. Bach and Allen (2010, p. 41) state that “sustained competitive
advantage arises from tackling social, political and environmental issues as part
of a corporate strategy – not just pursuing business as usual”. It is obvious that
strategy is related to resources. And resources are derived mainly from social and
political environments. In China, there are many channels and approaches to
obtain resources from society.
24
Another view of strategy is in terms of goal and mission. Chandler (1962) states
that strategy is the determination of the basic long-term goals and objectives.
Johnson and Scholes (2002, p. 15) offer a similar point of view: “Strategy is the
direction and scope of an organization over the long-term which achieves
advantage for the organization through its configuration environment, to meet the
needs of market and to fulfill stakeholder expectations.” Furthermore, Johnson
and Scholes (2003) define strategy as mission, strategic intent, goal and objective.
Thompson and Strickland (2003) highlight and combine the strategy mission,
formulation and implementation as three questions of “What is our business?”,
“What will it be?” and “What to do now?”. Phillips (2011) also considers that
strategy includes operations and results. Smith (2006) classifies strategies into
business strategy, functional strategy and product strategy. Although the author
argues that Smith’s classification has a few limitations, she agrees with his view
of the significance of product strategy in business strategy. It has been suggested
that strategy can guide businesses in getting on with their primary activities
(Harland, Lamming and Cousins, 1999), gaining competitive strengths (Porter,
1985), and achieving “strategy value” (Bowman, 2007).
Sometimes the issue of strategy is complicated for practitioners in SMEs. They
may misunderstand and encounter pitfalls in the practical activities. The author
considers that those pitfalls have practical implications for companies. Based on
her practical experience, practitioners in SMEs have no complete theoretical
system; normally, they rely on their empiricism to add theory piecemeal to
practical activities. Some projects succeed while others fail. Under the open
policy, a lot of SMPCs have been developing for many years. During the 1990s,
SMEs established themselves in a market that was advantageous for success.
They depended on one or a series of products, or on one policy in one province,
for example, drugs tender bidding regulation. Thus, another view of strategy that
has emerged is connected with practical insight. Dandira (2012) highlights
strategy as a practice perspective issue that would help executives achieve
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practical insights. At the same time, practitioners are involved in a knowledge
vacuum, which has been cited (Dandira, 2012) as a main error at strategy
implementation stage.
Many definitions and explanations of strategy have been proposed by scholars
such as: mission, goals, plans (Mintzberg, 1987); objectives, operations and
results (Phillips, 2011); resource (Davies, 2000; Phillips, 2011; Johnson and
Scholes, 2004, p. 9); and long-term goals or objectives (Chandler, 1962). Phillips
(2011) considers that strategy has pluralism. External forces such as political,
economic, and social forces influence "the viability of alternative strategies for
achieving objectives" (Phillips, 2011，p. 926). Therefore, consideration of context
is significant for understanding strategy. Given the various definitions and
perspectives on the term of “strategy’, the author considers that it is important to
articulate the position of strategy adopted for this thesis. In the context of China’s
economic transition period and in particular the policy environment of National
Medical Reform for 2009, strategy is unique resource and long-term objectives.
Strategy work, then, aims to achieve competitive advantages and being different
is one core element (Porter, 2008, p. 43). This definition is adopted in this thesis
and echoes the author’s own 20 years of experience in China’s pharmaceutical
industry.
2.1.2 Strategy Formulation and Implementation
A number of scholars have demonstrated theoretically and have written on the
importance of strategy formulation and implementation over the past three
decades. Chaharbaghi and Feurer (1994) state that strategy formulation and
implementation encompass issues such as competitive environments, values,
goals, capabilities, structures and processes brought together with action. It is a
complex process.
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McCarthy (2003) demonstrates that strategy making should be a “bottom-up”
process and not just a “top-down” process. Micheli, Mura and Agliati (2011)
argue that the “how to” of balancing between top-down control and bottom-up
empowerment can be critical for strategy implementation. At the same time, they
also suggest that researchers need to adjust objectives and processes and update
their knowledge continuously so as to face the challenges presented by the highly
dynamic environment. In relation to this viewpoint, Feurer, Chaharbaghi and
Wargin (1995) also argue that dynamic strategy formulation and implementation
are carried out simultaneously while the strategy formulation and implementation
are underway. So it is the process of strategy management. Ramaseshan, Ishak
and Kingshott (2013, p. 1224-1225) explain that “market competition negatively
influence strategy” and strategy formulation and implementation should be
“simultaneously applied”.
Mair (1999) states that employees can play an important role in strategy
formulation and have the power to influence some decisions. The employees see
the venture from another perspective and are often able to provide information or
points of view from a different perspective; they often have contacts and can
report on implementation factors that can help with the strategic mission. Not
working with employees in this manner will risk important factors in the process
of strategy formulation.
Okumus (2001, 2003) illustrates the key implementation variables as
environment, strategy formulation, organizational structure, leadership,
organizational culture, operational planning, resource allocation, people,
communication control and feedback, outcome and external partner companies in
his writings. Thus, strategy implementation is crucial to ensure a firm’s success
(Love, Priem and Lumpkin, 2002; Micheli, Mura and Agliati, 2011).
Sterling (2003) states the misalignment of strategy implementation as the real
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reason for strategy failure, thus suggesting a checklist for successful
implementation as: an assessment of organizational design and capabilities;
consideration of potential competitor reactions; involvement of managers;
attention to communication; action planning and budgeting; and establishment of
a monitoring system. Kazmi (2008) points out that strategy implementation is a
sophisticated process and that during the processes of strategy implementation,
many researchers and managers are misaligned, unable to view the objective in
the same way and to meet the primary goals. Accompanied by economic changes
and significant changes in our society’s development, the external conditions
impacting SMPCs’ strategy development are unpredictable, making the strategy
implementation extremely difficult. As a result, the strategic understanding and
framework of SMPCs are difficult to effectively or efficiently define, develop or
implement.
The author considers that strategy formulation and implementation are dynamic
processes. Organizations need to combine their resources such as guanxi with the
practical environment such as government policy to develop strategy. At the
same time, during the strategy formulation process, the executors need to
consider and avoid a series of potential obstacles such as unrealistic mission
statements and overestimations of organization capacity.
2.2 Porter’s Strategy Theories Reviewed
Porter (1980, 1985) describes the Five Forces model to understand industry
structure and existing competitors. Five forces determine industrial profitability.
Therefore, by understanding all changing competitive forces and their underlying
causes, firms can seek competitive advantages, for example, by using generic
strategy.
The theory of value chain is arguably also relevant to this thesis and the
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interviewees did touch on it. However, given the objective need to maintain
focus, this thesis considers just the two theories of generic strategy and Five
Forces, which will be explored and updated in this chapter. In this thesis, the Five
Forces theory is more important because two research themes of government
policy and guanxi influence the five forces and determine SMPCs’ entry, cost,
market coverage, and profitability.
2.2.1 Generic Strategy
Porter (1985, p. 11) states that strategy is about achieving competitive advantages.
He proposes that a firm’s primary profitability is its position in the industry, the
foundation for maintaining the two basic types of strategy advantages of “cost
advantage and differentiation”. Moreover, the two types of advantages deriving
from industry structure and the five forces determine whether a firm possesses
capability to compete against rivals. Therefore, generic strategy (see Figure 2.1)
is also relevant to this thesis.
Although generic strategy has been researched in Documents Two, Three, and
Four from both literature and practice, for this thesis, the updated literature of
generic strategy is also important. The value of updating generic strategy is to see
what factors such as political factor influence the application of generic strategy
from literature.
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Figure 2.1 Three Generic Strategy
Source: Porter, 2004, p. 12
Porter’s generic strategy application has received various comments from
different researchers. Generic strategy theory is testified to and verified both
academically and practically (Pertusa-Ortega, Monina-Azorin and Claver-Cortes,
2009). But Salavou (2013, p. 302) argues that “it lacks consistency” and “was
neglected in the first 20 years in the EU”.
Porter’s original conceptual study is traceable from empirical evidence in North
America (Jacome, Lisboa and Yasin, 2002). Brown and Pirani (2007, p. 25) state
that “cost leadership and differentiation are not mutually exclusive strategies”.
Allen et al. (2008) compare the application of Porter’s generic strategies in Japan
and in America. In particular, cost-leadership has been applied in Japanese firms
extensively. It was rooted in the Total Quality Management based (TQM) tactics
so as to reduce cost and waste. Further important support came from the Japanese
government’s economic strategy. Allen et al. (2008, p. 39) also state that “To
achieve a low-cost advantage, an organization must have a low-cost leadership
mindset, low-cost manufacturing with rapid distribution and replenishment, and a
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workforce committed to the low-cost strategy”. On the contrary, the
differentiation strategy was much less utilized in Japanese companies. Frequently
resorting to Porter’s generic strategy application, American companies were
willing to utilize focus-differentiation, focus-cost, cost leadership and product
differentiation.
Magretta (2012) considers practitioners may misunderstand the theme of generic
strategy. Therefore, Magretta (2012, p. 114) explains that “Focus refers to the
breadth or narrowness of the customers and needs a company serves.
Differentiation allows a company to command a premium price. Cost leadership
allows it to compete by offering a low relative price.” Based on empirical
evidence, Banker, Mashrueala and Tripathy (2014, p. 891) argue that
“differentiation is a source” that can enhance a firm’s competitive advantages as
well as make the firm’s profits more volatile. Meanwhile, “pursuing a
differentiation strategy enables firms to sustain performance more than pursuing
a cost leadership strategy.”
Hunt (2007) considers that Porter’s theory was well defined and based on the
understanding that a company’s strategy should correspond to the opportunities
and threats in the company’s external environment. Thus, external environment
factors, for example, social, economic, and political factors, affect firms’ strategy.
Parnell (2014, p. 56) also argues that cost leadership and differentiation shift in a
political environment are negatively associated with performance. Cost
leadership, differentiation and focus could be seen as component parts of a firm’s
value proposition. Yoo, Lemake and Choi (2006, p. 354) argue that it is necessary
to use “a different way to think about the implementation of the Porter’s
cost-leadership and differentiation strategies. But Porter’s theories are more
generic and not easy to implement.”
As the competitive environment is changing with uncertain business conditions
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and dynamic political stress, companies have to adjust and modify their strategies.
Regarding this point, Parnell (2006) argues that Porter’s generic strategy has
generalizability. The relationship between generality and practicability needs to
be worked out by practitioners in SMEs. Changing the external environment
brings big changes of business model structure and application. When the
environment changes, firms need to redesign and re-plan their former strategy
and utilize the strategic tools of business models, value networks and resource
management to conduct “deliberate strategy explicitly” (Ghezzi, 2013, p. 1351).
According to the updated literature, generic strategy application is influenced by
external environment too, such as political factors. The success of the generic
strategy application depends on steady national conditions and business
environment changes. In China’s context, the author considers that Porter’s
model still has some major limitations. It does not take into consideration the
new dynamics of markets, for example, non-market factors of political power. At
the same time, the Chinese element of guanxi plays an important role and
functions during business process. This had been commented on in Documents
Three and Four. The author is more interested in research on the links between
Five Forces application with the government policy and guanxi influence.
Given the author’s previous research and experience, operating business needs to
consider two important elements of government policy and guanxi under China’s
context, especially in the pharmaceutical industry. Based on Porter’s works on
strategy, strategy formulation is more related to consideration of industry
structures and looks at each competitive force’s strengths and weaknesses. Those
competitive forces drive company’s cost and profitability. Therefore, the Five
Force model is more relevant and significant to this thesis.
In the next sections, first, the Five Forces application and its critical arguments
will be explored based on the previous research. Then the author focuses on
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exploring the influences of government policy and guanxi on the Five Forces
applications from literature. Further, a modified Five Forces model and its
application are researched. Specifically, the applications of a modified Five
Forces model in China have been included and updated in this thesis.
2.2.2 Five Forces Model
Porter (2004) expounds that the state of competition and the best use of generic
strategy depend on five basic competitive forces, namely, entry of competitors,
threat of substitutes, rivalry among the existing players, and bargaining power of
suppliers and buyers (see Figure 2.2). Porter (2004) advances the concept that
industry factors determine the profitability of organizations. It is suggested that
through understanding the Five Forces model, companies should be able to
choose an appropriate strategy to compete successfully in their market (Thurlby,
1998).
Porter has emphasized five competitive forces that impact every industry and
every market. These forces define the intensity of competition and the
attractiveness and profitability of an industry (Porter, 2004). The purpose of a
company’s strategy must be suitable for these competitive forces so that the
position of the company can be improved. Porter’s model supports the analysis of
the driving forces in a market and can be used by management to decide how to
manage particular characteristics of their industry on the basis of data taken from
the Five Forces theory.
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Figure 2.2 Porter’s Five Forces
Source: Porter, 2004, p. 5
It was suggested that by a thorough understanding of the Five Forces model,
companies should be able to choose an appropriate strategy to compete
successfully in their market (Thurlby, 1998). Strategy formulation starts to
analyse industrial competition (Lee, Kim and Park, 2012, p. 1784). Industrial
competition is the main force in the Five Forces model. In Porter’s model, the
five forces exert influences on the competitiveness of a firm. They jointly
determine the competitive intensity and attractiveness of a market in an industry
(Ramaswamy and Renforth, 1996). In the traditional economic model, in order to
operate a firm’s competitive advantage to overcome its rivals, a firm can choose
competitive activities such as lowering cost to gain price advantage, improving
products or services for differentiation, creatively changing channels of
distribution to keep customers or brand loyalty, and high concentration of market
share to ward off rivals. For instance, for SME makers in the Turkish brick
industry, cost differentiation is the main competitive advantage which is utilized
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widely to fight existing rivals (Oral and Mistikoglu, 2007).
In a free market, if there are viable alternative products and services to suit the
same needs, firms face the threat of substitutes. Faced with this threat, firms use
cost advantages, specialized products or other core competency to protect
themselves against new competitors. A producing industry requires raw materials
– labour, components, and other supplies. This requirement leads to
buyer-supplier relationships between the industry and the firms that provide raw
materials used to create products. Suppliers, if powerful, can exert an influence
on the producing industry, for example, by selling raw materials at a high price to
capture some of the industry’s profits. Supplier power is driven by the number of
suppliers of each key input, the uniqueness of their product or service, or their
strength to control rivals. The fewer suppliers you choose, the more you need
suppliers’ help, and the more powerful your suppliers are.
Dobbs (2014, p. 32) suggests that the Five Forces model taken as an industry
analysis template can be utilized to obtain sophisticated and deeper insights. In
reality, the Five Forces theory is useful to guide practitioners to think about and
confront industry structure and supply chains, to understand strengths and the
threat of competitive forces and then find their own inner or outer core
competency. Dobbs (2014, p. 33-34) provides a list of academic evidence to
show that people lack understanding of the depth, structured analysis and
strategic insights of Porter’s Five Forces model. He suggests a practitioner
should gain perception of “how a firm can compete more effectively within its
industry” and “many contingency factors to consider”.
Sheehan (2005) argues that Porter’s generic strategy and Five Forces models do
not work in knowledge-intensive firms, for example, pharmaceutical companies.
They should utilize those classic old tools in new ways so as to achieve
profitability. McGowan and Mahon (2007) argue that Porter’s analysis was based
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on the confines of the product-market-technology troika, and firms need to
consider the effect of non-market issues in political and social factors. Those
impacts are undeniably powerful. “Political and social actions can and often do
have profound economic and financial impacts on an industry and on individual
firms” (McGowan and Mahon, 2007, p. 192). The author agrees that political
dynamics, the force of non-market issues, are beyond firms’ control, for example,
DCBP policy. Policy issues are dynamic for every industry and firm. The policy
of New Good Manufacturing Practice (new GMP) of 2010 must be implemented
before 2016 in China. New GMP policy is the industry entry barrier for SMPCs.
If small companies do not have a unique product, they have to give up their
business to be acquired by and merged with big companies.
Ryall (2013) commends the contribution of the Five Forces model, which has
transformed the strategy field, as well as arguing that Porter makes the
complexity that five forces can be seen as one force. Because “each player in an
industry (whether a firm, a customer, or a supplier) experiences a single force of
competition for itself” (Ryall, 2013, p. 83). That force is value-based: industry
intensity is between value created or value appropriated by each player. The
author thinks Ryall’s one force view is not suitable in China’s pharmaceutical
industry. In China’s context, there are different categories of companies existing
and competing in the industry. Every company fights for its own existing value
or future value created. Moreover, each force may be influenced by government
policy and guanxi and this is what the research is exploring.
Porter’s Five Forces model has been applied in different government policies and
economic environments. Due to different contexts and personal experiences, the
Five Forces model meets critical arguments. Anyway, regarding the author’s
study, the value of the Five Forces model provides a vital system to categorize
competitive forces which influence a firm’s profitability (Grant, 2008). Further,
researchers also employ the Five Forces model as a tool which has added
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important factors as a modified model based on their different industries and
research fields. For this thesis, the author agrees that government policy and
guanxi are seen as forces in terms of Porter’s strategy theoretical schemes that
need to be added to the modified model. Therefore, the next sections introduce
influences and applications of two important forces combined with the Five
Forces model.
2.2.3 Government Policy and the Five Forces Model
In this section, the author has sought several modified Five Forces patterns from
literature. Those modified patterns cover both the public and private sectors.
Most of the modified patterns are about the private sector including strategy
formulation, strategic choice, and strategy implementation. In the public sector,
Vining (2011) added the two forces of political institutions and influence and
economic external forces to the Five Forces model as a modification framework
to guide public agency management. Grundy (2006, p. 223) argues that Porter’s
Five Forces are the theory of the textbook and have less appeal to actual
practitioners. As “Porter’s five competitive forces are highly interdependent”
(Grundy, 2006, p. 217), he suggests the Five Forces should be “Competitive
Pressures/Five competitive Forces” and explores each of the Five Force
interdependencies. He also combines the Five Forces with PEST (political,
economic, social and technological factors), growth drivers and competitive
position as an “onion” model format. It helps a practising manager to think about
the competitive environment from multiple angles.
Dulcic, Gnjidic and Alfirevic (2012) believe that the time dynamics issue (past,
present and future/anticipated) should be considered in the Five Forces model,
which can help practitioners understand today’s dynamic industry’s structure and
interaction between company and industry. Because the broadband market in
Korea is constantly and dynamically changing, it is emphasized that policy needs
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to be presented in the Five Forces model. And government should play an
important role to consider the policies which “prevent interference among
different markets”( Lee, Kim and Na, 2007, p. 1590). Lee, Kim and Park (2012,
p. 1794) suggest that to the modified model would be added relevant sub-forces
such as government regulations as a “sixth force”, to operationalize the Five
Forces model to deal with competitive dynamics. Given China’s context, Wu and
Yang (2014) use Porter’s Five Forces model to analyse the shale gas industry.
They point out that policy is a strong force to limit new entrants and to control
marketization in the industry. At the same time, policy is the principal
influencing factor in the industry structure.
Government, as a state machine, has proven to be useful on many occasions. “In
heavily regulated sectors” (Sutherland, 2014, p. 2), such as the pharmaceutical
industry, healthcare, food etc, concerning people’s health and safety, there are a
set of regulations to control and administer. Thus, Sutherland (2014, p. 13) also
suggests that a “full set of market and non-market opportunities and actions”
need to be taken into account when firms develop their strategy. Those views that
“government influences industry profitability” and can be a “sixth force” are
proposed by researchers (Magretta, 2012; Lee, Kim and Park, 2012, p. 54;
Grigore, 2014, p. 33; Mathooko and Ogutu, 2015, p. 350). Further, the term
“sixth force” is considered an important element that would be added based on
Porter’s Five Forces model (Lee, Kim and Park, 2012, p. 1794), although they do
not elaborate and explore this term widely. At the same time, the author also
agrees with those views above that the Five Forces should be combined with
political factors. Grigore (2014, p. 33) just says the “sixth force is government”
and does not explain government’s role and function.
Different researchers suggest the terms of “government” or “government policy”,
which can be seen as a “sixth force” influencing the Five Forces model. Porter
(2008) responds that government policies are more understandable to impact on
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industry or firms’ profitability rather than government. Porter (2008, p. 264) also
mentions that “government policies inflict costs on firms without conferring any
compensation”, thus it can be seen that government policy is a strong force. But
Porter does not explore this element in his strategy works. This reflects his
neutral stance.
In answer to critical comments on the Five Forces model from researchers, Porter
(2008) emphasizes that making sense of the competitive forces and their
underlying causes leads practitioners to anticipate competition. However, Porter
does not explore two issues of what are the underlying causes and how those
underlying causes influence the five competitive forces. The underlying causes
may be specific government policies or other causes. As this thesis will show,
one cultural cause or factor that can be seen is guanxi in China’s environment.
Although Porter (2008) proposes government policies which can affect the Five
Forces, he does not elaborate and explore this important element in his model.
However, Porter (1980, 1985, 2008) does provide a principle framework for
understanding, analysing, and anticipating in practice. The author agrees that the
Five Force model helps practitioners understand the attactiveness of industry
(Ortega, Jalón and Menéndez, 2014) so as to formulate strategic scenarios.
Specially, in China’s unique context, Qin (2010) indicates that policy is the
influential force during China’s transitional reform period. Yuan (2014, p. 23)
also supports the view that China’s transition economy is very
relationship-oriented. Regarding the researched literature, the author proposes
that government policy and guanxi need to be added to Porter’s Five Forces
model in the context of China. The modified “seven forces” can provide a more
sophisticated and comprehensive understanding of China’s pharmaceutical
industry.
Overall, government policy is seen as a “sixth force” in the literature, so the new
value of this thesis is that guanxi is seen as a competitive force to be added in
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Porter’s Five Force model. This view will be explored in the next section.
2.3 Guanxi
Guanxi has rich cultural connotations and permeates all aspects of Chinese life
including politics, the economy and business activities. Guanxi has been defined
and researched in different ways in the literature by Westerners for decades. As
this review will show, the definitions of guanxi have many implications and
understandings.
Guanxi implies an intricate and ambiguous web of inter-personal,
intra-organization, inter-organization, and government regulatory agencies.
Because there are no clear boundaries to clarify its expression it is researched
and updated constantly by Western and Chinese experts. Looking at a number of
critical comments about guanxi, Chinese scholar Zhuang (2012, p. 28) argues
that “some references are confused about guanxi’s cognition and application”.
The adaptability of guanxi has extensive and different historical contexts in
China (Barbalet, 2015). Guanxi is still an important factor in the Chinese
business environment during the transition period (Tan, Yang and Veliyath, 2009).
As a practitioner, in this thesis the author’s interest is in the applicability of
guanxi as it influences SMPCs’ strategy formulation and implementation in the
Chinese context. In this section, the implications, definitions, functions, and
operations at individual and organizational level of guanxi will be extended. The
interactions of guanxi and the five forces will be explored too.
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2.3.1 Review of the Implications of Guanxi
Research into the implications of guanxi is started with individual research in
Chinese society. Many references have shown that guanxi is germane to Chinese
culture, with a long history from Confucianism to the modern day (Anderson,
2008). Guanxi is also a Chinese cultural influence (Tong and Mitra, 2009), a way
of life (Gong, He and Hsu, 2013), and the main way to work (Chen, Wang and
Hsu, 2013). In the research of Markus and Kitayama (see Han and Altman, 2010,
p. 39), “in the Confucian society, people are interdependent rather than
independent”. This means individuals connect with each other to share favours
and benefits. Thus guanxi is one aspect of Confucian moral standards that can be
developed as an open-ended and potentially long-term relationship (Han and
Altman, 2010, p. 41). Among all the different attempts to explain guanxi, the
following literature has distinguished the sense of worth, classifications,
hierarchy and strata. Chang (2011, p. 318) considers guanxi is “a purposive
network behaviour” and its behavioural forms include accessing, bridging and
embedding forms. Accessing guanxi is to “acquire something desirable”.
Bridging guanxi is to connect two or more groups benefiting each group.
“Embedding guanxi” emphasizes future mutual benefits and has strategic
significance and objective.
According to Sathe (1985) and Schein (1984), culture has three strata: manifest
culture, expressed values, and basic assumptions. Guanxi also has different strata
of culture and various connotations, such as human relations, psychological
connection，cognition, and emotion. Further, Zhuang (2012, p. 18, 27) identifies
that guanxi has several notions of guanxi states, guanxi behaviour, guanxi norms
and guanxi orientation (see Figure 2.3). Guanxi norms and orientations that
determine Chinese people’s behaviour have rich cultural connotations. Guanxi
starts with two or more personal relationships. So guanxi reflects an individual’s
relationships as being close or distant. And family bonds, emotions and trust test
41
and reflect guanxi’s intimacy. Guanxi norms mean principles of social action and
behaviours. For instance, etiquette, manners, human sympathy and “face” belong
in this category. Human sympathy adheres to social norms and rules of behaviour.
Human sympathy (Barnes, Yen and Zhou, 2011), reciprocity (Hwang, 1987) and
empathy (Ingram and Zou, 2008) are involved in the guanxi environment. The
potential rules are based on the mutual benefits (Jia and Lamming, 2013) and
trustworthiness (Efferin and Hopper, 2007) at personal and individual level.
Figure 2.3 Analytical framework of Guanxi
Source: Translated by the author, cited in Zhuang, 2012, p. 22
Huang (2009) also explores face and etiquette as “Confucian Relationism”.
Guanxi behaviours are a series of actions and efforts that an individual builds,
develops, maintains and uses (Zhuang, 2012, p. 22). Shou et al. (2011, p. 503)
define “guanxi behaviour as a relational effort in building and maintaining good
guanxi relationships specifically requires saving face (wei hu mianzi) and affect
investment (ganqing tou zi)”. Renqing (sympathy) and face belong to Chinese
cultural values (Qian, Razzaque and Keng, 2007), and both have an
interrelationship with guanxi. Jia and Rutherford (2010, p. 256) argue that
building guanxi is “essentially personal and informal” and addressed by the
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interaction of face and renqing too. Zhai (2011, p. 153) considers that renqing
and guanxi are two notions which are derived from face (mianzi). Guanxi
orientations are in relation to the fundamental perceptions and beliefs of guanxi.
Guanxi orientation also includes two aspects of guanxi’s significance and
objective. Zhuang (2012) also classifies guanxi into four models of inherent
guanxi, embedded guanxi, emerging guanxi and developed guanxi. Developed
guanxi is seen to build a relationship with someone who can bring current or
future interests.
The author considers that Zhuang (2012) provides a model for the
interrelationship and clues between guanxi and Chinese culture. It covers wide
categories and links many norms, definitions and terms of guanxi together. Zhai
(2007) states a theoretical framework about Chinese guanxi: personality
expresses guanxi and guanxi reflects personality. He considers that guanxi
research should be used to compare the association with logic between Chinese
and Western cultures. Long-term and involuntary guanxi, such as with family
members, classmates and superior–subordinate guanxi, is core for the Chinese.
Zhou (2011, p. 30) argues that guanxi should be formed based on special norms
rather than on interpersonal relationships. Zhou (2011, p. 32) also compares the
differences between the guanxi of the Chinese cultural environment and the
relationship marketing of Western culture. In Chinese culture, guanxi facilitates
mutual benefit and trust through rules of human obligations. So guanxi works
from the basis of a unique social culture and its institutional system.
In the end, guanxi reflects Chinese culture and business elements. From a wide
perspective, guanxi culture is about Chinese lifestyle including knowledge, art,
ethics, law and custom. From a narrow perspective, guanxi is a unique Chinese
symbol (Zhuang, 2012, p. 19). In this social and cultural context, guanxi is
embedded in Chinese social activities, social behaviours (e.g. authority, ethic and
benefits), and personal principles. As researched in the author’s previous
43
Documents Three and Four, guanxi is adapted by individuals in business
activities. It is therefore necessary to look first at definitions of guanxi.
2.3.2 Definitions of Guanxi
The author has compiled views of guanxi that are relevant to this research in
Table 2.1. The value of this table is to list and show different views of guanxi
from literature so as to generate a definition of guanxi which is used in this thesis.
Views of guanxi from references include both positive and negative, which in
direct relation to the thesis will be investigated from the two case studies. This
enables a comparison of the different guanxi definitions and functions and to
make sense of the implications of guanxi from practice in the following case
studies.
Fei (2008) does not define guanxi in his research. The “spider web” (Fei, 2008, p.
28) and “ripple” (Fei, 2008, p. 30) are used to define guanxi’s basic implications.
These are very abstract and have abundant connotations and denotations.
Therefore, it is too abstract to use words to express its connotations. The
implications of guanxi are very complex too (Fan, 2002).
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Table 2. 1 Views of Guanxi from Literature
Reference
Positive sides:
●Addresses personal relationship (Fei, 2008; Han and Altman, 2010)
● A pillar of Chinese culture (Anderson, 2008; Tong and Mitra, 2009)
● Enables competitive advantage (Li and Zhang, 2007; Li, Poppo and Zhou,
2008; Chen and Chen, 2004; Pablos, 2005; Chong, Fu and Shang, 2013)
● Important for face and etiquette (Qian, Razzaque and Keng, 2007; Huang,
2009; Shou et al., 2011)
● Enables social capital (Song and Werbel, 2007; Zhai, 2007)
● Social activities (Liu, Bao and Liu, 2013).
● Enables social networks (Whilpert and Scharpf, 1990; Szeto et al., 2006;
Pablos, 2005)
● Guanxi as a model of states-behaviours-norms-orientation (see Figure 2.4)
(Zhuang, 2012)
● Improves business performances (Cao, Baker and Schniederjans, 2014)
● Benefits of building good relationships with government (Gao and Tian, 2006)
Negative aspects:
● Gift economy (Chen, 2011), articles of luxury (Chen and Kim, 2013)
● Favours and commission (Yang, Meng and Lau, 2015 )
● Bribery and corruption (Wei and Xi, 2001; Luo, 2008; Besha, 2010; Zhao,
2014 )
● Unfair, weak, unethical and inefficient enforcement mechanism (Berger and
Herstein, 2014)
● Illegal ( Zhang, 2007)
Source: Compiled by the author based on literature
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Based on the existing literature, guanxi is a personal connection (Fei, 2008), or a
new of personal connections (Chang, 2011), or connections between
organisations (Yen, Wang and Kao, 2015). Guanxi starts with connecting
personal relationships (Han and Altman, 2010) through social activities (Liu, Bao
and Liu, 2013) and social networks (Whilpert and Scharpf, 1990; Pablos, 2005;
Szeto et al., 2006) to share favours (Yang, Meng and Lau, 2015) and benefits
( Xu and Li, 2013). Therefore, guanxi is that individuals connect with each other
to share favours and mutual benefits (Cao, Baker and Schniederjans, 2014). A
working definition of guanxi used for this thesis is that guanxi is a connection
between organisations and individual persons who have resources to be
employed in strategic development of organisations.
The functions of guanxi mentioned in Table 2.1 will be explored in the next
section.
2.3.3 The Functions of Guanxi
In starting this section, there are two questions that arise. How can guanxi be
built, developed, and used? What are the functions of guanxi in relation to
strategy formulation and implementation? Following questions arising from the
literature, the next subsections will explore guanxi operations at individual and
organizational level.
Why are the Chinese involved in guanxi practice? Both Western and Chinese
researchers perceive guanxi as useful social capital (Song and Werbel, 2007; Zhai,
2007). At the same time, “guanxi acts as the roles of both the catalyst and the
buffer” (Wong, 2007, p. 258) during business activities. Therefore, guanxi
improves business performances (Cao, Baker and Schniederjans, 2014) as well as
facilitating business success. In talking about guanxi functions, it reflects other
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simple questions of how to build, develop, and use guanxi and what approaches
guanxi be utilized. The issues are explored in Appendix 8.
Although Fan (2002) considers that guanxi is not a competitive advantage but a
tactical tool that facilities strategy development, for many others in China’s
business environment in both domestic companies and foreign invested
enterprises (Yuan et al., 2014), guanxi can be considered as competitive
advantage (Chen and Chen, 2004; Pablos, 2005; Li and Zhang, 2007; Li, Poppo
and Zhou, 2008; Chong, Fu and Shang, 2013) to facilitate strategy development.
During strategy formulation and implementation, in all cases guanxi remains an
important force (Liu and Porter, 2010), and a critical factor (Park and Luo, 2001).
From the existing literature, it is apparent that much has been written on the
function of guanxi, especially on competitive advantage, but there seems to be
little in relation to the pharmaceutical industry in China. The characteristics of
China’s pharmaceutical industry such as “overcapacity of cheap and low-cost
pharmaceuticals and highly fragmented market” (BMI, 2014, p. 9) show
pharmaceutical existing competition is extremely intense. Those features of the
industry offer developing opportunity to those who possess guanxi. This feature
builds the foundation for and marks the importance of this research. Given this
research context, the author considers guanxi is a competitive advantage to
facilitate the achievement of organizational strategy goals. But there is less
literature that links the functions of guanxi with strategy formulation and
implementation. Therefore, this will be sought from the two case studies.
2.3.4 Guanxi Operations
As shown in section 2.3.1, the implications of guanxi are very complicated.
Consequently, the types of guanxi are similarly complex. There are many types
of guanxi in literature (See Appendix 9 ). The types of guanxi (See Appendix 9,
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Table A9.1) are mainly categorized under politics, economy and culture. It is
obvious there are no criteria to categorize guanxi types. In summary, those types
are more various. However, given the objective need to maintain focus, guanxi
types are not considered in this thesis.
Chinese business operations rely on individual or organizational networks (Feng
and Wang, 2013). As shown in Figure A8.1 (See Appendix 8), whatever the
political or commercial intentions, building and developing guanxi starts with
individual emotional connections as well as identifying the process of quality
guanxi is the process of building trustworthiness guanxi.
Chang (2011, p. 317) considers that guanxi behaviours have a “significant
overlap” at individual and organizational levels. Especially, organizational
performances are represented by individuals who work in them. The author
highlights more the individual than the organizational level. Individuals use
personal guanxi to work for and serve their organizations. At the same time, the
individual builds overlapping guanxi, both personally and on behalf of the
organization with the government official who is also at the individual level.
Guanxi at organizational level in this thesis is more relevant to firms’ strategy
formulation and implementation. Strategy formulation and implementation are
clusters of dynamic and complex process, activities, and decisions. Those
clusters of activities in the organizations are more complex than what individuals
do (Chang, 2011).
Guanxi at Individual Level
The Chinese sociologist Fei (2008, p. 28-31) presents the “pattern of
differentiation” (Pinyin: Chaxu geju, 差序格局) theory, which explores guanxi’s
networks in Chinese society. He explains that China’s social structure and
patterns are totally different from those in the West. The Chinese guanxi network
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is like a web. Each individual is at the centre of a personal web to impact on
everyone else. The centre is oneself and the web is flexibility. Value orientation is
based on egoism. Given this, individual “social relationships are like ripples” (Lu,
2012, p. 468).
This web indicates guanxi has cultural legitimacy in China’s history.
Differentiated social status determines individual values. When different
individuals handle different personal matters or events, their individuality is
manifested in different intentions, behaviours, actions and manners. Under the
general standards, rules and regulations, the individual will follow guanxi-based
principles to make decisions.
According to Fei’s (2008) pattern of differentiation theory, guanxi starts between
and among individuals. Every individual is rooted in the self and looks from the
internal to the external. So what exactly can guanxi do for an individual? Guanxi
can contribute “tangible (e.g. securing employment) and intangible benefits (e.g.
increasing social capital)” (Xu and Li, 2013, p. 834) in study, work and business.
Lu (2012) links the research between guanxi and equity and equality rules and
argues that guanxi can be an intangible asset to make differentiation rules for
individual and organization when doing business. So in this thesis, whether
employees, or senior managers, every individual is building and connecting
guanxi with what they want or what they need. Every position requires guanxi
that carries out different functions.
Normally, through the approaches mentioned above, an individual builds guanxi
“which is base for generating goodwill” (Ingram and Zou, 2008, p. 178) with
business partners or government officials to facilitate their performance. So, is
guanxi also important inside the organization? The next section will explore
organizational guanxi and whether it is based on individual guanxi to exert
effects on internal and external organizations.
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Guanxi at Organizational Level
An organization comprises many individuals who work in different positions and
carry out different functions. Every individual utilizes personal guanxi for
personal affairs, business matters, and government affairs. Yen, Wang and Kao
(2015, p. 10) suggested three types of company guanxi including external,
inter-organizational, and intra-organizational (See Figure 2.4).
Figure 2.4 Types of Organizational Guanxi
Source: Modified by the author based on Yen, Wang and Kao, 2015, p. 10
In Yen, Wang and Kao’s model (2015), external guanxi is in relation to links with
government. This will be explored in the next section. In this section, the author
focuses on intra-organizational and inter-organizational guanxi.
The intra-organizational guanxi includes two aspects. Normally, basic
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relationships are based on the employee–employee, employee–employer
(individual to individual) (Yen, Wang and Kao, 2015). Now, there is an important
relationship in the intra-organizational guanxi named supervisor–subordinate
guanxi. Supervisor–subordinate guanxi is exchanging mutual benefits based on
personal trust which improves “building group/team or family identities” (Han,
Peng and Zhu, 2012, p. 321). And good supervisor–subordinate guanxi can boost
job satisfaction in the workshop (Zhai, Lindorff and Cooper, 2013). Working
together and more positive job satisfaction link members who are closely allied
in opinion and feelings voluntarily and become a “small circle” (Luo and Cheng,
2015), in-group members and work team (Han, Peng and Zhu, 2012). Even more,
the members of the small circle, or senior managers, form intangible networks in
the intra-organizations. These guanxi networks “promotes a strategy of relying
on these networks and alliances to encourage firm growth” (Cai and Yang, 2014,
p. 5), especially in SMEs.
As well as the small circle manifesting itself intra-organizationally, it also exists
in inter-organization and in inter-organization and government. The author
considers it is important to define it here. The interviewees had mentioned the
existence of the small circle in relation to guanxi and so the author uses its form
to describe the manifestation of guanxi. This term will be utilized to analyse it in
the following discussion in this chapter. Therefore, the term “small circle” means
an independent individual voluntarily, constituted group of members who have a
common hobby, family background, or interest. Small circles can be established
in intra-organization, inter-organization or inter-organization and government.
Further, “small circle” is seen as an interest group.
Zhu et al. (2013, p. 248) state that managers agree that “one’s knowledge, skills
and performance are more important than guanxi”, but employees consider
“internal promotion is based on guanxi”. For individuals, guanxi can help careers
(Li and Wright, 2000; Song and Werbel, 2007). For China’s SMEs, most are
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family enterprises and key managers have kinship. They operate guanxi that is
confined to internal favourites.
In the context of commercial cooperation, individuals in the different
organizations also exercise guanxi to improve business performance and build
mutual benefits (Cao, Baker and Schniederjans, 2014); for instance, the
relationships between managers of suppliers and buyers. Inter-organizational
guanxi is also built on personal guanxi. The link between guanxi at individual
level and organizational level “acts as a bridge” (Zhang and Zhang, 2006, p. 376).
As shown in Figure 2.5 (Zhang and Zhang, 2006, p. 348), whether at
intra-organization or inter-organization level, the individual acts at micro-level
linking organizations which act at macro-level. In particular, guanxi at individual
level acts as an access to key resources and facilitates strategic implementation
for organizations. Therefore, the inter-organizational business transactions are
positively or negatively influenced by personal guanxi (Cai and Yang, 2014).
Following this principle, building good relationships between organizations is
cultivated by individuals or senior managers in the short or long term. And senior
managers often play double roles in the social and commercial environments on
behalf of the benefits to themselves or their organization. Guanxi between
individuals and organizations has duality (Wellman, Chen and Dong, 2002).
However, the principles of personal-based guanxi and organizational
relationships are less clear. Guanxi in organizational performance is
“controversial” (Zhang and Zhang, 2006, p. 389).
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Figure 2.5 The Framework of the Micro–Macro Link
Source: Zhang and Zhang, 2006, p. 384
In any case, Zhang (2007) confirms that guanxi’s operation implicates legal and
illegal ways. A number of scholars criticize intensively guanxi’s negative effects
in the Chinese context. Ren (2014) comments that China’s current political
system is imperfect and cannot be in place fully. Indeed, guanxi-led ideology
facilitates unfair, weak, unethical and inefficient enforcement mechanisms
(Berger and Herstein, 2014, p. 781), illegal behaviours of bribery and corruption
(Luo, 2008; Zhao, 2014 ) and enigma (Berger and Herstein, 2014). Wei and Xi
(2001) identify super-guanxi that “involves corruption, bribery, privilege,
interference and others”.
2.3.5 Guanxi and Five Forces Model
Porter (1985) explains that competitive forces influence industry structure and
position. In regard to the Chinese pharmaceutical industry, the prescription drugs
distribution structure is more complicated (for more information see Appendix 10,
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Figure A10.1). This structure determines each party’s strength and profitability.
For this thesis, guanxi will be explored in relation to its influence on each of the
five competitive forces from literature.
The relationship between suppliers and buyers is a basic transaction.
Guanxi-based business offers cost advantages to reduce uncertainties (Standifird
and Marshall, 2000). Therefore, buyers evolve in establishing guanxi gradually
with suppliers in order to obtain higher discounts (Liu, Luo and Liu, 2009) and
lowest price (Xie, Peng and Zhao, 2013). Once guanxi is established,
guanxi-related trust provides “powerful in effectively governing buyer-supplier
partnerships and even more so in nourishing long-term relationship performance”
(Liu, Luo and Liu, 2009, p. 306-307). This strategic relationship helps both cope
when “unforeseeable events arise” (Liu, Luo and Liu, 2009, p. 298). As an
operating company in China, supplier resource management is influenced by
guanxi. Then building strategic guanxi with a supplier can enhance long-term
partner relationship and heighten “competitiveness as a whole” (Yang and Jiang,
2008, p. 4). It is worth mentioning that supplier selection strategy is based on
relationship-focus, which here can be understood as guanxi, where “managers
select supplier through social relations including ties and referrals from partner
firms, friends, or relatives” and can save costs of seeking new partners (Xie,
Peng and Zhao, 2013, p. 1222). Hence, Cheng, Yip and Yeung (2012, p. 3)
highlight collaborating key suppliers through guanxi networks can “reduce risk”
and positively relate to “supplier performance”.
The existing literature above shows that buyers in other industries, such as the
illumination industry (Liu, Luo and Liu, 2009), are involved in building
relationships with suppliers. These suppliers have bargaining power when they
have technology or core products. In the pharmaceutical market, do the buyers,
including medicine distributors/agents and public hospitals, need to build
strategic guanxi with suppliers (medicine producers)? This will be revealed in the
54
discussion section.
The force of new entries to the market is obviously related to the limitations of
the licensing requirements of government policy (Porter, 1980, p. 13). Changes
to government policy affect lower entry barriers (Kranenburg and Pfann, 2002, p.
233) and new entrants’ survival and profitability as well as increasing
competition (Silva, Kosmopoulou and Lamarche, 2008). Although guanxi is a
competitive advantage adopted in the business context, few researchers have
studied guanxi as an important force influencing two forces of new entrants and
product substitution. To address this gap in the literature, this thesis will reveal
guanxi as a force to influence directly or indirectly new entrants and substitutions
from the empirical evidence.
The former director of the State Food and Drug Administration (SFDA, previous
name of CFDA), Zheng Xiaoyu, was executed in 2007 for accepting bribes from
pharmaceutical companies to approve new drugs, some of which did not go
through regular procedures. Because of the bribe taking and dereliction of duty
of Zheng Xiaoyu (BBC, 2007), an oversupply of products including chemicals
and TCMs was approved for market. During this period, guanxi directly
influenced policy making to reduce entry barriers and increase competition.
These historical events caused the pharmaceutical market’s characteristics. Yu
(2011) points out that China’s pharmaceutical market is oversupplied, with
limited market opportunity for development and low technological content.
SMPCs are competing based on products with low technological content and low
price. It is obvious that there is fierce rivalry in China’s pharmaceutical market
(BMI, 2014). Based on the author’s research in Documents Three and Four,
guanxi is an important competitive advantage over rivals. Downstream customers
(Porter, 2008), for example, public hospitals in the pharmaceutical industry,
determine the bargaining power. Moreover, a strong buyers’ market determines
that products are often replaced by substitutes (Porter, 2008).
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Since the Zheng Xiaoyu affair, incumbents of central government have been
responsible for pharmaceutical industry administration including production
certification, product registration and regulatory policies. Then the question
arises: Does guanxi influence policy making which indirectly affect rivals’ entry
and substitutions? This will be revealed in the two case studies.
2.4 Government Policy
According to updated literature, government policy is a force that directly
influences industry structure and competitiveness (Dulcic, Gnjidic and Alfirevic,
2012; Wu and Yang, 2014). In this thesis, the main element under consideration
is government policy. However, the role of government and its administrative
system are also relevant to this research. In particular, the medical administrative
system reflects the process of medical policy making. The next section looks at
the role of government and the functions of the medical administrative system in
China. And the critical policy, DCBP is be explored in the literature.
2.4.1 The Role of Government
So what is the role of government for an industry? Porter (2008, p. 261) explains
that “Government inevitably plays a variety of roles in an economy. …
Government’s basic role in an economy is to achieve macroeconomic and
political stability”. The government plays the role of policy maker (Hadiyati,
2015). The role of government means that through significant functional
interventions it seeks to affect the entire economy (Wint, 1998). Regarding the
drug market, literature suggests that the government could play multiple roles to
act as a system designer, medical insurance provider, drug purchaser or
subsidizer and market regulator. Zhao (2012) states that any government
intervention in the economy has its own natural boundary. And government
intervention policies are always blind justice. So the government’s interventionist
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policy making will be based on cooperation rules that cause a high cost to be
paid by social groups.
In the public healthcare sector, government plays a significant role. For example,
the Indian government issued the National List of Essential Medicines for 2012
and the Drug Price Control Order in 2013 to reduce and control drug prices
(Adige, 2014). Thus, policies to control drugs prices are a strategy frequently
used by governments. Based on the research by Barros (2010, p. 3-4), all
European countries “regulate prices of pharmaceutical products” and
“governments strongly intervene in healthcare to cost containment”. Unlike
China’s medical insurance system, in many European countries governments are
the main third-party payers. And pharmaceutical product prices are controlled in
European countries.
In the next section, China’s medical system and its structure will be explained in
relation to the making of medical policies.
2.4.2 The Chinese Medical Administration System
When discussing policy issues in China, principally the Chinese central political
system needs to be taken into account. The political system is one-party, the
Chinese Communist Party, and a hierarchical management system from central,
provincial, municipal, county, to town government. All the following agencies
relate to the pharmaceutical industry.
Giving the priority of the research, it is important and essential to present the
policies which were issued by both central government and provincial
government following the regulatory structure (See Figure 2.6; for more
information see Appendix 11). If an important policy is issued by central
government, every provincial government also issues a local policy which will be
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supplemental to the national policy in order to develop the local pharmaceutical
economy and healthcare. For example, the main policy of the National Basic
Medical Insurance List (NBMIL) had been also issued by every provincial
government. In other words, on the one hand, local SMPCs have more
opportunities to get their product into the local insurance list. Every provincial
insurance list is different including the products and the cost. On the other hand,
SMPCs will have to address different provincial government bodies and distinct
policies.
Figure 2.6 The Structure of the Government Medical Regulatory System in
China
(CFDA: China Food and Drug Administration; DNRC: The National
Development Reform Commission; MDCG: Municipality Directly under the
Central Government)
In the research of Kuang (see Wang and Ap, 2013 p. 224) it is stated that
government plays a dominant role in policy making and implementation in China.
China’s Medical Reform for 2009 is government-oriented. Wen and Fang (2014,
p. 39-41) state that the role of government is misguided. They suggest that the
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functional orientation of government should be to plan and supervise. Planning is
not just about formulating macro medical care policy; it is government
investment and overall arrangement as well. Supervision of quality and safety,
and medical cost management are needed.
According to Xing (2006), under the governance mechanism, pharmaceutical
industry policies are lacking in systematization and legal restraint. And
multi-regulatory supervision causes a defect in the management system. The
regulatory system has been uncertain and confused (Deng and Kaitin, 2004) for
companies; some principles are even contradictory. Some limitations and
enforcement of policies are beyond the control of any type of pharmaceutical
company (Chan and Daim, 2011).
China Pharmaceutical & Healthcare Report (BMI, 2014, p. 11) is strongly
critical saying that “China’s political system is inherently unstable” and
“provincial governments often fail to enforce central government directives”.
The author disagrees with BMI’s first point but agrees with the second point.
During 30 years of reform and development, the rapid growth of GDP maintains
an annual mean at 10%. China is the second largest economy in the world (Yi,
2014). Economic development is based on overall political stability.
Shen and Li (2012) argue that government intervenes in the market directly. The
methods will seriously affect the development of the national drug market and
fair competition in the pharmaceutical industry. The pharmaceutical industry
policies are the sum of the various national and provincial policies that
government is involved with and intervenes in to achieve and develop certain
economic and social objectives (Xing, 2006; Xi, Zhu and Zhu, 2012).
Based on the literature, it is interesting to note that China’s medical
administration system has been critically debated by these researchers: the roles
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of government are critical, dominant and misguided (Wen and Fang, 2014);
therefore, it seems that some policies are uncertain and confused (Deng and
Kaitin, 2004) and lacking in systematization (Xing, 2006) such as the policy of
the Drug Centralized Procurement Bidding. However, the author does not want
to argue about the government’s system. She is more interested in how those
policies influence SMPCs’ strategy and how SMPCs cope with them in the
policy environment. Thus, the next section will discuss how researched policies
influence the industry.
2.4.3 The Influence of Policies on the Chinese Pharmaceutical Industry
In this thesis, four major policies – New Goods Manufacture Practice for 2010
(See Appendix 6), Drug Centralized Bidding & Procurement (DCBP) (See
Appendix 7), National Basic Medical Insurance List and Sub List for Provinces
(See Appendix 12), National Essential Drugs List (NEDL) (See Appendix 13,
abbreviated medical insurance schemes) – are very important to SMPCs. The
NEDL and NBMIL are main important parts of the Medical Reform for 2009.
The two lists have differentiation in drugs amount, structure, and forms (Wang
and Li, 2013; Yang and Yang, 2013). The two lists also have other important
differences (See Appendix 14). This outcome has been shown in Document Four.
Information on the New GMP and the two medical insurance schemes is rarely
found in the literature. But the policy of the DCBP policy has been researched
critically. Thus, this section explores literature mainly about DCBP policy. In
addition, it is worth mentioning that the policy of drugs pricing is equally
important and directly influences SMPCs’ business operations. The drug pricing
system was a complicated system which set the maximum retail price for drugs.
It was arguably detrimental to the pharmaceutical industry. Therefore, this policy
was cancelled by the central government in 2014. The author has researched and
updated its implications while writing this thesis. However, since drugs pricing
policy does not influence pharmaceutical industry anymore, it is out of the
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research scope.
The Drug Centralized Procurement Bidding
He and Li (2011) studied the literature of drug bidding published from 1999 to
2010 and state that the Drug Centralized Procurement Bidding (abbreviated here
as tender bidding) system is indispensable for Chinese medical and healthcare
reform and a significant system that must be implemented. Based on research
findings published in China, groups including medical organizations, colleges
and universities and scientific research institutions pay close attention to Drug
Centralized Procurement Bidding, whereas the main participants of
pharmaceutical companies including manufacturers, distributors and drug logistic
companies have rarely published articles about this issue. The author considers
that pharmaceutical manufacture is an important and indispensable actor for drug
tender bidding with plenty of interests and opinions. But pharmaceutical
manufactures lack discoursing power and influencing power in the tender
bidding system. They focus on taking part in different provincial bidding and
lack of time for or experience in academic research.
There are several parties, including government, making pharmaceutical industry
policies, interconnecting tendering centres, formulating regulations and
establishing platforms, hospitals as buyers, pharmaceutical companies as sellers
and social medical insurance departments as payers. These complex systems lack
coordination and consistency. The literature (Geng, 2010; He and Li, 2011)
reveals that the tender bidding policy and system poses many problems
including:
• Disunity of tender subjects
• Lack of standardization
• Regional protectionism
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• Burden of pharmaceutical enterprise
• Most hospitals are not bound by purchasing contracts
• Delay in payment to pharmaceutical companies
• Intermediary agencies’ indiscriminate collection of fees
For the 14 years of the tender bidding experience, the DCBP policy has been
unable to reduce the medical cost and price. And the principle of policy is to cut
price, which violates the objective laws of the development of social economy
(Tao, 2012). Wang (2011) also points out that the objective of the policy is to
reduce drug bidding prices, abolish commercial bribery during purchasing
activities and ease patients’ medical expenses. It has been given political appeal.
Drugs price cutting influences producers’ competition and profitability (BMI,
2014). Based on the author’s practical experiences, the low-price-oriented
strategy of rivals shakes up producers’ national price system stability. The
behaviours result in new competitive configuration that new entrants fight
against with substitute products instead of the existing market. Based on the
regulation of DCBP, medical organizations are required to pay drugs payment to
medicine logistics companies within 30 days. Effectively, the average payment
term is about 163 days (Xue, 2015). And the main influencing factor is that many
medical organizations have failed to bear the responsibility of fulfilling contracts
to pay medicine producers and logistic companies. On the one hand, this
phenomenon indicates public hospitals in the role of buyers have bargaining
power to negotiate with suppliers in the pharmaceutical industry. On the other
hand, government policy implementation indirectly increases firms’ financial
costs and risks.
According to Li and Reimers (2012), the drug procurement practice driven by the
government model has illustrated the failure of implementing third-party
electronic platforms. “When prices cannot perform their coordinating role”
(Stiglitz, 1996, p. 160), “the government may have to assume a more active role
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in performing this function” (Yu, 2000, p. 994). Therefore, government can
assume the role of coordination to tackle uncertainty. The fundamental purpose
of controlling drug prices is to control drug cost. Thus, Chinese drug pricing
policies have failed in the intention of controlling ever-increasing drug
expenditures. At the same time, the policy process is not the process of reducing
drug expenditures and commissions on sales. Rather, it is the process of
involving drug distribution by related government departments.
Yet a unified tender bidding policy has still not been achieved (Geng, 2010; He
and Li, 2011). Tender purchasing price is the most critical factor that influences
drug market entry, drug competitiveness, drug secondary price and medicare
payment price-setting. But although it is criticized and imperfect, it is still an
important reference for drug pricing. According to the literature (Geng, 2010; He
and Li, 2011; BMI, 2014), the DCBP policy is changing fast and creating
uncertainty. Furthermore, the DCBP has also been influencing SMPCs’ business
activities and financial costs (Xue, 2015) since this policy increases operation
costs “without conferring” (Porter, 2008, p. 264). It is shown from the literature
that government policy is a force which directly influence firms’ operations,
costs and profitability. Hence, the author will explore and reveal this view from
case studies in chapter four.
After reviewing understanding of strategy, application of Porter’s Five Forces
model, and the implications, definitions, and functions of guanxi. The next
section mainly explores the relationship between guanxi and government policy.
Moreover, the underlying causal mechanisms of guanxi will be revealed from the
literature too.
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2.5 Guanxi and Government Policy
In order to clarify the interrelationship between guanxi and government, it is
essential to be aware of China’s political system structure (see Section 2.4.2), the
structure of Chinese government medical regulatory system (see Figure 2.6), and
China’s medical reform background (see Appendix 2 and 3). .
Guanxi not only exerts its influence in interpersonal relationships and business
connections, but it also generates intangible (Ying, 2007) and subtle and intricate
force as relational power. Based on Gao and Tian’s (2006) research, guanxi is
connected with political system, policy formulation and implementation,
economic context and business. Networks from a powerful, complex and
extensive system can support the smooth operation of a business (Gibb, 2006). In
this scheme, “Guanxi is endemic and uniquely influences the character of
China’s legal system and offers an alternative dispute resolution mechanism”
(Berrell and Wrathall, 2007, p. 66). So guanxi has a social level in the Chinese
political system.
Berger and Herstein (2014, p. 779) reveal the interrelationship between
government and guanxi issues. “China is government-led and tightly controlled”
(Berger and Herstein 2014, p. 781), where guanxi can solve uncertainty so as to
reduce transaction-cost, gain valuable future government policy trends and then
create efficiency (Wang and Ap 2013, p. 231). On behalf of organizations,
individuals are involved in building good guanxi with government so as to
facilitate company and project implementation fast and well. “Guanxi becomes a
source of power to a leader and also influences the leader’s attitudes and
behaviour in ways different...” (Chong, Fu and Shang, 2013, p. 55-56). In this
way, an individual could utilize guanxi connections to government to collect and
share inside information (Yang and Lau, 2015), consult on detailed schemes and
then influence policy making or bypass and overcome administrative hurdles. At
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organizational level, however, the process and approaches of building guanxi
with government are more complicated and expensive but they provide higher
returns and profits (Yuan et al., 2014, p. 23). Naturally, the author considers that
establishing good guanxi with any decision-maker who works in any political
system is part of the business thinking pattern for Chinese companies.
Interest organizations and influences on policy, guanxi plays vital functions and
it is important to look at which approaches can be used by individuals to
influence policy making. Gao and Tian (2006, p. 77) show that registered firms
in China can adopt several approaches (see Figure 2.7) such as guanxi-based
lobbying and commonweal contributions to influence policy making. Normally,
guanxi-based lobbying is utilized by individuals. An example of intangible
influence over policy making can be found in contributions to so-called
commonweal projects. Chinese domestic companies or subsidiaries of
multinational enterprises in China: These may contribute to welfare projects such
as the Hope Project which helps children who cannot afford to go to school
because of poverty, and in order to make contact with the government officials
involved. Or in the face of natural disasters, companies may contribute to charity
relief funds in answer to government appeals. These approaches help to build a
good public image so as to obtain government's favour and trust (Gao and Tian,
2006, p. 79).
Kennedy (2005, p. 3) states that “firms influence the policy process indirectly via
their trade associations and other intermediaries”, for example, lobbying
activities in steel and software industries in China. Given Chinese
pharmaceutical context, very few studies research government policies and
guanxi influence SMPCs’ strategy. This thesis addresses the gap for literature.
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Figure 2.7 Approaches Used by Firms to Influence Government Decisions
Source: Gao and Tian, 2006, p. 77
Chen, Chen and Huang (2013, p. 177) argue that guanxi is opaque and unofficial
and has an impact on selection decisions. Fan, Woodbine and Scully (2012) also
describe guanxi as two-dimensional – both positive and negative. Guanxi has
also been identifies as a double-edged sword (Warren, Dunfee and Li, 2004) to
apply in non-Chinese cultural contexts (Fan, Woodbine and Scully, 2014).
According to published articles (Wei and Xi, 2001; Luo, 2008; Besha, 2010;
Zhao, 2014), its connotations have many critical implications. When people
mention guanxi regarding issues of business and politics, guanxi implicates many
ideas and qualities that reflect negative aspects of manipulating powers, bribery,
corruption and illegal utilization.
Since everyone in China knows the benefits of building relationships with
government officials, individuals on behalf of organizations are at different
stages of building, developing and maintaining guanxi with government. For
facilitating guanxi with government within a short time, there exist illegal
approaches manipulated by some organizations. Undoubtedly, some phenomena
exist from national government regulatory agency (i.e. The National
Development Reform Commission (NDRC) to local hospitals. Three officials in
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the prices department of NDRC, Liu Zhengqiu, Zhou Wangjun and Li Caihua,
were arrested for bribes in September 2014 (Wangyi, 2014). The prices
department is the most powerful department in NDRC. Officials in this
department have the power to decide a drug’s price. At the provincial level, every
pharmaceutical company wants to build good connections with them to obtain
information of policy trends and support for making drugs prices higher.
2.6 Guanxi as an Underlying Causal Mechanism
In order to reveal the underlying causal mechanisms of guanxi, it is important to
show the historical Chinese social context, social behaviours, and social
interactions (Zhai, 2011). Culture is one factor which is implicated by underlying
determinants of behaviours (Li and Cai, 2012). Several thousands of years of
agricultural civilization is the China’s traditional characteristic. Therefore,
kinship and geography are the base of Chinese interpersonal relationships.
Chinese interpersonal relations are mainly about acquaintance circles such as
relatives, friends, and classmates. A personal principle for Chinese is to avoid
disagreement or conflict, or to find reconciling ways (Zhai, 2011, p. 141).
Confucianism is the main ideology. The Chinese thinking pattern has been
associative, analogous, and continuous (Zhai, 2011, p. 145). This social context
of psychological and behavioural models for Chinese determines the prevalence
of guanxi.
As noted earlier, Zhuang (2012) identifies dimensions individual roles, status,
positions, and stratum. Status determines personal resources and behavioural
intentions. Consequently, the individual gains self-benefits through private ways
to bypass current systems, regulations, and structures to achieve aims (Zhai, 2011,
p. 153). And the aims are the end result and methods are the ways in which the
aims are achieved. This mechanism fits mutual benefits of decision makers and
beneficiary.
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Historically, concentration of power is characteristic of China’s political system.
“Confucian authority chains and guanxi should be viewed as two complementary
and interactive principles” (Hong and Engestorom, 2004, p. 553). At the same
time, guanxi and authority constrain each other too (Zhai, 2011). Based on status,
the individual possessing more power influences or constrains another, as in the
example of Zheng Xiaoyu, executed in 2007 for bribe taking and dereliction of
duty (BBC, 2007) as discussed earlier. These events reflect that influence at
individual level formulates directly national policies. Those influences are
profound for Chinese pharmaceutical industry.
The point of underlying causal mechanism of guanxi is significant for this thesis.
After that, the relationship between guanxi and strategy will also be explained.
Finally, based on all literature research, the conceptual framework will be
outlined to guide this research.
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2.7 Guanxi and Strategy
Some have proposed guanxi as a business strategy, and its development and
maintenance, can “achieve favorable market position and competitive
advantages” (Chen, Ellinger and Tian, 2011, p. 551). In the study by Harris et al.
(see Leitner 2014, p. 355), SMEs strategy formulation is shown to be based on
personal relationships or personal networks (Huang, 2009). In China, this
personal relationship refers to guanxi. Leitner (2014, p. 370) suggests that the
strategy maker in SMEs “should be cautious” during deliberate strategy
formulation. Owners in SMEs constantly hunt for information, identify
opportunities and make decisions quickly (Huang, 2009, p. 98). Huang (2009)
also suggests that SMEs’ strategic decision-making should take into account
political activities or behaviours.
Furthermore, guanxi “can be seen as an organizational strategy” (Gao, Knight
and Ballantyne, 2012, p. 464-465). “With guanxi most things are possible” (Liu
and Porter, 2010, p. 331). When people have to face seemingly interminable
obstacles, guanxi is like a shortcut that is highly active and effective. Without
guanxi, “it seems at times to be an interminable obstacle” (Liu and Porter, 2010,
p. 331). Although people know the risks of utilizing guanxi, people still want to
utilize guanxi to make decisions. According to previous literature, guanxi, as
competitive advantage, can facilitate organizational strategy goals.
2.8 Guanxi-givers and Guanxi-receivers
There are many parties including hierarchical government systems, medicine
producers, distributors, logistics companies, and public hospitals in the
pharmaceutical industry chain in China. In order to describe those complicated
interrelationships and connections in the industry, the author creates two new
terms about guanxi in this thesis, namely guanxi-giver and guanxi-receiver, so as
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to describe, analyse and argue about some sensitive and debatable issues. The
new terms have similar concepts to guanxi builder and guanxi maintainer (Zhao,
2014).
A guanxi-giver refers to a person or an organization that has ability or power to
offer physical or human resources, either tangible or intangible, which can meet
the demands of the one who receives them. In the Chinese pharmaceutical
industry, a guanxi-giver refers to an official in government, a policy maker, a
director in a hospital department and a medical doctor who has prescription
powers. A guanxi-receiver, however, refers to a person or an organization that
desires to build trust and close relationships with a guanxi-giver to reach aims
and goals. In the pharmaceutical industry, a guanxi-receiver refers to any drug
producer, medicine company, drug agency, medicine logistic company, drug store,
chain drug store or intermediary who is engaged in the drug business, selling,
promotion or after-sales services. The person from this type of company may be
an owner, a CEO, a general manager, a sales manager or a representative. Not
every guanxi-giver and guanxi-receiver can directly connect with and benefit
each other. Thus, an intermediary, who has influencing power, resource or
connection with both groups, can support them in connecting and benefiting each
other. This intermediary is a person or an organization.
“Guanxi is a dynamic process involving many parties” (Fan, 2002, p. 550).
Personal guanxi resource is always limited for individuals. Normally, if the
guanxi-receiver wants to start a relationship with the guanxi-giver, they need an
intermediary to match their requirements and needs or to help both the
guanxi-giver and guanxi-receiver to exchange favours. Therefore, intermediators
play a bridge to link and transfer information or deals. Intermediators can be
individuals or any types of organizations. Guanxi between guanxi-receiver and
guanxi-giver is dynamic too. Even when both have been initiated, built and used
(Chen and Chen, 2004), the “guanxi quality is reevaluated and adjusted during
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this dynamic process” (Zhao and Timothy, 2014, p. 492).
In the pharmaceutical industry, because a lot of policies and regulations can
influence industry development, the relevant participants of drug producers and
operators will arguably utilize all the guanxi they have to improve regulation
changes or to get their drug onto the insurance lists. Guanxi is regarded as
collaboration between a guanxi-giver and a guanxi-receiver among different
parties.
2.9 Conceptual Framework
In the context of this thesis, the existing literature shows that guanxi is deemed to
play a critical role and force that influences government policy at provincial level,
business partners and performances, to create competitive advantages and in
some cases then avert fair competition so as to prevent new entrants entering the
competition and be a threat by introducing substitute products. Under the current
changing environment, SMPCs have to run their businesses according to
government medical policies and provincial regulations to survive and create
margins.
Although Porter (2008) proposed that government policies and underlying causes
can affect the Five Forces model, he did not elaborate and explore them in his
model. Porter (1980, 1985, 2008) proposed that strategy formulation is more
related to consideration of industry structure and looked at each competitive
force’s strengths and weaknesses. Those competitive forces are then deemed to
drive company’s cost and profitability. Without doubt, Porter (1980, 1985, 2008)
provided a principle framework for understanding, analysing, and anticipating in
practice. In other words, the Five Force model can be seen to help practitioners
understand the attractiveness of industry (Ortega, Jalón and Menéndez, 2014) so
as to formulate strategic scenarios. Yet, in the author’s previous research, she
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emphasized that Porter’s generic strategy and Five Force theories did not work in
their “pure form” in the Chinese pharmaceutical industry because the influencing
factors of policy and guanxi were not taken into account in Porter’s strategy
model. Specifically, in China’s unique context, as Qin (2010) indicates, political
force exerted influencing forces during China’s transitional reform period. Yuan
(2014, p. 23) also supports the view that China’s transition economy is very
relationship-oriented. Given this context, individuals are motivated by employing
and selecting relevant guanxi to connect with the officials of government.
Drawing on the three aspects of guanxi literature (functions, operations and
causal mechanisms), together with China’s policy environment and Porter’s Five
Forces theory, a conceptual framework is proposed to guide this thesis (see
Figure 2.8). The conceptual framework is a modified “seven forces” model in
which government policy and guanxi are added to Porter’s Five Forces model in
the context of Chinese pharmaceutical industry. According to Porter (2008, p. 9),
“underlying drivers of each competitive force” determine the strength and
weakness of five competitive forces that “shape strategy” (Porter, 2008, p. 3).
Existing literature – and the research reported here - shows guanxi is deemed to
play a critical role and force that influences government policy (Gao and Tian,
2006) and the other five forces (Liu, Luo and Liu, 2009; Yang and Jiang, 2008;
Kranenburg and Pfann, 2002). In other words, individuals are motivated by
employing guanxi to connect government officials and business partners (Chen
and Wu, 2011). At the same time, guanxi is seen to offer cost advantages
(Standifird and Marshall, 2000) and improve business performance (Cao, Baker
and Schniederjans, 2014). It is also shown in the literature that government
policy is a force that directly influences a firm’s financial costs and risks (Xue,
2015), as well as, operation and profitability (BMI, 2014).
In light of this literature review, and importantly, given the research conducted
and reported here government policy and guanxi need to be studied and see
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whether these guanxi and government would be valuable to add to Porter’s Five
Forces model generating a modified “seven forces” model in the context of
China. The “seven forces” modified model begins to provide a guide to
understand the complex policy and business environment as practitioners
formulate and implement organizational strategy goals.
Figure 2.8 Conceptual Framework
Source: modified by the author, based on Porter, 2004
This is the conceptual framework. The next chapter will discuss issues of
methodology and methods.
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CHAPTER THREE: METHODOLOGY AND METHODS
In this chapter, the critical realist approach is outlined and the choice of this
philosophical approach advanced. The research design, case study and
interviewee selection, data management and analyses are discussed, together
with data reliability and validity issues.
3.1 Philosophical Approaches
Three paradigms of positivism, constructivism and realism, each with the
elements of ontology and epistemology (Guba and Lincoln, 1994; Perry, Riege
and Brown, 1999; Healy and Perry, 2000; Riege, 2003), are considered.
“Ontological is the ‘reality’ that researchers investigate, epistemology is the
relationship between that reality and the researcher, and methodology is the
technique used by the researcher to investigate that reality” (Healy and Perry,
2000, p. 119).
Ontology concerns the natural reality (Healy and Perry, 2000) and investigates
the nature of objects (Winn and Williams, 2012). Thus, “ontological assumptions
shape the way in which you see and study your research objects” (Saunders,
Lewis and Thornhill, 2016, p. 127). This is the first step. In terms of business,
those objects include individuals, teams or organizations. In order to distinguish
an appropriate philosophical approach to be utilized in this thesis, ontologically,
a belief of objectivism is “the view that external world exists independently of
our sense and experience, ideation, and volition, and that it can be known”
(Bunge, 1993, cited in Weber, 1997, p. 174). Thus, objectivism embraces realism.
Objectivists are concerned with the existence of social entities in an external
reality and, therefore, believe that social actors are experiencing a true social
reality. In contrast, constructivists construct their knowledge from the
experiences, behaviours and interpretation of reality which interacts with their
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social values (Fisher et al., 2007; Saunders, Lewis and Thornhill, 2015). “From a
constructivist’s perspective, truth is a construction which refers to a particular
belief system held in a particular context” (Perry, Riege and Brown, 1999, p. 18).
Thus, constructivist researchers are often interested in different topics and
accounts that people offer which suggest different social realities.
Epistemology is another important philosophical element. Epistemology deals
with human knowledge and the beliefs that people come to know, and the
principles that are confirmed by propositions. Different types of knowledge such
as textual data, descriptions and stories, can be reasonably considered (Saunder,
Lewis and Thornhill, 2015). The methods adopted are not only influenced by
their philosophical elements but also in choice the researchers make. According
to this principle, at one end, positivists are inclined to utilize quantitative
research methods (e.g. questionnaires) to advocate the position of the natural
scientist in the social reality. However, the positivist approach is deemed
inappropriate when research involves social science phenomena (Perry, Riege
and Brown, 1999). “Realism believes that there is a ‘real’ world to discover even
though it is only imperfectly apprehensible” (Healy and Perry, 2000, p. 120).
Therefore, realism recognizes the role of subjectivity in developing knowledge
based on the practice. The critical realist aims to understand the relationship of
an objective environment and the internal/external individual through
observation or experience. From the critical realist perspective alongside what is
directly observed or experienced, there are also hidden mechanisms which might
have cause what is observed or experienced. Critical realism delves deeper and
considers that the real world has three domains: events, experiences and
mechanisms (Bhaskar, 1978) (see Table 3.1). Realist researchers may utilize
qualitative methods to explore and discover differences between reality,
experiences and individual views (Riege, 2003; Fisher et al., 2007), while case
studies are utilized to research those “process-oriented” (Perry, Reige and Brown,
1999) and “causal’ tendencies (Bhaskar, 1978). It is the latter stance that is
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adopted in this thesis.
Table 3.1 Ontological Assumptions of Realism
Source: Perry, Riege and Brown, 1999, p. 19
Figure 3.1 shows the series of considerations around selecting a philosophical
approach undertaken by the author. The next section justifies the selection of
critical realism as a philosophical approach to be utilized in this thesis.
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Figure 3.1 Consideration of Philosophical Approach
Compiled by the author, based on Bryman and Bell, 2003; Saunders, Lewis and Thornhill, 2015
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3.2 Research Approach: Critical Realism
Realism is deemed to be a middle ground that provides “an element of
unification by offering a philosophical ‘bridge’ between the positivist and the
phenomenologist view” (Stiles, 2003, p. 265), or between ideas and reality
(Synmon, 1994). Realism takes two major forms: empirical realism and critical
realism (Bryman and Bell, 2007). Easton (2010, p. 118) suggests that “critical
realism however provides not only a basis for justification but also guidelines as
to how case research might be done and how theory can be fashioned.” Critical
realism is rooted in a positivist philosophical stance and aims to see reality and
explain experiences, events and mechanisms (Collier, 1994, p. 42-45, cited in
Fisher et al., 2007). There is an interest in the underlying mechanisms but also
deeper reality is in dynamic, complex and multi-disciplinary contexts.
Importantly, the mechanisms cannot be directly observed and can only be
logically inferred from real events (Fisher, et al., 2007, p. 285). Therefore, what
people experience is taken from external and independent sensations. Knowledge
of reality is generated from the interaction of structures, procedures and process.
Critical realists are inclined to recognize multi-level case studies to interpret
observable events.
Ontologically, critical realism has a stratified reality (see Figure 3.2). The three
ontological assumptions can be seen as “three worlds” (McGee, 1985, p. 61).
They are the empirical, the actual, and the real world. Understanding the world
includes two steps that are “sensations and events we experience” and “reasoning
backwards” (Saunders, Lewis and Thornhill, 2015, p. 139). Here, reasoning
backwards is known as retroduction. Tsang (2014, p. 175) summarizes usefully
that “retroduction [is] used to create theories regarding the structures and
mechanisms that generate the observable events, emphasizing explanation over
prediction”. For critical realists, the empirical events that people see are only part
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of reality. The actual event that may not be observed is underlying the reality.
Rather, “the deeper reality is the underlying dynamics or mechanisms that are
driving changes in society in general and in organizations in particular” (Fisher et
al., 2007, p. 285). Therefore, critical realists take “the form of in-depth historical
analysis of social and organizational structures, and how they have changed over
time” (Saunders, Lewis and Hornhill, 2015, p. 140).
Figure 3.2 Critical Realist Stratified Ontology
Source: Saunders, Lewis and Thornhill, 2015, p. 139; developed from Bhaskar,
1978
Epistemologically, those underlying causes and mechanisms can be explained,
observed, and inferred from organizational daily events. The three elements of
experiences, events and mechanisms provide clear guidance for the author using
this philosophical approach. Hence, in this thesis, the “real” practitioners of two
“real” case companies are deemed to be influenced by changing policies. In the
actual world, guanxi is a competitive advantage that influences their daily
activities in which they have participated. Events can be observed from the
practitioners’ experiences or exposed by the public. In other words, the
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researcher can observe these events but cannot observe the influence of guanxi.
Given the events of Zhegn Xiaoyu, guanxi did influence policy making, but the
researcher cannot observe how guanxi influenced policy making. The author’s
task is to discover, recognize, depict and analyse the causal structures and
mechanisms with presented evidence. This mechanism is inferred from the
interview data and set against the existing literature with particular attention paid
to outcomes.
From the critical realist perspective, one key causal mechanism is the unique
phenomenon of guanxi arguably underlying the complexity of real society.
“Causal social mechanisms, usually unseen, by virtue of which one event causes
another” (Gross, 2009, p. 361) and offer “a bridge between the philosophical and
the empirical” (Mason, Easton and Lenney, 2013, p. 354). Mechanisms can be
any real entities, for example, human, non-human (e.g. guanxi), or an institution
(e.g. government). Critical realists postulate their theoretical entities and then
identify evidence for the “real” world. Danermark (2002, p. 5) argued that the
real world which critical realists study is a “structured, differentiated, stratified
and changing” world. Thus, “what is real is not exhausted by what is experienced
or readily apprehensible” (Banta, 2012, p. 389). For example, guanxi implies an
underlying complex phenomenon that influences policy making and
implementation, which in turn impacts on strategy formulation and
implementation. Ontologically, guanxi reflects a deeply structured social reality
even though those experiences or events cannot be observed by social actors.
Thus, the interaction between guanxi and policy making is the relationship of
“ontologically objective and socially consequential existence” (Porpora, 1993, p.
222).
Critical realism, then, construes the world not only from accumulated empirical
information but also aims to acknowledge the “unobserved entities, structures,
and causal mechanisms which are existing and acting independently of
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scientists’ knowledge of them”(Lewis, 1996, p. 487). In China’s pharmaceutical
context, the process, applications and adjustments of SMPCs’ strategy
formulation and implementation are the observable appearances of underlying
causal mechanisms that guanxi embeds and in turn influences the crystallization
of five forces. The semi-structured interview has been recognized by
interviewees and discussed with regard to practical and real events and has
generated empirical information about practitioners’ strategy management and
their handling mechanism under the same political policies. Those actions “carry
with the intentions of and the meaning of consequences” (Miles and Huberman,
1994, p. 10). In this light, critical realism is identified as a particular
philosophical approach to explain practitioners’ empirical experience, where
events may or may not be observed, and guanxi is conceptualised as an
underlying causal mechanisms to influence policy formulation as well as the
other Five Forces. Table 3.2 further presents a summary justification for choosing
critical realism as a philosophical approach utilized in this thesis.
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Table 3.2 Justification for Choosing Critical Realist Approach
Critical Realism
Discipline Social science:
(1) Political issues: government policies.
(2) Culture: guanxi.
(3) Business/management/marketing: organization
strategy.
Ontology (1) Pre-existence of social structure: government
political system.
(2) Stratified reality: real, actual and empirical domains
of practitioners’ empirical and actual activities and
experiences.
(3) Observable events.
(4) Social actors (practitioners) intentions: reasons as
real causes.
(5) Consisting of structures, mechanisms and events:
constant policies changing, loops of SMPCs strategy
formulation, implementation and adjustments.
(Continued)
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After outlining Table 3.3, critical realism is adopted as the exact methodological
approach to be utilized in this thesis.
Epistemology (1) Knowledge: the beliefs of guanxi; the perspectives
of policy; the formulation of strategy.
(2) Inference of building theories based on the causal
mechanisms.
(3) Subject-matter: internal necessity (SMPCs’ strategy
formulation, implementation); external relations:
building good guanxi with government.
(4) Practice: guanxi provides competitive advantages to
SMPCs’ strategy formulation and performance. Critiques
of guanxi.
Methodology (1) Historical process analysis: evolution of China
Medical Reform for 2009; evolution of two case
companies strategy; changing government main policies.
(2) Underlying complexity: causal mechanism of
guanxi.
(3) Theoretical research: Porter’s strategy application in
China.
(4) Empirical research: SMPCs’ strategy formulation
and implementation.
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3.3 Research Design
Against the philosophical approach, the methods of data collection are outlined
next.
Case study research provides “in depth” inquiry (Yin, 2014, p. 24). Following the
research themes of guanxi, government policy and strategy, “deals with
operational links needing to be traced over time”. The case studies were utilized
to collect more detailed information (Yin, 2014, p. 10) to understand the
interrelationship of influencing factors when a policy changes. According to
Urquhart (1999), the case study can involve single or multiple angles from which
to analyse a subject and to conduct an analysis at numerous levels to build theory
and develop a conceptual framework. Case studies discover differences between
reality, experiences and individual views (Riege, 2003; Yin, 2014). This was
matched with critical realism to make inferences related to causal relations
among variables (Yin, 2014, p. 28).
3.3.1 Research Approach: Two Comparative Case Studies
One case study, featuring a chemical medicine producer, was deemed too limited
to identify distinction. Therefore, comparative case studies were employed to
“elucidate the causal social processes underlying events” (O’Brien and Ackroyd,
2011, p. 39). Traditional Chinese Medicine (TCM) is a unique feature of Chinese
medical science and theory and TCM is largely used in the public medical
organizations in China. Hence, another case study of a TCM producer was
chosen. These two different types of medicine producers have many differences
including their product lines, product quality system, production standard,
marketing mode, the reimbursed rate in the NBMIL and NEDL, and the
regulations of DCBP. Therefore, comparative case studies can compare the
differences and outcomes of formulating strategy based on different products.
Using the case studies of two different types of producers enabled the author to
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compare and contrast findings under the same influencing forces of policy during
the same period. The goal was to distinguish differences in the strategy
formulation between the chemical drug manufacturer and the TCM manufacturer.
Based on the author’s experience and contacts, identifying two companies began.
In light of the need to consider also practical aspects such as the convenience,
accessibility, cost and time issues, ultimately, the author made the decision to
filter the study cases from SMPCs that were known to her or had collaborated
with her (see Figure 3.3). The author studied for her TCM degree for five years
in Guizhou and has worked and lived in Guangdong for 16 years and has a good
reputation and rich experience in cooperating with suppliers in Guangdong and
in Guizhou provinces for many years. Thus, it was easier to connect and access
the data from these companies.
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Figure 3.3 Case Studies Selection Process
The two case studies were selected based on the criteria described in Table 3.3.
The criteria was formulated based on two considerations. In this thesis the
research subjects are medicine producers. Based on the author’s experience,
competition among medicine producers arose from the need to be listed in the
NBMIL and NEDL. Products listed in the two medical insurance lists decide
market coverage rates. If the products of the case study companies were not
listed on the insurance schemes, practitioners had no experience of selling those
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products. And interviewees might not provide in-depth understanding about
policy influences relating to those products. Accessibility to interviewees who
work in different departments and positions is very important. Interviewees
working in different departments and positions have different empirical
information and understanding about the influences of policy too. Following
these criteria, one typical prescription drug producer of chemical medicine called
“Company A” and one TCM producer called “Company B” were selected for this
thesis (for more detailed information see Appendix 15). The two case studies
have the same characteristics in terms of being private medium-sized
manufacturing companies and have prescription drugs systems including at least
one product listed in the two important insurance schemes NBMIL and NEDL
(See Appendices 12 and 13). The interviewees in the companies were senior
managers and decision-makers of departments.
Table 3.3 The Criteria of the Case Studies Selection
(NBMIL: National Basic Medical Insurance List; NEDL: National Essential
Drugs List； SMEs: Small and Medium-sized Enterprises; TCM: Traditional
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Chinese Medicine)
Company A is involved in producing chemical medicines and has three
professional teams to improve business. One team focuses on the prescription
drugs market. The prescription drugs are mainly anti-cancer drugs and
cardiovascular medicines. The other two teams focus on the over-the-counter
(OTC) market, for instance, cold medication. The author’s own company is
Company A’s distributor for anti-cancer medicines in Guangdong Province. The
author has over seven years’ collaboration experience with Company A and
implements Company A’s strategy in the local market. She has built good
connections with the decision-makers of the different departments of the
company.
Company B is located in Guizhou Province. It is also a private medium-sized
enterprise in the industry. Company B is involved in producing Traditional
Chinese Medicines (TCMs). Because the author graduated from Guiyang
Traditional Medicine School, she knows many local owners of TCMs producers
in Guizhou Province. Company B is a famous medicine producer in Guizhou.
She has no previous experience of cooperating with Company B in any medicine
business but has brought opportunities to collaborate with Company B in the
medical device field from companies in European countries.
When access to the two representative cases were confirmed, the interviewees of
the two case studies were selected and the ethical approval sought. The process
of selecting the interviewees is discussed in the next section.
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3.3.2 Interviewees Selection
The organizational structure of the two SMPCs consists of five decision-making
departments: CEO or general managers, sales and after-sale service, marketing,
R&D and production, and financial. Companies A and B, both well-known in
China, are medium-sized pharmaceutical companies. The senior managers of the
departments are the departmental decision-makers. Having considered the
sensitivity of financial information, the author decided not to interview managers
of the financial departments. The interviewees selected were responsible for
making decisions in their department for business operation purposes. Their
opinions and decisions directly influence their companies’ strategy formulation
and implementation and hence were the focal source of data.
The following criteria applied to all interviewees:
1) Professional education background in medical treatment, medicine and
business management.
2) Decision makers of department: over ten years’ work experience as a
pharmaceutical producer.
3) Leader of a department/company.
4) Experience in the tendering and bidding policy process from 2009 to 2013.
5) The decision makers of the company: over 25 years’ work experience; deep
and broad understanding of China’s pharmaceutical industry; have witnessed the
changes and evolution of China’s opening-up and reform and China’s New
National Health Reform. The CEO of Company B is the owner of the company.
Nine interviewees, the leaders in four departments, were selected from the two
companies (see Appendix 16 for more about the interviewees). When the
selection of interviewees was confirmed, the next step was data collection.
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3.4 Data Collection
A semi-structured interview is recommended to gain a detailed picture of a
respondent’s beliefs and perceptions of a particular topic (Smith, 1995, p. 9). It
lets participants show their understanding of policies, decision-making and
implementation through following a list of questions. This method gives the
researcher and respondents much more flexibility than the structured interview
and more focus and direction than the unstructured interview (Sekaran, 2003).
Semi-structured interview was adopted to collect primary data from the
interviewees’ points of view directly and to obtain detailed answers. The data
collection process included two steps to collect satisfactory data. Before the
interviews, questions for semi-structured interview were formulated. Seven
questions were formulated (see Appendix 17), with questions focused on how
national and provincial policies influence SMPCs’ strategies and why? The first
stage of data collection was completed between July and August 2014. During a
detailed review of transcriptions, what emerged was that all practitioners
mentioned guanxi. Subsequently, the author went back to conduct both a
literature search and a follow-up review about guanxi. Six questions were
formulated for the follow-up interviews (see Appendix 17). Follow-up interviews
were set up for March 2015. The research & development (R&D) manager of
Company A and the factory director of Company B are in charge of production in
their companies. During a review of transcriptions, both were seen to have less
experience to explain guanxi operations. Therefore, they were not chosen to be
interviewed in the follow-up interview. Furthermore, the sales director and sales
manager of Company A had an important conference to attend in Beijing in May
and needed to stay in Beijing. The author did not go to Beijing to interview them.
The sales manager of Company B, had asked for leave of one month to take care
of his father in another city. Therefore, four interviewees, the CEO and marketing
director of Company A and the CEO and sales director of Company B, were
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interviewed a second time. Those key decision-makers were interviewed to the
follow-up interview.
Before any interviews were held, the author complied with ethical regulations
and received the Ethical Approval Checklist Form and a consent form was
developed. Owing to the author’s relationships with these business partners, it
was easy to contact them and arrange face-to-face interviews. The author
obtained consent from every interviewee and she informed all interviewees in
advance that the face-to-face interviews would be recorded.
The face-to-face interview process followed the following steps:
Step 1. In order to obtain consent, contacting and phoning the interviewees to
present the purpose, intention, goal, methods and the length of time needed.
Step 2. Obtaining the approval and confirming the location and time for the
interview.
Step 3. Meeting at the agreed time and location; introducing the research topic,
presenting the letter for the semi-structured interview (See Appendix 18) and
obtained their approval for being recorded; asking the questions, and taking notes,
observing.
Finally, there were nine interviewees involved, four of whom conducted a second
follow-up interview to explore guanxi further, giving a total of 13 interviews
completed successfully (see Table 3.4). To travel from Guangzhou to
Shengzheng takes under two hours by car. To travel from Guangzhou to Guizhou
takes four and a half hours by train and one and a half hours by air. Most of the
interviewees of the two case studies chose an interview location in working time
at their offices or in a meeting room. The average length of time was about 55
minutes. All interviewees of Company A spoke Mandarin. The interviewees of
Company B chose the local Guizhou dialect, which was probably more
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comfortable for them and easier to express their understanding and insights.
Table 3.4 Background Information on the Interviews
Just one female member of staff of Company A interrupted to ask questions of
her sales director and the sales manager of Company B took several short
telephone calls. Other interviewees set their phones to the silent mode. With all
the interviewees, the interviewing process was effective and efficient. The CEO
of company A, who had a PhD degree, talked a lot more than others based on the
author’s questions.
3.5 Data Management and Analyses
Face-to-face methods are best suited to the exploratory stages of research when
the researcher is trying to get an impression of concepts or situational factors
(Sekaran, 2003). Through the face-to-face interview method, the interviewees’
attitudes, feelings, tones and body language can be observed directly (Hill and
Wright, 2001). Face-to-face interviews allow the researcher to investigate the
respondents’ views, opinions and beliefs more effectively, as the respondents are
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given much more freedom in the survey interview (Bryman and Bell, 2007).
Face-to-face interviews can collect deep-level details and approaches about
guanxi utilization and can allow observation of the interviewee’s attitudes, body
language, and rational understanding in relation to guanxi’s functions in
someone’s life and work.
After collecting the data, the author followed six stages to carefully manage it.
The first stage was to listen to the recordings three times. The second stage was
to generate ideas after listening to the records. At this initial stage, it was found
that central and provincial government policy was a main influence on them. But
it was also interesting that practitioners mentioned guanxi in relation to the
emerging main theme of policy. That appeared to be a critical factor too.
The third stage was to transcribe the recordings into Chinese and analyse them in
Chinese; especially as the three interviewees of Company B spoke in the
Guizhou dialect. The author comes from Guizhou and works in Guangdong, so
she can speak in the Guizhou dialect, Cantonese, Mandarin and English. During
two interviews, the two languages of Mandarin and the Guizhou dialect were
utilized by interviewees. The interviewees of Company A are from different
provinces, work in Shenzhen, and can speak both Mandarin and the local dialect.
Shenzhen is a pilot city of the policy of reform and is open. Thus, Shenzhen is a
city of immigrants. People working in Shenzhen speak mainly Mandarin. So all
interviewees of Company A spoke Mandarin to the author. And all interviewees
of Company B are from Guizhou province and can speak both languages of
Guizhou dialect and Mandarin. The sales director and manager concentrate on
business customers who come from different provinces in China. They
accordingly speak fluent Mandarin and the Guizhou dialect.
The author made use of whichever language was easier for the interviewees. The
CEO of Company B also speaks both Mandarin and the Guizhou dialect fluently.
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Interestingly, when the author was with him, when the CEO was facing
customers, he spoke Mandarin. He spoke in the Guizhou dialect to the author and
when the author interviewed him, he utilized the Guizhou dialect. He was used to
using the Guizhou language to communicate with internal staff and Guizhou
friends. However, the factory director is a technician. He has been working for
Company B for over 10 years, but was not good at speaking Mandarin. It was
notable that the Guizhou dialect made him more comfortable to complete the
interview. Overall, the author was flexible, aiming to put them at ease to get the
fullest answers possible. The sales director of Company B also directly utilized
the Guizhou dialect to speak to the author at the second interview. This is the
local culture. Where Guizhou people know that the speaker is from Guizhou,
they usually use the local language to talk and communicate with each other.
The author was born in Guizhou and studied for 16 years from primary school to
university. She can fully understand and speak fluently the Guizhou dialect with
all interviewees of Company B so as to complete the two interviews and then
transcribe them into Chinese. Transcriptions in the Chinese version made the
author comfortable to understand and to generate themes. After obtaining the
Chinese version of the transcriptions, the following analyses began.
The fourth stage was to print all transcriptions, read them, and mark key words or
expression. After the three stages of managing the data and with themes
emerging at the fourth stage, the author went back to look at the literature. The
analyses continued and check were based on the transcriptions and subsequently
compared to the research literature. The fifth stage was to generate categories in
the notebook, group similar ideas, and eventually to locate key quotes to
illustrate key themes. Then, organizing the analysis was based on key quotations
and the key themes. At the final sixth stage, the author translated the Chinese
version of the transcription and themes into English. This stage was important.
The author made sure that the transcription and themes were translated carefully
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and accurately. Although the author knows the Chinese words, old sayings and
idioms were not easy to translate into English and care had to be taken.
The process of data management and analyses aimed to ensure a systematic and
consistent approach at all stages noted above. The transcriptions in Chinese first
enabled the author to become comfortable in understanding the practitioner's
views and to generate emerging themes. The author repeatedly listened to the
records of interviews. Marking up key words/expressions and locating key
quotes helped the author to begin to categorize similar ideas. As part of this
process, typical quotations were noted and eventually utilized to illustrate the
themes in this thesis. The final stage was to translate transcriptions into English
since terminology management is clearly significant for this thesis. The next
section will focus on defining key terms.
3.6 Terminology Management and Analyses
One phenomenon in this thesis is the terminology (e.g. government, medical
administrative system, policy-making) where there are different ways to refer to
things in Chinese. Therefore, it was essential to define those terms which were
frequently mentioned by interviewees and discussed by the author. For the DBA
thesis, the author has selected key terms to be defined and ensured that they were
used consistently throughout this thesis.
The notion of government relates to politics, government departments,
government agencies, authorities, and power in the Chinese context. Based on
the structure of the government administration system in China (See Figure 2.6),
government means central, provincial/municipal directly under the central
government, city, county and town government. Normally, it is the surrounding
talk/context that gives it the unique or specific meaning. Pharmaceutical policies
refer to all medical and pharmaceutical policies relevant to laws and regulations
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of drug production, sales and services which are promulgated by the Chinese
central and provincial government. However, significant pharmaceutical policies
are mainly issued by central and provincial government. It was approval that the
term of “government” was used mainly to express both central and provincial
government.
Similarly, policies need to be defined, especially those mentioned in this thesis.
Policies are mainly issued by both central government and provincial
government following the governmental body structure. When an important
pharmaceutical policy is issued by central government, every provincial
government also issues a local policy which will be supplemental to the national
policy in order to suit the local situation and develop the local pharmaceutical
economy and healthcare (BMI, 2014). For example, when the main policies of
the National Basic Medical Insurance List (NBMIL) (See Appendix 12) and the
National Essential Drug List (NEDL)(See Appendix 13) were issued by central
government, subsequently, both of them would be issued by every provincial
government named “provincial name” NBMIL and NEDL (e.g. Guangdong
NBMIL, Shanghai NBMIL, Beijing NBMIL etc.). This regulation is the same as
NEDL. Thus, the provincial insurance list is based on the same national policy
with new and different medicines added. Consequently, every provincial
insurance list is different including products and costs. The result is that, on the
one hand, local SMPCs have more opportunities to get their products onto the
local insurance list but, on the other hand, SMPCs will face different provincial
government bodies and distinct policies. Therefore, policy making by
government is mainly pointed towards provincial policies formulation.
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3.7 Data Reliability and Validity
Although the realism approach is increasingly used in marketing research there
are still challenges in thesis of its reliability and validity for researchers. From
the realist perspective, “realism emphasises the building of a theory rather than
the statistical testing of the generality of a theory to a population” (Healy and
Perry, 2000, p. 124). In particular, based on value awareness, perceptions from
multiple angles from different positions in an organization, could be “a window
to reality through which a picture of reality can be triangulated with other
perceptions” (Healy and Perry, 2000, p. 125). Healy and Perry (2000, p. 122)
summarized six comprehensive criteria that could be utilized to judge reliability
and validity in the realism paradigm (for more details see Appendix 19). And
Riege (2003, p. 78-79) highlighted, “four design tests of construct validity,
internal and external validity and reliability can improve the quality of case study
design” (See Appendix 20).
From the criteria and paradigms of Healy and Perry (2000) and Riege (2003), the
author used the six facets to demonstrate this thesis’s quality and its reliability
and validity.
First and foremost, Table 3.2 presents the justifications for choosing critical
realism based on case-oriented research. The key elements of guanxi,
government policies and SMPCs’ strategy are related to complex social
phenomena. Thus, ontological appropriateness relates to the selection of “how”
and “why” issues. For example, the first research question is how national and
provincial policies influence SMPCs’ strategy formulation. Second,
methodological trustworthiness – the author represents practitioners’ quotations
and supporting public government reports to both summarize data and illustrate
this vital notions; she depicted the principles for the selection of the two
comparative cases and also selection process and the detailed interviewing
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procedures.
Second, the case study method focuses on theory construction based on the
interviewees’ real-life experience. Thus, realist researchers have an intimate
relationship with the organization. Hence, the researchers need to prevent
inclusion of personal subjective judgements during data collection so as to
enhance the construction validity (Riege, 2003). Regarding internal validity, the
author has utilized cross-case patterns to discover the similarities and differences
between the two cases. Both cases are medium-sized companies and the
interviewees are decision makers within the same departments. They are located
in different local markets, facing different local governments, and have different
products and distribution systems. Finally, the research results showed that the
two companies have the same principles of strategy formulation. These results
were generalized to form a broader theory that was matched against a previous
conceptual framework.
Third, reliability in case studies is related to whether other researchers can
replicate the findings. In this research, the author used consistent interviewing
techniques and procedures with the same interviewees for the two interviews.
Also, the author has carefully used precise data management such as in recording
data and transcription in both Chinese and English versions. This data assists
assurances on the accuracy of the findings across comparable data sources. These
techniques are deemed to increase the validity of construction (Riege, 2003, p.
78-79).
Fourth, the selection of the business partners maintained the case reality of the
research. On the one hand, the connection between the author and companies A
and B gave the author accessibility. This close relationship between the
researcher and the interviewees helped the research achieve validity and
reliability. Since the face-to-face interviews were to focus on the practical
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situation for analysis of the facts and consequences in light of policy change, the
practitioners’ quotations recounted and represented reflected the empirical and
the historical events being generated and exchanged in the analyses. The
interviewees described their companies’ internal and external actions and
thinking frameworks, as well as the basis for decision-making. On the other hand,
although the business partner connection could bring accessibility, it could also
lead to a bias where the respondents did not express in-depth views on sensitive
issues such as guanxi. Interviewees of Company A have known the author over a
period of five years and in order to overcome bias, the author employed different
techniques to ask the questions following their viewpoints and to let the
interviewees quote examples in answering the questions. And interviewees were
encouraged to expend their views following the author’s questions and other
questions enabled the author to cross check for consistency.
Fifth, the author constructed a relaxed and comfortable environment in which to
undertake the interviews. For instance, she gave the interviewees a cup of coffee
and introduced her recent circumstances and research before starting the
interviewing. Before the interview, the researcher prepared and also shared with
the interviewees a lot of detailed information including a government industrial
report and an international pharmaceutical report in China (BMI, 2014). During
the interviewing, the author established a trusting relationship through validating
and exemplifying both the interviewer’s and interviewee’s experiences as the
foundation for asking critical questions that challenged assumptions about
sensitive issues. This rapport enabled ideas that might have been difficult to
articulate were raised and discussed in depth.
Sixth, the languages of Mandarin and the Guizhou dialect were both adopted in
the interviews. The author could clearly state and ask the questions, clarify
doubts and ensure that the interviewees understood the issue without confusion
caused by language (Sekaran, 2003). When talking about sensitive questions,
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industrial reports and news, other company’s examples were used to explore their
understanding. And when the author held different views from the interviewees,
she respected their responses and did not comment on their answers. After data
collection, transcription and noting themes, the next chapter will analyse and
discuss how guanxi and government policy are interacted to influence Porter’s
Five Forces in the pharmaceutical industry.
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CHAPTER FOUR: ANALYSES AND DISCUSSION
The analysis suggests that guanxi plays a critical role in connecting the other six
forces outlined in the conceptual framework (see Figure 2.8). This chapter begins
by presenting the analysis and discusses guanxi which, the author suggests, is
key in combining policy and SMPCs’ strategy. First, a summary discussion of
guanxi’s properties is outlined, along with its implications, functions and
operations. The consideration of the functions of guanxi in strategy formulation
and implementation as articulated by practitioners. Guanxi operation leads on to
analysing guanxi at individual and organizational level, as articulated by the
practitioners in this study. Following this, the next section examines the
interrelationship between guanxi and government policy and also the underlying
causal mechanisms. Porter’s Five Forces theory will be looked at in relation to
these two forces of guanxi and government policy as the analysis is presented.
The final section outlines the analyses and discussion of SMPCs’
self-organization development. Throughout the presentation of the analysis, the
discussion will also inherently refer to, and make connections to, the relevant
literature.
4.1. Complications of Guanxi in Practice
The analysis begins with a reminder summary of the definitions of guanxi. Given
the space considerations, the findings are summarized in Table 4.1 and it remains
interesting that none of the interviewees could define guanxi clearly. This reflects
the literature review (See Table 2.1) in terms of the complications of guanxi
where there are no uniform definitions and no criteria to generalize about guanxi
from literature and practice. Indeed, the meanings of guanxi and the forthcoming
analysis – summarised in Table 4.1 – supports this too.
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Because of their different positions in organizations, and their levels of education
and working experience, the practitioners had different views (See Table 4.1) and
yet all interviewees emphasized guanxi as a resource. Four interviewees
mentioned guanxi was a competitive advantage which facilitated strategy goals.
Five interviewees specifically considered guanxi to be something unique to
Chinese culture. Except for providing broad understandings of guanxi, two CEOs
and the sales director of Company B described guanxi as a “small circle” and it
was described as a “lubricant” (CEO of A), “catalyst” and “ multiplier” (CEO of
B) and “information collector” (sales director of Company B). This points to both
its complexity and elusiveness.
When talking about the causal mechanism of guanxi with respect to government
affairs, two CEOs used historical institutional examples of when guanxi
influenced government policies, and the effects on the pharmaceutical market;
others used public events, commercial rivals’ cases or the press to describe it.
The author had to carefully analyse and interpret what they were pointing
towards. Indeed, only when practitioners were talking about issues or events,
could they define guanxi based on that situation.
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Table 4.1 Views of Guanxi in the Two Case Studies
Interview
ees
Company A Company B
CEO ● In relation to social legal system
and spirit of commitment.
● Narrow sense as a negative word
and negative side.
● Like lubricant to achieve the
goal, reduce cost and improve the
effectiveness during strategy
implementation.
● “Small circle” culture.
● Difficult for foreigners to
understand our guanxi.
● In relation to civic culture (e.g.
“what guanxi have I?”, “can it be
faster?”, “can I take a short cut?”
● Guanxi and government policy
are like twins which need to be
considered comprehensively.
●Making you more confident
● Like a catalyst, multiply to
facilitate and help achieve your
strategy goal.
Marketing
director
● Including external and internal
guanxi. External guanxi means the
relationship with government,
internal guanxi means the network
inside the enterprise.
● Traditional code of conduct
(Face, sympathy etc.).
Sales director is also in charge of
marketing department. Thus, the
understandings are the same as
below.
Sales
director
● In relation to Chinese Confucian
culture.
● Using guanxi to develop fast.
● Core competitiveness.
● To establish an interactive
relationship with government.
● Like information collector or a
bridge to link with government.
(Continued)
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● Competitive advantage and then
avert fair competition.
● A series of tactics
● Narrow sense as asymmetrical
competition
Sales
manager
● SMPCs needs to build good
guanxi with government,
distributors and doctors, which
can:
● Be helpful to formulate business
strategy.
● Be competitive advantage.
● Improve business performance.
● A powerful tool to improve our
goal.
● Facilitating SMPCs’ products to
be listed in the medical insurance
scheme.
R&D
manager/
Factory
Director
● To guide us in how to work and
what to do.
● More useful to sales people.
● Guanxi is resource.
● Helping you succeed fast.
● Supporting commercial deals.
The complications of guanxi are also manifest from its dual nature. Regarding
the properties of guanxi, guanxi has been described as two-dimensional – both
positive and negative (Fan, Woodbine and Scully, 2012) and a double-edged
sword (Warren, Dunfee and Li, 2004). Except for a number of positive
advantages and benefits to individuals and organizations, it was also evident that
interviewees felt that guanxi’s negative side was linked mainly to government
(Wei and Xi, 2001; Zhang, 2007; Luo, 2008; Zhao, 2014; Berger and Herstein,
2014). The negative sides were in relation to interest groups. And three
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interviewees – two CEOs and the sales director of Company B – used the term
“narrow sense” to link guanxi’s negative sides. As one typical illustration here,
the CEO of Company A said:
Guanxi in the narrow sense means any type of irregular guanxi. It could influence
decision making … If policy formulation and implementation are not genuinely open
and transparent, guanxi works … As long as governmental behaviour lacks
standardization, it is consequent that interests of small groups influence policy making.
The account from the sales director of Company B also conveys a narrow and
negative sense of guanxi, for example, here as asymmetrical information
competition which averts fair competition. The next section begins to further
explore guanxi operations but from the individual level and the organizational
level.
4.2 The Functions of Guanxi
Using guanxi to improve business is an open secret existing in China’s
pharmaceutical industry. People working in the sector do not need to talk about
this issue. Indeed, the interviewees were not interested in talking about detailed
approaches which are utilized when they improve business activities. This is
because there are no standard patterns to refer to either. The process and
orientation of using guanxi is based on the significance and the objective of the
task or interaction ( Zhuang, 2012; and see Figure 2.3).
From the literature it was apparent that different approaches (See Appendix 8)
could be used to build guanxi, and to develop and use it during strategy
formulation and implementation (See Appendix 8, Figure A8.1 ). The
interviewees provided several patterns for developing and using guanxi at the
individual level and the organizational level (See Appendix 21, Figure A21.1 and
Figure A21.2).
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Undoubtedly, guanxi was found to be like an information collector or bridge to
support all stages of SMPCs’ strategy formulation, implementation and
adjustment. As literature also showed, “Guanxi acts the roles of both the catalyst
and the buffer” (Wong, 2007, p. 258); In this context, guanxi acted as an internal
and external factor to facilitate business integrated success and interviewees’
understanding and the terms used to describe guanxi’s functions are summarized
in Figure 4. 1.
Figure 4.1 The Functions of Guanxi in Strategy Formulation and
Implementation
Notably, eight of the interviewees mentioned that guanxi acted as an information
collector (only the factory director of Company B did not). The decision makers,
including the two CEOs and two sales directors, conveyed a deeper
understanding of guanxi’s functions during their efforts at strategy formulation
and implementation. The analysis found that they utilized guanxi to collect
important information about government policy so that their company strategy
could conform with policy trends and thus, align their strategic direction too.
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Guanxi, then, enables information collection to help decision makers formulate
strategy. The sales director of Company B offers one typical illustration when he
said:
Sometimes, the competition is information competition. So I think guanxi is like the
information collector. This function goes through strategy formulation and
implementation. For example, regarding NBMIL and NEDL, we need to know those
information. How long will the state adjust the policies? What are the basic
requirements? In what time the national policy will be implemented? What time
provincial supplementary drug lists will be formulated? If I knew that information early,
I shall prepare early.
The detailed analysis of the accounts of all the senior managers, including the
sales director of Company B and the marketing director of Company A,
highlighted that they all have the same broad principles, patterns and process to
build guanxi with government and to achieve their goal (See Figure 4.2).
Figure 4.2 The Functions of Guanxi with Government
Crucially and conceptually, building guanxi at organizational level with
government is based on individual-level operations. This will be explored in the
next section. Given the structure of the government administration system in
China (See Figure 2.6), SMPCs need to build different guanxi with central,
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provincial and local governments. It was stated as impossible for them to obtain
all the information and detailed policies in time given the available resources. Yet
the interviewees tried to collect useful information or details to support their
decision making by building relationships and hence, building guanxi, and then,
to work out if alternative plans were needed to remain competitive.
Although guanxi is not the determining factor in strategy formulation, it was
important in seeking out and obtaining local government policy support to
facilitate SMPCs’ formulation, and to do so fast. The government imposes
various policies at central and regional level to facilitate and support SMEs’
development (Hadiyati, 2015). Undoubtedly, obtaining local policy support was
important for SMPCs, and both of the two case companies worked hard to build
good relationships with local government. One way to do so was to attend more
professional governmental conferences and decision-making forums – to
network.
An analysis and discussion of the different functions of guanxi in strategy
formulation and implementation is essential to compare them together so as to
build on the next section’s analyses and discussion.
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4.3 Guanxi Operations
In this section, guanxi operations at individual and organizational level will be
explained by practitioners.
4.3.1 The Interrelationship of Individual Guanxi and Organizational Guanxi
The conduct of business between organizations is actually run by individuals at a
personal level (see Figure 4.3). In China’s pharmaceutical market, existing
competition is intensive. The analysis here confirms that an individual’s personal
guanxi, especially in relation to the sales department is seen to assist
organizational performance (Yen, Wang and Kao, 2015). Indeed, individual
guanxi and organizational guanxi mutually promote each other, where personal
guanxi improves career development (Li and Wright, 2000) and is said to
facilitate the company’s performance too. Two interviewees, the sales director of
Company B and the marketing director of Company A, firmly believed that
individual guanxi could improve company business and their careers. For
example, the marketing director of Company A said:
If you are a professional manager in a company, you can achieve your personal value and
development in the company via your personal guanxi and network. You can also
enhance your personal guanxi with the company’s platform and guanxi. Company is a
big platform. These two guanxis interact with each other.
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Figure 4.3 The Interrelationships between Guanxi and the Individual and
the Organization
The CEO of Company A also mentioned the dual nature of guanxi in relation to
the organizational level. He described the positive side of guanxi which
facilitated achieving their strategy goal, very much like the functions of a
“lubricant”. Regarding the negative side, he referred to a “small circle” (Luo and
Cheng, 2015) to describe the inter-employee guanxi inside the company. In his
words:
Besides and more importantly, guanxi is a means to achieve your goal. If you use it well,
it can serve you and help you develop. Use all kinds of resources, reach consensus
during the course of communication, with guanxi you can reduce cost during strategy
implementation just like a lubricant, you can reduce cost and improve the effectiveness
of communication and implementation. Regarding internal organization, sometimes,
people in “small circle” breaks the company’s rule due to the different levels of
closeness. This kind of guanxi often hinders the development of the company.
So this complex interrelationship can be seen in this description.The next
sub-section considers the nature of guanxi at organizational level.
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4.3.2 Guanxi at Organizational Level
Regarding organizational guanxi, Yen, Wang and Kao (2015, p. 10) suggested
three types of firms’ guanxi: external, inter-organizational, and
intra-organizational. (See Figure 2.4). Again, two senior interviewees, the
marketing director of Company A and the sales director of Company B,
categorized organizational guanxi as two types: intra guanxi and external guanxi
(Figure 4.4). While aspects of the analysis here differs from the accounts by Yen,
Wang and Kao (2015, p. 10), the main elements remain the same. The
intra-organizational guanxi is related to employee–employee gaunxi. The
external guanxi is related to government officials. The marketing director of
Company A offers us a typical illustration of the ways they recounted this
element:
For company, it is still two kinds, external and internal guanxi. External guanxi means
more about relationship with government. As a matter of fact, external guanxi also
include commercial relations. It is also very important. Our upstream is raw material
company, downstream are mainly medicine logistics companies and medicine
distributors/agents.
Figure 4.4 Types of Organizational Guanxi in Practice
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The author has combined Figure 2.4 and Figure 4.4 as one graphic to compare
their particular differences (See Figure 4.5). The difference between Figure 2.4
and Figure 4.4 is the implications of external guanxi. External guanxi in the
literature and given the research here, indicates that government officials are
from a hierarchical political system and a medical regulatory system (See Figure
2.6). As this research found that external guanxi also means commercial relations
such as suppliers, producers and customers (See Figure 4.4). The common point
is external guanxi which links government relations. The difference is that
practitioners categorize inter-organization as external guanxi. This principle of
classification is more like Fei’s differentiation theory (2008).
Figure 4.5 Comparison of Types of Organizational Guanxi
Source: Left: Yen, Wang and Kao, 2015, p. 10; Right: from the interviewees’
views
All interviewees mentioned the benefits of building guanxi with government at
the organizational level. No interviewees mentioned supervisor–subordinate
guanxi in the intra-organization relationships. Given that all the interviewees had
been working for their company on average for 10 years and were all senior
managers in their company, the team was arguably stable. In the follow-up
interviews, only one interviewee, the CEO of Company A, mentioned the
existence of this phenomenon in terms of a “small circle” in the
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intra-organization. He also pointed out if intra-organizational guanxi has no spirit
of commitment it brings damage to the company.
Inter-organizational guanxi is directed at commercial relationships and as shown
in Figure 4.4, two interviewees – sales director of Company B and marketing
director of Company A – described inter-organizational guanxi as external guanxi.
This was mainly in relation to guanxi with upstream and downstream customers.
In China’s pharmaceutical industry, the industrial chain runs from raw material
suppliers, medicine producers, medicine distributors/logistics companies, to
medical organizations. Five interviewees, two in Company A and three in
Company B, emphasized that SMPCs must build good relationships with
medicine distributors/agents. Because China’s pharmaceutical market potential is
huge, while SMPCs lack capital, channels, human resources, and opportunities to
build, develop and maintain guanxi directly with public hospitals, they need the
help of local distributors. Local distributors were seen to have strong guanxi with
local public hospitals. The CEO, sales director and manager of Company B
considered that collaborating with professional local distributors enhanced
company performance. The sales manager of Company B also indicated:
Our business strategy is an agency system. Because competitiveness is stringent. From a
business perspective, cooperation with local distributors can reduce management cost
and coverage market fast. At the same time, sales performance in public hospitals is
going up promptly. If we build our own sales team to improve sales, it is really hard to
do. And local distributors have good guanxi at local market. They do better than us.
Furthermore, Company A had adapted their own sales team to improve business,
in view of the intensive competition: a team who primarily focused on seeking
for distributors was built. This will be explored further in Section 4.6.2. The sales
director and manager of Company A also emphasized the importance of
distributors. The sales manager of Company A said that:
Our products are generic chemical drugs. This market is so competitive. Therefore,
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finding a good local distributor is very important. Local distributors have good
relationship with local public hospitals. Distributors’ performance is going fast than our
own teams.
Two interviewees, the CEO of Company A and the sales director of Company B,
mentioned that inter-organizational guanxi also manifests itself in
inter-organizational alliances. They suggested this kind of alliance is normally
organized by individuals, or by a company, or by industrial associations. All
members in the alliances act on behalf of their organizations. The intention of
alliances is to collect and share governmental or commercial information and
then seek collaboration opportunities.
The next section connects the influence of guanxi on government policy
formulation and implementation. And then the underlying causal mechanisms of
guanxi will be explored.
4.4 Guanxi and Government Policies
As discussed above, contributions and benefits arose from the interviewees
building good guanxi with government. In this national and cultural context, and
for these two companies, the analysis suggests that the real force which can
influence Porter’s (2008) five forces is government policy. Porter did not declare
government policy as a “sixth force” and it was deemed to be neutral. In this
section, the focus is on analysing the roles and functions of guanxi during
government policy formulation and implementation and its underlying causal
mechanisms.
4.4.1 Guanxi and Policy Formulation
Two sales directors emphasized that China’s government has “powerful controls”
(Berger and Herstein, 2014). The sales director of Company A said:
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Chinese government has powerful controls, under this system, government policies
strongly impact on our business. If you do not obey, you are out. This is primitive.
All interviewees considered that government policy was a significant force in
China and this counters Porter’s neutral stance. Relatedly, how can guanxi
influence policy formulation? Existing literature (Gao and Tian, 2006; Woodbine
and Scully, 2012; Chen, Chen and Huang, 2013) (see Section 2.5) has shown
guanxi’s negative effect on China’s political system with the cause being an
imperfect political system (Ren, 2014). Wei and Luo (2013, p. 9-11) state that
China is going through the process of a transformational stage and during this
period, power and guanxi is the decisive social norm in China (Zhao and Timothy,
2014). Indeed, “guanxi is often employed as a tool for economic or political
gains” (Zhuang, 2012, p. 23). Unavoidably, interest groups (Wang and Ap, 2013)
are growing and seemingly influencing public policy formulation too. Wang and
Ap (2013, p. 224) define an interest group as “any association or organization
which makes a claim on government so as to influence public policy without
itself being willing to exercise the formal powers of government”. For this thesis,
interest groups are like guanxi-givers who have power and strength to influence
government’s official attitude and decision making.
Any type of inter-personal relationship in official circles, such as guanxi of
leaders and secretaries, officials and business people, family members and
heterosexual relationships can benefit personal interests. Success is a set of
building blocks with pluralistic guanxi. This spreads through the central
government and then local government and results in a deterioration of the local
political environment. Interest groups utilize a variety of legal or illegal ways to
present their requirements and political intentions. In China, those organizations
that have advantages of resource, professional knowledge and guanxi have an
influence on policy formulation and implementation. Both CEOs noted the
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interrelationship between guanxi and policy. The CEO of Company A, for
example, indicated:
China’s economy changed from planned economy to market economy. The market
keeps upgrading and updating. It is not fully a free competitive market. Thus, policy
influence is strong. Because government controls most of resources in China it
influences SMPCs’ development.
The CEO of Company B said:
Sometimes, guanxi does influence policy making. Because this is game of interest
groups. An interest group has a speaker. If one side wins, they may have guanxi.
Sometimes, China’s society is not entirely rule of law. Guanxi and policy are
inseparable like twins. They supplement and benefit each other.
The CEO of Company B expressed the interrelationship between policy and
guanxi as being like inseparable twins and that guanxi could play a crucial role
on the political stage. Two interviewees, the CEO of Company B and the
marketing director of Company A, mentioned the Zheng Xiaoyu case (BBC,
2007). They considered that these events reflected that guanxi influenced
national policies including pharmaceutical entry, drugs approval, medicine
registration and production. At that stage, the State Food and Drug
Administration approved a number of generic drugs including chemical drugs
and TCMs. Over-production, low technology, and intensive competition are the
existing competitive environment (BMI, 2014). The events have been influencing
SMPCs’ market competition (Wang, 2007, p. 2). After the events, the national
government enhances functions and improves the administrations of national
agencies and advanced drugs production standards such as New GMP, drugs
registration approval and national essential medical insurance lists (NEMIL). The
sales manager of Company A described the changes which the new director of
China Food and Drug Administration (CFDA) had formulated in the NEMIL.
She said that:
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The director, Chen Zhu, is an expert. When he was formulating the first edition NEMIL,
he checked the international definition, scope and list of essential drugs based on the
evidences of European countries, Japan and Korea. At the same time, he did market
research too.
After the case of Zheng Xiaoyu, the interviewee’s explanation reflected that the
national government reinforced medical administration management and
reformed the structure (Yu, 2007). Given this strict national government policy
environment and intensive competition, how can guanxi be used to achieve
strategic goals for SMPCs? What is the causal mechanism by which guanxi
influences medical insurance lists?
Except for the research & development (R&D) director of Company A and the
factory director of Company B, the interviewees considered that guanxi is in
close relation to the national and provincial basic medical insurance list and
essential drugs lists. Those seven interviewees strongly emphasized the
significance of the two medical insurance schemes regarding company strategy.
Two CEOs pointed out that having products listed on one or both of the two
insurance schemes is strategic direction. CEO of Company B said:
If your products are not listed on the medical insurance schemes, and you make them as
key product to improve. This is not realistic and you need to be adjust your strategy.
Two sales directors and two sales managers emphasized the significance of the
two medical insurance schemes in relation to market coverage (Wang and Li,
2013) (and see Appendices 12, 13 and 14). The sales manager of Company B
described:
I think it is very important that your product must be listed in the two medical insurance
schemes. If yes, because the reimbursed rated is high, patients are acceptable; patients
can be reimbursed, doctors are willing to prescribe your product; because doctors are
acceptable for the products, therefore, it is easier to improve product at public hospitals,
and then distributors are willing be local agents. In the end, medicine producers’ sales
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are going up.
According to the four interviewees’ opinion, those factors cause SMPCs to be
involved in finding a way to get products listed on the two medical insurance
schemes. In 2009, two medical insurance lists at national level were issued. The
national list required all primary medical organizations use the drugs listed in the
NEDL. At the same time, provincial governments issued supplementary lists
based on the local economy and incidence of a disease. Figures A13.1 and A14.1
(Appendices 13 and 14) show how the differentiation in the amount of
supplementary drugs of the different provinces. At the same time, government
administrative agencies are different. The National Health and Family Planning
Commission (NHFPC) formulated NEDL, and the Ministry of Human Resources
and Social Security (MNRSS) reimbursed drugs. The two government agencies
adopted different models to filter, price, use and reimburse drugs. Moreover,
conflicting interest result in divergences in allocations which were formulated at
different interested party (Wang and Li, 2013, p. 905). The sales manager of
Company B explained why SMPCs are involved in improving the products in the
local supplementary essential drugs lists. He said that:
The State government will adjust the NBMIL and NEDL once every five years. I
consider this is opportunity to a drug producer. Therefore, if drug producer develops
one product that has been listed over 14 provincial level BMIL or EDL, that means this
product will be listed in the national level lists when the NBMIL and NEDL are
adjusted.
According to the sales manager of Company B, this regulatory system of
formulating medical insurance provides rent-seeking opportunity for guanxi at
provincial level (NFZM newspaper, 2014). Four interviewees, two sales directors
and two sales managers, considered guanxi influences local policies. The sales
director of Company B gave the example of Wu Xinming, former section chief of
Guangdong Health and Family Planning Commission (HFPC), who was accused
of bribe taking and dereliction of duty for formulating Guangdong provincial
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supplemented essential drug list in 2014 (Zhou, 2014). This event also related to
three medicine agents. As shown in Figure A13.1 (Appendix 13), 29 provincial
supplemented essential drug lists were issued from 2009 to 2011. Moreover,
those provincial supplementary lists of Jiangxi, Qinghai, Sichuan, and Guizhou
have been included in provincial basic medical insurance list. The scope of
reimbursement in those provinces has been explored (Wang and Li, 2013).
Regarding this phenomenon, national government issued a directive to restrict
provincial governments from supplementing drugs at provincial level in 2014
(Zhou, 2014). It shows provincial governments failed in central government
policy implementation (BMI, 2014) and that government policy formulation at
provincial level was influenced by guanxi.
4.4.2 Guanxi and Policy Implementation
Both the sales manager of Company A and the sales director of Company B also
provided examples to show how the national policy implementation was
insufficient. Both of them mentioned the event of “Anhui 1118 list”. The sales
manager said that:
Regarding the NEDL policy, Anhui government formulated independent drugs list based
on the local hospitals’ drugs utilization. This list included 1118 products which were
used and filtered in the local Great Class AAA hospitals.
The sales director further explained that:
If your product is listed in this “1118 list”, your product can be sold in this area. If not,
even though your products are listed on the NEDL, the sales coverage may not good.
For the interviewees local competition was extremely intensive and the
contradiction between national policy and provincial policy had a heavy
influence on SMPCs. Clearly, such local policy directly influenced sales in the
local market and the question was: How to enter this “1118 list”? This occupied
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them and according to all the interviewees, guanxi works and this was why the
local distributor was important for medicine producers. So, local government was
seen as having the power to formulate local policy, thereby influencing the local
market. Importantly, for these interviewees, local policy required a corresponding
shift in the ways they then implemented SMPCs strategy too. Based on this
phenomenon, the marketing director of Company A summarized:
Even the initial purpose of the State’s strategy is good, but during execution in
provinces and cities, the result of execution doesn’t always match with the initial
purpose due to different reasons. If we only consider policy and its execution, it relates
to many aspects. For example, one company in one place, this company contributes
local tax and employment. Therefore, this local company gains the supporting from
local government. It refers to local industrial problems. Even more it is related to
stability problems.
This summary by the marketing director points to another example of “regional
protectionism”. This was also mentioned by the sales director of Company A:
After formulation of national policies, national policy implementation manifests
problems. Actually, regional protectionism emerges recent years. This is big problem, I
think. What do the regional protectionism show? On the one hand, local companies
attend local DCBP, they obtain preferential policy to win local DCBP. On the other
hand, for example, Chongqing government required local hospitals used the drugs that
are produced by local SMPCs. This requirement benefits local companies, because they
have good local guanxi with local government.
Regarding the influence of contradictory government policy, two interviewees,
the CEO and the sales director of Company A, both explained the causes. The
public hospitals are state owned but government’s compensation is insufficient.
Thus, the model of supporting hospitals through the sale of drugs is the current
popular means of survival for hospitals. Under this medical policy system, public
hospitals operate under a non-profitability policy but they follow a profitability
model. Market behaviour in public hospitals where they can sell drugs for profits
crucially gives guanxi an important role in local hospitals. Then, naturally,
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China’s prescription drugs market is irregular. On the other hand, if policy
implementation is not stringent enough, market behaviour in hospitals is
distorted: for instance, the business model of prescriptions is based on
commission to doctors. This is an open secret in China. There is, then, limited
pharmaceutical industry policies of contradiction, non-standardization and slack
supervision, hence providing rent-seeking spaces for guanxi-givers and
guanxi-receivers. The CEO of Company A said:
As long as policy formulation and implementation were not genuinely open and
transparent, guanxi works. Policy implementation does not genuinely go marketization.
Regarding policy implementation, the penalty is weak to illegal behaviour as well as
supervision is insufficient.
Policies then, are uncertain and confused (Deng and Kaitin, 2004) and lacking in
systematization (Xing, 2006). For example, the implementation of policies of the
Drug Centralized Procurement Bidding (DCPB) has distinct conditions,
requirements, and criteria in different provinces. Given this context guanxi
flourishes and all must try and access and utilise it to survive.
4.4.3 Guanxi as an Underlying Causal Mechanism
Given the analysis of interviewees’ accounts in Sections 4.4.1 and 4.4.2, guanxi
was deemed to be interrelated to provincial government. Specifically, guanxi
influences government policy formulation at provincial level and plays important
functions during national policy implementation at local market. Guanxi is, then,
the underlying ‘causal mechanism’ shaping government policy formulation and
implementation. In this section, a connection back to the critical realist scheme is
made: looking at guanxi as a causal mechanism in the literature, then one aspect
is to conceptualise guanxi as one underlying determinant of behaviours (Li and
Cai, 2012). Thinking patterns are ways which may enable individual in private to
bypass regulations, and structures to achieve aims (Zhai, 2011, p. 153). Guanxi
as a ‘causal mechanism’ seems to provide an expedient and flexible way for
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individuals to achieve their aims. Looking at the interviewees, they referred to
events and empirical experience to begin to outline what guanxi does. Those
actual events had been exposed publicly.
The analysis of their accounts found that guanxi was indeed one influence on
policy making, and this is evident in the literature too, with both elements
summarized in the Table 4.2.
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Table 4.2 The Evidences of Causal Mechanisms of Guanxi and Government
Policy
Contents
Literature ● Pharmaceutical industry policies are lacking in
systematization and legal restraint ( Xing, 2006)
● The regulatory regime has been uncertain and confused
(Deng and Kaitin, 2004)
● Provincial governments often fail to enforce central
government directives (BMI, 2014, p.11)
● China’s political system is imperfect that cannot be
implemented well. (Ren, 2014)
Example events
referred to by the
interviewees
● The public case of Zheng xiaoyu (BBC, 2007)
● The public case of Liu Zhengqiu, Zhou Wangjun and Li
Caihua (Wangyu, 2004)
● Anhui government formulated “1118 list” restricting drugs
utilization at local market. (Quoted by sales manager of
Company A and sales director of Company B)
● Chongqing government required local hospitals to use the
drugs that are formulated by local drugs producers. (Quoted
by sales director of Company A)
Empirical
illustrations from
the accounts
● “From broad perspective, the state’s medical
administration system is not very standard yet.” (CEO of
Company A)
● “This system is still under the slow reform of the
separation of prescription and dispensing. The medical
treatment system is not open yet, and prescription and
dispense of medicine are not really separated yet, leading to
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the medical institution’s excessive power on prescription and
dispensing.” (CEO of Company A)
● “The problem now is the government intervenes too much.
Government intervenes in drug pricing and national health
insurance. The current medical administration system is not
official and fair competition. So guanxi kicks in.” (CEO of
Company B)
● “The current medical administration system is not well
built and has defects, but it is implemented for the good of
patients and people.” (Marketing director of Company A)
● Policy makers in medical administration system have no
criteria. The medical administrators have two different
medical backgrounds, i.e. the Western medical system and
TCMs, thus they may ignore one side to make policy that
benefits the other side. (Sales director of Company B)
Given the analysis, and set against the literature noted here, when the
interviewees pointed to the medical administration system, it was felt that
government policy lacked criteria for deficient conduct or unsound competition
and where a handful of interest groups were found to leverage guanxi to sway
policy making in their favour. The interest groups with guanxi worked to have
policies or regulations passed that were beneficial to them in the local market. In
the industry, any pharmaceutical company’s shareholders, consultants,
distributors and any person who makes deals with them could be together a small
interest group. The detailed analysis, then, suggests that there are three aspects
and nine factors, summarized in Figure 4.6 as the causal mechanisms of guanxi
in China’s pharmaceutical industry.
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Figure 4.6 The Factors: Guanxi Influences on Policy Formulation
As shown in Section 2.8, given the analysis, two new terms arose: guanxi-givers
and guanxi-receivers, with the latter being the two SMPCs. Guanxi-givers refer
to an official in government, a policy maker, an intermediary who links to
government and SMPCs. That is, an individual in a “small circle”, and an agent
who is acting on behalf of an interest group.
The next section explores the relationship between guanxi and strategy.
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4.5 Guanxi and Strategy
Sutherland (2014) suggested that organizations should create and preserve
barriers to restrict potential competitors involved in the industry, even though it
is hard to do this. Importantly too, Gao, Knight and Ballantyne (2012, p. 464-465)
added that “guanxi can be seen as an organizational strategy”, but, they did not
explore the influences of guanxi and strategy formulation and implementation.
This thesis begins to address the gap in linkages between guanxi and strategy. As
discussed in Sections 4.2 and 4.3.2, guanxi is important for organizational
strategy formulation and implementation. In the following sections, the author
presents the analysis of how the interviewees consider and use guanxi when
dealing with strategy formulation and implementation. It was noted that guanxi at
the individual and the organizational levels plays different functions in strategy
formulation and implementation. After analysing the data for these two medicine
producers, external guanxi, such as guanxi at the governmental level, is seen to
play an important role but is not the determining factor in strategy formulation.
Intra-organizational and inter-organizational guanxi are mainly in operation in
strategy implementation. This will be explored in this section. Based on the two
case studies, analysing and discussing the two companies’ strategy formulation
process first is important.
4.5.1 Strategy Formulation Process
The author has summarized the analysis of the strategy formulation process
based on the interviews (see Figure 4.7). Without doubt, SMPCs’ strategy
formulation is a dynamic process, where both strategy formulation and
implementation had to be adjusted following policies that were changing
constantly too. Whether considering chemical drugs or TCMs, all interviewees
felt that strategy formulation needed to be based on product-oriented rules. Six
interviewees, two CEOs, two sales directors and two sales managers, emphasized
that all product market characteristics depend on whether a product follows
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changing policy and satisfies market demands. Although SMPCs’ strategy
formulation is product-oriented, in choosing products it is still necessary to
consider existing competition. For example, the decision maker of company B
considers the existing competition, although he has guanxi such as professionals,
experts, distributors in a particular field of medicine. The CEO of Company B,
considered prioritizing that category of product. He indicated:
Strategic considerations must centre around market. And I will identify product
structure and system based on policy trends. Only by having good product structure can
you have good strategy. Therefore, guanxi is not determining factor when strategy
formulation for pharmaceutical producers. But guanxi is a catalytic agent and lubricant
to facilitate strategy implementation.
As the decision makers, the two CEOs confirmed that a product’s core
competitiveness is important. So what is a product with core competitiveness?
This will be explored in the next section 4.5.2.
SMPCs’ strategy formulation process is not as a linear process but like recursive
loops which, from a product-oriented base, constantly take into account existing
competition and changing policies, and hence keep adjusting to satisfy market
demands before going onto the next strategy implementation process (see Figure
4.7) . Thus dynamic strategy formulation and implementation is arguably carried
out and applied simultaneously (Wargin, 1995; Ramaseshan, Ishak and Kingshott,
2013, p. 1224-1225). The interviewees know that policies in China have been
changing fast. Thus they aim to adjust their strategy and operations in a timely
way. SMPCs’ strategy adjustment was product-based and as the sales director of
Company B mentioned,
Your strategy, your position, your operation and management shall be subject to the
reality and practical operational environment.
According to the CEO of Company B, dominating influences included particular
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policy and existing competition. Therefore, SMPCs’ strategy formulation and
implementation needed to be adjusted constantly, For example, we see here a
direct referral to the company’s position in the industry, operation model and
management system.
Figure 4.7 SMPCs’ Strategy Formulation Process
Crucially too, guanxi was considered an important factor in determining and
facilitating a strategic goals. With regard to the two medicine producers, guanxi
was ranked as a secondary factor in strategy formulation whereas guanxi’s
ranking was different for distributors. As the CEO of Company B elaborates:
Because of our position in the industrial chain, we have to invest considerable capital in
the permanent assets of production, Good Manufacturing Practice (GMP), product
R&D and registration, and market promotion. It is harder to utilize guanxi to build a
factory.
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The sales director of Company A added that medicine producer management is
based on a series of mechanisms of product technology, registration and
promotion. But for distributors and agents, guanxi was considered a core factor
in their business transactions.
From the analyses of the follow-up interviews, the decision makers, the two
CEOs, considered that the three factors of policy trends/opportunities, existing
competition, and product were all taken into account in strategy formulation.
Notably these two comparison case studies had the same principles of strategy
formulation. In sum, the two companies’ strategy is product-oriented and
adjusted to changing government policies. Different product categories such as
chemical medicine product lines and TCMs product lines had the same strategy
formulation principle. The existing competition was the second factor to guide
strategy decisions. These findings are common across multiple examples. Indeed,
it is one of the characteristics of China’s pharmaceutical industry. Although
China’s pharmaceutical market has huge potential, it is highly intensive. Because
of high technology, high investment and high risks, the SMPCs will be unlikely
to find a “blue ocean” market - that is, an “untapped market space, demand
creation, and the opportunity for highly profitable growth” (Kim and Mauborgne,
2005, p. 4) in China. Indeed, in this context, both government policy and guanxi
were additional key ‘forces’ that these interviewees had to take account of.
4.5.2 Product-oriented Strategy
SMPCs do, of course, try to find ways to change the competitive situation. Porter
(2004) suggested that if pharmaceutical companies use innovative products their
strategic positioning constitutes a barrier force to block competitors from
entering the market. Licensing and regulatory constraints also need to be taken
into account for decision-makers in the pharmaceutical industry. So when the
five forces are intensive, SMEs are facing a harsher environment, where firms
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may utilize product innovation to change business operations (Hernandez and
Delgado, 2009). Leitner (2014, p. 356) argues that dynamic strategy formulation
is formed on implementation in the light of product innovation and market
development. That is an ongoing process which the accounts of the senior
managers support. However, the two CEOs also described the interrelations
between guanxi and product relationship. In the words of the CEO of Company
B:
In China, if a medicine producer has a patented product with high quality and
uniqueness, you may use less guanxi force to improve your business. In my opinion, a
good product should match conditions of current government policies. Policy is
changing fast. We should capitalize on every guanxi we get to improve our business.
The CEO of Company A adds:
Eventually, strategic manifestation will be implemented through product. Of course, a
product with core competitiveness has close relationship with guanxi. The process of
guanxi influencing and product is to build and accumulate guanxi.
Technology changes industry structure and the competitive environment.
Technology as a potential powerful tool (Burgelman, Christensen and
Wheelwright, 2009) is improved to deliver cost leadership and differentiation
(Hua and Lu, 2013). Here, the two sales directors suggested that SMPCs
facilitate product technology to meet the demands of customers or market trends
and make price differentiation in the market place better than in other companies.
Differentiation in drug pricing strategy had been utilized by them from
innovation in drug dosage to the formulation of bidding rules in China’s
pharmaceutical industry. Producers create or change drug formulation or dosage
to create differentiation and SMPCs or their agencies have developed so-called
new drugs.
Here, the sales director of Company A said that their competitor, Company XXX,
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changed the form of medicine by adding an injection device to anti-cancer
chemical drugs; the sales director of Company B also mentioned how their rivals
changed the form of their products, for example, TCMs tablets were reformulated
as granules; both actions created “new” drugs so as to have a legitimate reason to
“command a price premium” (Banker, Mashruwala and Tripathy, 2014, p. 873)
and differentiate the pricing of drugs’ bidding prices. The chemical injection drug
with the infusion set can obtain a higher biding price than the chemical injection
drug alone. Certainly, this kind of product innovation cannot be sustained for a
long time. But for domestic companies and medicine agencies, this brings a
short-term interest in the local market. This phenomenon reflects how
competitors react fast to adjust product strategy based on DCBP policy and
existing competition intensity. At the same time, guanxi is used to differentiate
DCBP price so as to gain competitive advantage.
Company A had two categories of products: anti-cancer medicines and
over-the-counter medicines (OTC). Due to overlap production and DCBP policy,
the market of anti-cancer chemical chemotherapy drugs is very competitive. And
guanxi works for this competitive market. All drugs made by Company A are
medicines for a standard chemotherapy regimen and are listed in the medical
insurance schemes. Although, theoretically, Company A could share the potential
market, there are existing competitors fighting for the same market. Therefore,
the big policy threats for Company A is DCBP policy. DCBP directly influence
Company A’s product bidding price and profits. Because of this situation,
Company A insists on R&D for chemical generic first serial drugs. Based on the
DCBP policy, generic first serial drugs can gain a high bidding price during
DCBP policy. In this situation, both the sales director and the marketing director
of Company A mentioned the importance of developing the generic first serial
drugs.
In the 2000s, in the local minority culture and geographical environment, central
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government allowed and supported the Guizhou government to have the
independent right to formulate localized national policies that had been
supporting local SMPCs’ development. The Guizhou government worked to
develop and support the local TCM economy. Company B and many other
SMPCs gained opportunities and advantages to develop. Company B had been
improving its products line based on minority TCMs. This product-oriented
strategy had been improving for three years so that Company B perfected the
structure and lines of gynaecological products. This products line and structure
provided a focus for Company B.
In the discussion of the two companies’ strategy evolution, every interviewee
emphasized the significance of R&D in strategy formulation. The introduction of
China Food and Drug and Administration (CFDA) has slowed down the process
of examining and approving new drugs recently. As a result, new drugs have
become a scarce resource for drugs producers. In the end, it has been hard to
reach the goal of product innovation for the two companies. Company A focuses
on R&D generic first serial drugs; their big competitors are the international
giants. When the patent on globally patented drugs expires, producers of patented
drugs have been preparing various measures to limit local domestic companies
entering the market. The policy of new drugs registration is more stringent than
before. For a long time, higher capital and risks have blocked and depressed local
SMPCs’ motivation for innovation. Further, there is strong resistance from
foreign companies towards the local companies.
The CEO of Company B interpreted the reasons for the present situation of
R&D:
In the pharmaceutical industry, most products are facing competition due to product
homogeneity. For SMEs, it will take a very long time for registration, approval and
marketing. Risk is very high and investment is too much. Why few companies invest in
these is maybe because they don’t have capability, finance and enough resources.
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Importantly, building guanxi with government was seen to provide effective
protection that would enhance technology capabilities so as to improve
performance. These twin forces of policy threshold and guanxi were deemed,
then, to have enhanced their competitiveness. So how do guanxi and government
policy enhance a product with core competitiveness? The next section explores
this from the practitioners’ viewpoint. How products will be improved to become
products with core competitiveness will be discussed in next section.
4.5.3 Guanxi and Products with Core Competitiveness
In considering drugs as a special product, as well as the characteristics of high
quality and effectiveness, the analysis highlights that for medicine producers a
product’s core competitiveness relates to guanxi. Importantly, SMPCs utilized
guanxi to obtain prioritized policy direction and early action to push for the
products to be listed in the insurance scheme. In other instances, they used
guanxi to differentiate the products to the independent tendering bidding
regulation so as to obtain a higher price. Those subsidiary advantages enhanced a
product’s competitiveness in the market.
More generally too, in the Chinese prescription market, public hospitals share the
main pharmaceutical market. In considering the kinds of products that are more
acceptable to hospitals, further information came from the follow-up interviews.
The four interviewees chosen for the follow-up interview were key decision
makers who implemented company strategy and operations. They have rich
experience in developing their business for more than 10 years in China’s
pharmaceutical industry and analyses of their accounts showed that products with
core competitiveness include one or more characteristics including high quality,
effectiveness, reputation of medical doctors and patients, new R&D drugs,
patented drugs, unique, cutting-edge technology: these were more likely to be
listed by medical insurance and higher tendering bidding price (See Figure 4.8).
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Figure 4.8 Prescription Drugs with Core Competitiveness
The marketing director of Company A summarized the characteristics of a
product with core competitiveness:
I think the product with core competitive advantage should have the following
characteristics: big enough market, leading technique, broad application and few
competitors. And, as for guanxi, you should also consider questions such as whether
your products are included in National Basic Medical Insurance List or National
Essential Drugs List, is it an item with charge, is it exclusive.
As noted earlier, NBMIL and NEDL are very important policies that directly
influence product market sales and share rate (further information can be found
in Appendices 12 and 13). In practice, if a product appears on any provincial lists
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of NEDL, a potential market can be explored. Thus, products listed on the two
medical insurance schemes offer core competitiveness for SMPCs.
The CEO of Company B emphasized the importance of the two insurance
schemes, and that, if a product cannot be listed on those two insurance schemes,
company strategy needs to be adjusted. He said:
For example, if your products are not listed on the national basic medical insurance list,
and you promote them as main products, this is not realistic. Since the products are not
national medical insurance products yet, you should adjust your strategy.
The sales manager of Company B elucidated the big differences in whether
products can be listed on the National Essential Drugs List or not:
Even though your product is unique, if it is not on the insurance list and essential drug
list (NBMIL & NEDL), it is harder to sell in hospitals. Doctors are not willing to
prescribe to patients, and patients are unaware of your products. Or even if you promote
your products to hospitals, the sales rate is very low. For example, there is one product
named XXX in the same class III hospitals of Zhengjiang province, if it is not on the
essential drug list, the sales is about 500 units per month, but it’s sales are increasing
fast when listed on the essential drug list; it is about 8,000 units per month. It is an
obvious change.
From the analysis of the interviewees’ quotations, the author learns that if a
product is listed on the two medical insurance schemes it has strong core
competitiveness. It means it is possible to share a huge potential market. Bach
and Allen (2010, p. 41) state that “sustained competitive advantage arises from
tackling social, political and environmental issues as part of a corporate strategy
– not just pursuing business as usual”. Crucially, just how is this condition to be
achieved? As the sales director of Company B indicated:
There are individuals or third party/consulting companies that may use guanxi or
channels to improve the chance of your product being listed in the medical insurance
schemes. Because this process is very complicated. Of course, the product must be
matched to the requirements issued by government.
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Hence, social and political advantages enhance product competitiveness and in
this context, in light of the Figure 4.8, a visual depiction of this analysis of
characteristics, guanxi sits close to the centre and this is like a centrigugal force.
Having drugs with core competitiveness relates to policy making and
implementation. A product needs to have the advantages of being listed in the
medical insurance schemes and obtaining a good tendering bidding price, and in
the background or rather, as an ostensibly hidden ‘causal mechanism’ lies guanxi.
This notion of it being a ‘causal mechanism’ can be consistently inferred from
such accounts.
The next section now turns to a summary of the findings and the nature of the
contribution to Porter’s five forces scheme.
4.6 The Interactive Influence of Guanxi and Government Policy on the Five
Forces Model
As discussed in Section 4.4.1, government policy is an important‘force’ in the
pharmaceutical industry in China. Crucially too, guanxi is an underlying cause
mechanism which is deemed to influence government policy at provincial level.
Guanxi and government policy interact in complex ways to influence the other
five forces. In China’s pharmaceutical context, this addition to Porter’s Five
Forces model is critical as the research reported here has begun to empirically
highlight. This section further explores how guanxi and government policy
interact to influence the five forces.
4.6.1 The Interactive Influence of Guanxi and Government Policy on
Existing Competitions
Porter (2008) explains that a number of rivals having equal company size
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determine industrial intensity and profitability. Yu (2011) states that China’s
pharmaceutical companies are small scale and over-producing low-technology
products. Two illustrative quotations provide a sense of China’s pharmaceutical
market characteristics: “China’s prescription market is irregular market” (CEO of
Company A) and “Chinese pharmaceutical market is main homogeneous market”
(CEO of Company B). This industrial configuration determines that China’s
pharmaceutical market is one of fierce rivalry. SMPC competitors “converge to
compete” (Porter, 2008) in the homogeneous market. As discussed in Section
4.5.2, strategy formulation was based on product-oriented strategy, therefore,
having patented, unique, innovative and high-technology products provides
advantages against competing rivals as expected. However, the role of two other
‘forces’ and this section will highlight why guanxi is important to existing
product competition.
In the two case studies, seven interviewees (the exceptions were the factory
director of Company B and R&D director of Company A) emphasized that
strategy formulation is product-oriented and existing competition is based on
product competitions also. At the same time, the two companies and their
partners (e.g. distributors or agents) used guanxi to improve business in the
market and hence, guanxi also plays an important function during strategy
implementation. In summary, and given the analysis of the interviewees’
accounts, guanxi was found to foster a good environment or develop competitive
advantage over rivals in certain markets. It is interesting, though, that the CEO of
Company B had a slightly different view from Company ACEO on this:
When products are homogeneous, especially all are products in national health insurance
list, i.e., Product X and Product Y, the hospital face same medicine and effect, which
one will they choose? It will depend on their guanxi. For instance, what kind of product
to be listed in national health insurance list? Listed or not listed, that’s a fundamental
difference! How to compete? Use guanxi!”
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According to Company B’s CEO, the interrelationship between the product with
core competitiveness and guanxi can be based on different product properties and
the competitive context (See Figure 4.9). When there is competition between
different brands of products that all have core competitiveness, one side wins by
having prioritized guanxi. When competition is between different brands of
homogeneous products, guanxi played the role of a primary competitive power.
When the competition is between a product with core competitiveness and a
homogeneous product, guanxi was less frequently utilized by the side having the
product with core competitiveness. For the side having the homogeneous product,
guanxi was deemed to be more frequently utilized. Further, both companies have
product competitiveness, they could also more easily cooperate with local
distributors who have local guanxi. Local distributors, who had a competitive
advantage, strength and guanxi, were actively contacted and negotiated with
these two SMPCs to be their local agents. In this case, the two companies have a
product with core competitiveness that gives bargaining power to distributors. In
contrast, if a product lacks those subsidiary conditions, local distributors will
provide the bargaining power for producers.
Figure 4.9 The Influences of Guanxi on Product Competition
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From the detailed analysis of the interviewees’ accounts concerning product
competition of guanxi, and given the literature review, the strength of guanxi has
emerged as a important consideration. Based on the competitive status that
competitors have built and maintained, they use “strong and right guanxi”
(Yeung and Tung, 1996, p. 61) with the same customers. The two sales directors
highlighted this phenomenon when they were competing with rivals. As one sales
director said:
For instance, two or three medicine producers have the same category of products that
are treating the same disease, and face the same public hospitals, normally Class III
hospitals. At the same time, all of them have products with core competitiveness. In this
highly competitive state, the one with prioritized guanxi wins.
Yeung and Tung (1996) identified three grades – strong, moderate and weak – to
estimate the strength of guanxi. Although they proposed the notion of strength of
guanxi, they did not explore it. To date, there is still little research into
distinguishing and estimating the strength of guanxi. The interviewees in the
research reported here frequently mentioned market intensity and application of
guanxi, especially, when facing the same competitive status, they emphasized
that strong guanxi offered more competitive advantage.
Regarding rivalry among existing competitors (Porter, 2008), price cuts are often
adopted by rivals. In China’s prescription market, drugs price cuts are formulated
under DCBP policy, again, influenced by government policy. This is different
from other industries. DCBP policy directly or indirectly influences other four
forces of suppliers, buyers, entrants, and substitutes. The next sections will
explore this further.
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4.6.2 The Interactive Influence of Guanxi and Government Policy on
Suppliers and Buyers
As discussed in Section 2.2.2, the relationship between suppliers and buyers is a
basic transactional one. For China’s pharmaceutical industry context, it is
important to first identify the roles of suppliers and buyers and the structure of
prescription drugs distribution system (See Appendix 10). As shown in Figure
A10.1 (Appendix 10), suppliers are medicine producers who are up-stream in the
industry. Medicine producers have three types of buyers: medicine logistics
companies, distributors and agents to distribute products in the hospitals (See
Figure 4.10). Due to the enormous size and spread of China’s market, the
medicine logistic companies help producers in conveying drugs to end-users. In
this thesis, and given the two case companies, the focus is on medicine
distributors/agents and public hospitals who play important roles and influences
in relation to suppliers – the next connection in the ‘chain’. The section begins
with noting the influences of two types of buyers.
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Figure 4.10 The Process of Medicine Delivery
“Pharmaceutical companies that offer patented drugs with distinctive medical
benefits have more power over hospitals … drug companies offering me-too
generic products” (Porter, 2008, p. 14). Based on Porter’s explanation, producers
command higher prices because of offering patented drugs to hospitals. Porter
only mentions the patented product which heightens producers’ bargaining power
and ignores guanxi and government policy given his dominant cultural context.
In this thesis, guanxi and government policy have been shown to interact in
complex and often hidden way to enhance suppliers’ power (See Section 4.5.3).
Producers with products with core competitiveness have bargaining power with
buyers of distributors/agents and as the sales director of Company B said:
If your product has core competitiveness, it is easier to seek local distributors/agents with
strength. This reduces promotion costs. At the same time, the product with core
competitiveness has competitive strength to formulate higher price during DCBP.
Whether distributors or agents, the main target is to promote the suppliers’
products to be sold in public hospitals. Those distributors/agents have
professional sales teams to contact hospitals. As shown in Section 4.3.2, building
good external guanxi with distributors/agents is important for drugs producers.
Five interviewees, two in Company A and three interviewees in Company B,
emphasized their distribution strategy where handling different sorts of guanxi
well directly influenced the organizational performance: further guanxi
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marketing was seen as the groundwork of firms’ survival and development (Han
and Li, 2013, p. 33). Against this cultural background, while business people are
good at building good relationships with their targets, guanxi is unique.
For the two case study companies, the analysis found that building a good
relationship with distributors/agents was their main business model. The sales
manager of Company A accounted:
When starting the business, we built its own professional team for marketing; but the
competition is more and more intensive. We are under higher competitive pressure.
Therefore, we have had to build an independent distributor system to supplement
marketing where its own professional teams have no guanxi and competitiveness.
And the senior managers including CEO, sales director and sales manager of
Company B knew guanxi’s significance in the market based on its product
system. Thus, they actively formulated a strategy that distributors must have
good guanxi in the local market as a main business model at both the business
starting stage and the development stage.
Being highly active and seeking forms of effective guanxi, not only in different
government departments but also in hospital departments, in the local market was
deemed to have facilitated these two SMPCs’ business performance. Clearly
guanxi exists in the whole pharmaceutical industry chain and although
interviewees had different definitions about guanxi, all of them displayed
remarkable uniformity of attitudes and beliefs in guanxi as an important force to
facilitate business performances, especially, building good guanxi with public
hospitals.
At the same time, given their accounts of guanxi and products with core
competitiveness, all interviewees considered that guanxi played a very important
role in the competition of public hospitals. This segment is the important terminal
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for strategy implementation. Therefore, it was essential here to elaborate the
characteristics of public hospitals and the process of accessing drugs in hospitals.
Together, a deeper understanding of the functions of guanxi in the fiercely
competitive market place becomes possible.
On the one hand, based on the existing medical administration system, as shown
in Figure A10.1 (See Appendix 10), the biggest buyers are public hospitals.
Public hospitals play the double roles of the stated-owned with non-profit
institutions as well as the biggest medicine sellers (Jiang, Lv and Zhao, 2014).
On the other hand, the institutional reform and management system of public
hospitals are critical (Ming and Su, 2011). Up to now, the State is trying to find a
suitable plan to improve this situation. And this situation cannot be changed in
the short term. However, public hospitals still have a dominant role in China’s
pharmaceutical industry. Whatever their different product properties, the two
SMPCs’ strategy implementation was still deemed to be the way to identify and
maintain guanxi with local distributors and gain a good reputation with the
doctors. Thus, it would seem, whether they are individuals (e.g. medicine
representatives) or individuals are on behalf of organizations (e.g. medicine
producers, distributors and logistics companies), all would need to build guanxi
with public hospitals, because the public hospitals are the main channel to sell
products for SMPCs. The CEO of Company A specifically explained the
causality of guanxi and medical administration system:
This is a question of cause and effect. The public medical organization is public, but in
fact, public medical organization’s behavior and measure are marketization. This is a
dual system. With the dual system, there must exist gray deal. According to human
nature, it is bound to be operated by a person. If this problem is not solved, the gray
deal can’t be abolished. That’s why gray deal is a “result”, not a “reason”. Now the
legal crackdown of gray behaviour (corruption), together with the rigid supervision, it
will also need to pay a heavy social cost.
All the interviewees also said that public hospitals have powerful bargaining
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leverage with drugs suppliers, including drugs producers, logistic companies and
distributors/agents. Whether chemical medicines or TCMs, every drug has to be
approved by a complicated process (see Figure 4.11). During this complicated
process, the two companies’ distributors/agents were noted as having to connect
with every relevant hospital department, and build good networks with hospitals.
This is very important for any company in the industry chain. This raises the
question of how guanxi is important between SMPCs and public hospitals. The
CEO of Company B offers a typical illustration here:
Because of the medical administration system issue, SMPCs have to invest time, and
guanxi to build relationships with public hospitals. That is why we are seeking for
those distributors who have good guanxi and strength with local hospitals in the local
market.
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Figure 4.11 The Process of Accessing Drugs in Hospitals
As shown in Appendix 8, guanxi approaches can be utilized by individuals
widely, visibly or invisibly a number of existing competitors are competing in the
same market. Striving for public hospitals’ resources is the main goal for sales
representatives, which includes a series of visible or invisible activities. It is an
open secret that building good guanxi with doctors in public hospitals is very
important for SMPCs. Sales representatives visibly visit public hospitals to
introduce products every day. Directors of hospitals, medical departments and
pharmaceutical preparation sections are target customers for SMPCs. SMPCs’
business pattern of prescription-based commission (also known as drug
kickbacks) (Hu, Chen and Zhao, 2012; Peng et al., 2013) is one dominant way to
prompt medicine sales. This way is quick and direct to achieve sales from public
hospitals. This business pattern is utilized not only by domestic companies but
also by international companies such as GlaxoSmithKline (GSK) (Wangyi, 2015).
Arguably, this sales mode can enhance connection, trust and loyalty between
guanxi and what came to be constituted as “givers” and “receivers”. But it also
damages the prescription market system and competitive environment and leads
to drug abuse. Drug abuse increases the cost of national health care. Thus,
smashing this pattern is not a simple series of actions of anti-commercial, drug
pricing cuts and public hospital reform: it involves system reform.
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Although public hospitals have strong bargaining power in the industry, they are
still influenced by the local government administrative regulations and directives
such as “Anhui 1118 list” and “Chongqing medical administrative requirements”
(See Section 4.4.2). This phenomenon reflects that local government’s
administrative intervention influences SMPCs strategy implementation at local
market.
4.6.3 The Interactive Influence of Guanxi and Government Policy on Market
Entrants
During the research period of 2009 to 2014, national government policy such as
New GMP has directly limited new entrants; guanxi and government policy are
integrated to influence market entry such as NBMIL, NEDL, and DCBP policy,
which influence and restrict entrants in the public hospitals.
Porter (1980, 2008) explains government policy such as licensing requirments
directly restricts industry entry. For medicine producers, New GMP policy is a
mandatory policy. It is a matter of life and death for SMPCs (See Appendix 6).
The New GMP certification is a higher quality standard, with stricter
requirements and higher cost for SMPCs than before. In the two case studies, the
two companies have totally different categories of product structure. With regard
to chemical drugs, it has been implemented with reference to the European
Standard. Thus, the rules are standardized. All interviewees of Company A
mentioned GMP’s significance and problems with certification. The R&D
director mentioned New GMP influencing the factory. She indicated:
Based on the requirements of the New GMP, our producers must be GMP certified. Its
implementation can upgrade production quality and company management skills. But it
increase our costs. Without the certification, we will not be able to file for drug
registration, participate in drug bidding and procurement and sell in hospitals. I think
New GMP will eliminate 30% of SMPCs.
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SMPCs are under high pressure from New GMP. Although companies obtain the
GMP certification, in the short term, the impacts are excess capacity and
increased costs. At the same time, New GMP speeds up the elimination of small
and medium-sized enterprises and the creation of mergers and expands
opportunities for listing corporations (Tang, 2013).
The sales manager of Company A also explained that New GMP strongly
influenced their market activities and performance during certification by New
GMP. But Company B seldom mentioned the New GMP issue. They mentioned
that they have strength and capability to improve the TCMs’ production lines. It
was obvious that improving the production line for chemical drug injection is
more costly than for TCMs. Besides, all interviewees from both companies
seldom made a link between guanxi and the New GMP policy.
The increased drug cost directly reduces company’s current profits. SMPCs have
to consider which production line will be certificated. This decision making is
based on the products’ characteristics. The factors to be considered are whether
or not a product is listed on the insurance scheme, estimating the future product
tendering bidding price and the existing market competition. At the same time,
homogenization of the market leads to drug pricing and tendering bidding pricing
becoming lower and lower. Thus, product competitiveness determines whether or
not to renovate a production line for New GMP.
Apart from New GMP policy, NBMIL and NEDL directly influence and restrict
drugs utilization in public hospitals when products are not listed in the two
national insurance schemes. It also reflects that guanxi is an underlying causal
mechanism to government policy formulation and implementation at provincial
level. In addition, DCBP policy also directly/indirectly influences products
entering the public hospitals market. Moreover, DCBP was focused on exploring
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its functional influence on substitutes. How DCBP influenced strategy
implementation is elaborated on in the next section.
4.6.4 The Interactive Influence of Guanxi and Government Policy on
Product Substitutes
Porter (2008) points out that positioning downstream is under the threat of
substitution. In China’s pharmaceutical industry, competition from substitute
products mainly happens in the public hospitals. “Advances in technology create
new substitutes or shift price-performance comparisons” (Porter, 2008, p. 25).
Adding an injection device for anti-cancer chemical drugs or changing drugs
forms from TCMs tablet to granules were adapted to create “new” drugs as
substitutes (See Section 4.5.2). Those substitutes obtain a higher price under
DCBP within a short time. At the same time, guanxi acts as competitive
advantage to compete with substitutes (See Figure 4.9).
This section looks at how government policy is an important force to influence
the power of substitutes. DCBP policy is the main factor that facilitates the
replacement of substitutes. All the interviewees emphasized the significance and
far-reaching impact of the DCBP policy. It has been developed alongside
Medical Reform for 2009. Winning tender purchase is a key goal for strategy
implementation. Because of lack of national standardization, its non-transparency
and its uncertainty (Geng, 2010; He and Li, 2011), this policy is mainly adopted
in centralized provincial regulations. Therefore, every province has different
regulations and entry thresholds but the directive has the same purpose of cutting
drug prices. The policy directly influences the product’s price and profits. The
sales director of Company B said:
We have to deal with different provincial standard of DCBP. It strongly influence our
strategy implementation. Winning higher drugs tender bidding price is important. But
drugs price cut is the trend this year (2014). Balancing national price system is strategy
for SMPCs.
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In the words of the sales director of Company A:
This tendering bidding price cut cannot be changed. It is becoming a direct threat for
prescription drugs and, since 2014, this policy has been getting stricter. Local
government’s purpose is directly to reduce medical costs. The union of local medical
organizations directly negotiate price with SMPCs. Under this context, guanxi has less
chance to influence this policy regulation any more.
DCBP policy is provincial government-oriented. In the face of the trend of drugs
price cutting, the two companies’ decision-making process is the same. Two sales
directors described the process and their decision making. The author compiled
and summarized the findings (See Figure 4.12). This policy influences strategy
implementation and business performance.
Figure 4.12 The DCBP Policy Influences SMPCs’ Strategy Decisions
As discussed in Section 2.4.3, DCBP is also a barrier for SMPCs entering the
hospitals market. Every drugs producer wants to win the DCBP. Regarding
generic drugs, rivals utilized low price strategy to compete in the existing
competitive market (Porter, 2008). But since 2013, DCBP price has been reduced
by provincial governments. Low DCBP price determines low profitability so that
did not inspire local agents. And then the goal of sales performance could not be
149
achieved. At this time, SMPCs were facing two completely different decisions. If
SMPCs accepted the DCBP prices formulated by provincial governments, they
maintained existing market but obtained low profitability. If SMPCs did not
accept the DCBP prices, they lost existing market. And then substitutes would
enter the existing market. The sales director of Company B also emphasized the
price of raw materials issue which inevitably influences SMPCs’ profitability.
The cost of raw materials has been increasing. But the DCBP policy still utilizes
a lower drugs price strategy. Cost and DCBP price have obvious conflicts in the
industry.
Due to the uncertainty and differentiation of local tendering rules, Company A
had misjudged the situation and lost the Fujian province market with the sales
director of Company A noting that:
Products with lower bidding prices have to be withdrawn generally from the market.
From 2009 to 2014, regarding generic drugs, many SMPCs had failed in the bidding
pricing system in the countrywide market.
The disequilibrium of the bidding price system directly affects SMPCs’ sales
model and company profits. In contrast, patented products listed in the
reimbursement scheme, with higher bidding prices, support and stimulate the
marketing model of prescription-based commission (Hu, Chen and Zhao, 2012;
Peng, et al., 2013). “Discriminatory drug pricing and reimbursement policy and
partial policy failures and drugs abuse in public hospitals cause the
disequilibrium of revenue and expenditure in medical insurance” (BMI, 2014, p.
10). In the end, local provincial government has adopted a compulsory execution
policy to constantly cut drug prices and a policy of drug prices negotiation to
reduce patented drugs and exclusive TCMs expenses.
Although this policy can be criticized, it is still the main policy to reveal the
drugs’ real and practical costs so that the government can formulate and calculate
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a drugs pricing strategy for the pharmaceutical industry. Up to the present, the
price system of the policy is still significant to manufacturing sectors. Stringent
price controls and “continued price cuts” (BMI, 2014, p. 10) heavily influences
SMPCs’ price system. Based on this stringent situation, SMPCs have to adjust
their strategy too. Then, policy is a central force, but so too is guanxi in particular
contexts as they seek to influence markets.
It is obvious, then, that not only did government policies directly impact SMPCs’
strategy formulation and implementation in China, but also more generally that
different provincial DCBP policies directly influence SMPCs’ profitability. When
the drug price cut is the main policy in 2015, price negotiation policy will be
issued for patented drugs and new drugs. The secondary pricing policy is critical
(Li and Huang, 2013; Wang, Fu and Li, 2015) to SMPCs too. Up to now, Hubei
provincial or Gaozhou city governments (in Guangdong province) have
permitted local hospitals directly to negotiate drug price with medicine suppliers.
However, those policies will accelerate the collapse of small companies in the
local market if the local government supports the secondary pricing policy.
Hence, it seems that these two companies’ strategy may be difficult to execute.
More specifically, for the two case studies (See Appendix 22), strategy
formulation has been one of continual adjusting based on the policies changing
since 2009. Both companies’ strategy formulation and implementation has been
dynamically adjusted from 2009 to 2014. Their industry environment
encompasses policy making during this Chinese economic transitional period
(Wei and Luo, 2013) as well as guanxi. While the two case studies utilized focus
on strategy or combination of focus on and differentiation strategy of Porter’s
generic strategy, their strategy has been notably influenced by government
policies and guanxi, the two additional key ‘forces’.
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In summary, this chapter noted that the four major policies – New GMP, NBMIL,
NEDL, and DCBP – are very important to our two SMPCs. The New GMP
policy is a mandatory policy at national level and it directly influences SMPCs
entry. NBMIL and NEDL and their sub-lists for provinces are related to SMPCs
strategy formulation (See Section 4.4.1); the two medical insurance schemes
decide market share rate and coverage with government policy formulation at
provincial level being uniquely influenced by guanxi. While both the literature
and seven of the nine interviewees expressed criticism of DCBP, since it is a
complex system lacking coordination and consistency (Geng, 2010; He and Li,
2011), they still considered it to be important enough to influence their own
strategy work formulation and implementation. This inherently included an
assessment of guanxi – that is, its strength and where it resides within their
networks. In other words, the guanxi givers and receivers.
4.7 Organizational self-development
As shown in Section 2.5, guanxi has close connections with government that
facilitates company development or not. Guanxi is likened to social capital, a key
to open a door for people - “who you know” or “who knows you” (Huang and
Aaltion, 2014). Yet, as well as the guanxi of who you know, the enterprise itself
must also have strength and capability including a competitive product,
technology, professional team and company certifications and reputation. This is
different from the past, when the more you had good guanxi the more advantages
you obtained. As the CEO of Company B indicated:
As a matter of fact, guanxi works and helps, but the enterprise itself will also need to be
strong enough … For example, if I have a good relationship with one expert, but he
can’t help accept my products in the hospital because of my face. What if my products
are fake products or bad quality products? He will surely check a series of things. For
example, he will study me, my enterprise, enterprise culture and products. If there is no
problem in all of these, it will be better if you have guanxi, because there are many
homogeneous products.
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Guanxi is one key force for effective company operation in strategy formulation
and implementation. Yet, it can work when guanxi matches an SMPC’s
operational capability. As the sales director of Company B highlighted:
Guanxi is only one part of the operation. We still need to have operational capability.
Even if the resources are abundant, it still won’t work if you don’t have the capability.
According to these practitioners, then, both individuals and organizations should
have capabilities to acquire, integrate and combine resources. Organizational
self-development is significant because organization cannot only rely on guanxi
to survive and develop in the future. There is a transition underway here and,
from the practitioners’ viewpoint, it is social progress. It does not mean that the
individual does not have guanxi to facilitate things successfully. But given that
policies and the commercial environment are changing constantly and
competition is dynamic, being able to continually assess what is needed is more
important. Today, as five of the nine interviewees – two CEOs, two sale directors,
and the marketing director of Company A – emphasized that guanxi remains a
competitive advantage for SMPCs in the current environment. Yet, at the same
time, they also mentioned that guanxi influences will become weaker as time
passes. The core competitiveness in the future was seen to lie in high technology
product. In the words of the CEO of Company B:
Then, must guanxi be bribery? Not necessarily! Clients will be more confident when they
know more about your products, contact more, know more about you and your way of
doing things, your professional background, expertise and behaviour......For example, if
competition is at the same starting line through proper competition, SMPCs give the
same products to the government, if the experts for approval are the same, they will
know you better and accept you if you have guanxi.
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CHAPTER FIVE: CONCLUSION AND FUTURE RESEARCH
This thesis has sought to explore the interrelationships between policy, strategy
and guanxi; it conceptualised guanxi as a causal mechanism and, from analysis
of interviewees’ accounts in two SMPCs examined how they saw both guanxi
and government policies interact to constantly influence strategy formulation and
implementation. The two research questions were then answered in section
4.4, section 4.5, and section 4.6.
In the next subsection, the author will note the contribution to knowledge and
practice as well as the limitations and areas for future research.
5.1 Conclusions
First, guanxi is complex. It is a force in term of Porter’s theoretical scheme. It
offers competitive advantage to facilitate achieving organizational strategy goals
and is embedded in the business practices of SMPCs and seemingly runs through
the whole process of their strategy formulation and implementation. Crucially,
guanxi at the individual level facilitated achieving strategic goals. Building good
guanxi with local government was a strategic directive for these two SMPCs. So
while guanxi is not the determining factor, it can be seen to play, for example, a
tactical function such as information collector to help decision makers formulate
strategy confidently. It also is a “catalyst” or have a “lubricant” function in
strategy implementation.
Second, the series of policies of New GMP, National and Provincial Basic
Medical Insurance Lists (NBMILs), National and Provincial Essential Drugs List
(NEDLs) and Drug Centralized Bidding and Procurement (DCBP) can be seen to
influence SMPCs’ strategy formulation and implementation. The licensing
requirement of New GMP does restrict industry entry (Porter, 1980, 2008) as
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well as increase drug costs and potentially, then, reduce company’s current
profits. The policies of NBMILs and NEDLs can determine products’ market
coverage rate and thus SMPCs’ business performance. As reported by the
interviewees here, they also directly influenced and restricted drug utilization
when products were not listed on those two medical insurance schemes in public
hospitals. Here, significantly, guanxi was conceptualised as one underlying
causal mechanism influencing government policy formulation at provincial level.
Provincial supplementary insurance lists complement market coverage. Because
of a lack of national DCBP standardization, this policy implementation was at
provincial level and SMPCs have to face different provincial standards and
regulations at the local market level. Hence, there is much uncertainty and threat
for SMPCs. Specifically, for our two companies, winning DCBP purchase was a
key goal for strategy implementation.
Third, a major contribution here can be summed up as follows: guanxi and
government policy do interact in complex ways to influence SMPCs’ strategy.
These forces also connect and influence the other five forces. So while the
SMPCs’ strategy formulation is based on product-oriented strategy, national and
provincial policies changing trends and existing competition, guanxi was one
underlying force for getting onto supplementary medical insurance lists so as to
enhance product competitiveness. Products with core competitiveness maintain
higher DCBP prices so that SMPCs also seek medicine distributors/agents with
the strength – guanxi – to facilitate business performance quickly and effectively.
In this thesis, then, the analysis of guanxi suggests that it sets up barriers to lock
out competitors or establishes higher standards to prevent new entrants.
Regarding the theoretical implications, for China’s pharmaceutical industry, the
“pure form” of Porter’s strategy theories do not work completely but do help as a
“scheme” for practitioners in the industry. Porter’s theoretical model did not
include such non-market factors as political and social forces. Here, given the
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Chinese context, guanxi and government policy, interacting in terms of influence
on Porter’s Five Forces model, adds two key forces to Porter’s theoretical model.
Turning to the practical implications, and given this author’s own professional
practice, the thesis findings can assist strategy makers’ understanding of the
interaction of guanxi and government policy associated with the process of
strategy formulation and implementation and, thus, may facilitate achieving
strategy goals. Given China’s pharmaceutical industry, this thesis does offer a
deeper understanding and insights into the evolution of the pharmaceutical
industry policies too, as well as conceptualizing guanxi as an underlying causal
mechanism in the industry. The “seven forces” model, then, could be utilized in
this complex industry to assist people like the author – practitioners – to make
sense of what they do and how. The essence of the “seven forces” model carries
value for pharmaceutical practitioners and ways to assist SMPCs’ strategy
formulation and implementation. The author herself continues to witness China’s
pharmaceutical industry going through a period of policy change, and given her
experience, the risk from these policy changes is higher for medicine producers
and distributors. The costs of being a medicine agent such as the author’s
company for a product with core competitiveness, market promotion, and team
management are higher than before. The research has deepened her
understanding of this dynamic context. Moreover, it has enabled the author to
systematically undertake research and to make explicit forms of tacit knowledge,
here, about guanxi and the ways China’s healthcare development and policies
interact to influence SMPCs strategy formulation and implementation.
In the end, authors agree that “the influence of guanxi will continue to be an
important factor in Chinese society for a long time in the future” (Zhang and
Zhang, 2006, p. 376). As well as using and applying guanxi, a need to update and
develop capabilities will enable companies to have the capability to effectively
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obtain and integrate guanxi with policy-supporting resources. It may well be the
case too that, in the future, the role of guanxi diminishes but this is yet to unfold.
5.2 Limitations and Further Study
This section will illustrate the limitations of this thesis and indicate areas for
future study, based on this thesis’s outcomes and emergent “seven forces”
conceptual framework.
5.2.1 Limitations of the research
Clearly, limitations arising from this research relate to the possibility for
geographical variations, and that the research is confined to a particular
ownership model. A third linked limitation may arise from efforts to undertake
generalization set against a small sample of interviewees. The author will
consider each of these in turn next.
First, geographical influences may indeed affect SMPCs’ strategy formulation
and implementation. China has 34 provincial-level administrative regions, and
the two case studies are located in Guangdong and Guizhou Provinces.
Pharmaceutical companies located in the east and north of China have to
confront regional/cultural differences as well as deal with specific provincial
policies and regulations. What this suggests, then, is that further research needs
to be conducted in a markedly different geographical location to add to our
understanding of the extent to which the findings reported here are specific or
generalizable across geographies.
Second, the two case studies chosen display one type of ownership model:
domestic private companies. The question arises then in terms of to what extent
the findings here apply to other ownership models? There are, for example, many
state-owned enterprises (SOEs), joint venture pharmaceutical producers, and
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corporations with foreign capital in China. The SOEs especially play a dominant
roles in improving China’s national economy (Zheng, 2015). Those SOEs in
pharmaceutical industry will also need to enhance their competitive advantages
to cope with existing competition and yet, due to the ownership issue, and having
direct connection with local government, the question arises - do the senior
managers from SOEs need to build guanxi with government? And, how should
they build competitive advantage during strategy formulation and
implementation? Both joint venture companies and corporations with foreign
capital in China are also working in China’s institutional system and the senior
managers may be Chinese or work with Chinese employees. These too give rise
to questions - Do they still use guanxi to impact on their strategy formulation and
implementation? How can foreign senior managers working in China understand
guanxi’s culture and its application? These issues and questions would be a
important area for further study, again, adding to the research findings in this
thesis
Third, and a linked limitation is the scope of its generalizations. While the
comments above indicate the need for further research, also offering a route for
careful generalization, the case studies chosen for this thesis were two
medium-size private companies. There are over 6,986 pharmaceutical companies
(CFDA, 2013) in China, and the two case studies cannot represent all the
characteristics of SMPCs. More specifically, the research case studies are
medicine producers, and they are positioned in the mainstream of the industry.
But China’s prescription drug distribution system is complicated. Medicine
distributors, agents and logistic companies also play important and different
functions in the industry. For example, medicine logistic companies deliver
medicines to local hospitals. Medicine agents are in charge of the contact,
promotion, and product information service to hospitals. Distributors have
functions of both logistic companies and agents and the main target of those
companies is to build good relationships with local hospitals. Without doubt,
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though, individuals working in these various companies are involved in building
good guanxi with decision-makers in different departments of local hospitals.
They may utilize different strategy formulation principles in the same policy
environment. And hence, the question arising is, will guanxi have different
functions in these different forms of strategy implementation? And, to what
extent does this add to/confirm Porter’s extended model developed here? In one
small way, then, the thesis makes a contribution and paves the way for further
research.
In sum, the research reported here and based on the selection of two specific case
organizations and a small selection of senior practitioners (the interviewees) has
begun to generate insight into the central role of guanxi and government policy.
The interviewees were decision makers who had more than ten years’ rich
industrial experience, and while it cannot be claimed that this small size has
universality, they offered a route into beginning to understand how the two
additional forces are important in their context. Accessing interviewees from
other organizations such as hospitals or the ends of the supply chain, would be an
important route for adding further insight in future research.
5.2.2 Practical Implications
Turning to the practical implications, the thesis’ findings will/can assist strategy
makers’ understanding of the interaction of guanxi and government policy
associated with the process of strategy formulation and implementation and thus
may facilitate the achievement of strategy goals. Equally, this research would be
of interest to different groups such as policy makers/government, researchers
working in the institutes of pharmaceutical industry, alongside senior governors
working in the medical organizations and more generally. For policy makers, the
provincial medical supporting policies, which are formulated by hierarchical
medical regulatory system, should be considered the significance of coordination
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and unity.
There are practical implications for the author too. As a practitioner, she agrees
with the views of CEO of Company B that organizational self-development is
far-reaching and that the enterprise itself needs to be strong enough so as to cope
with constant changing competition. The extended model offers a means to
understand the changing landscape and without doubt, through this research, the
author has gained a deeper understanding of and insights into the
pharmaceutical industry chain development and efforts at strategic positioning.
The development of skills – especially, the ability to look at phenomena from
different angles – has enabled her to understand new industries such as the
medical device industry. Her experience and research has generated knowledge
which will be utilized to generate new projects and collaborations in future too.
5.2.3 Future study
The questions raised in discussing the limitations above would provide useful
areas for future study. For this author and future research, an interest in
considering how the emergent “seven forces” conceptual framework might be
useful for other types of small and medium-sized pharmaceutical companies
including producers, medicine distributors/agents and logistic companies, will be
pursued. Equally, as noted above, it may also be useful for larger companies in
this industry and is another area for future research. A further interesting avenue
for further research is to explore more closely the phenomena of interest through
observational study where the question is - “To what extent does a ‘seven force’
framework influence small pharmaceutical companies’ strategy formulation and
implementation?”
Finally, then, the thesis has made a start to providing a conceptual framework
that would be used to guide SMPCs’ strategy formulation and implementation,
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through contributing insights from two case studies in China and offering a
conceptual framework elaborating on Porter’s influential strategic work.
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APPENDICES
Appendix 1: The Chinese Pharmaceutical Industry and Market Overview
The pharmaceutical industry is one of the leading industries in the People’s
Republic of China. Based on the definition of the Chinese pharmaceutical
industry from the National Bureau of Statistics, the Chinese pharmaceutical
industry includes seven sub-sectors as set out below:
1). Manufacture of chemical agents
2). Manufacture of chemical drugs
3). Manufacture of Chinese medicinal decoction pieces
4). Manufacture of Chinese traditional medicines
5). Manufacture of animal drugs
6). Manufacture of biological, biochemical and blood products
7). Manufacture of hygienic materials
BMI (2014, p. 17 ) reported that Chinese health expenditure reached US$595.2
billion in 2014 (see Figure A1.1). 6,986 domestic pharmaceutical manufacturers
and 142,609 domestic medical companies (CFDA, 2013) are providing the
pharmaceuticals and services to the medical institutions for end-users.
China continues to enjoy strong growth. Combined sales of prescription drugs
and OTC medicines are forecast to increase by 14.7% in US dollars terms
(15.7% in local currency terms) from CNY 532.4b (US$86.6bn) in 2013 to CNY
616.1BN (US$ 99.3bn) in 2014 (BMI, 2014, p. 14). BMI (2014, p. 19) also
forecasts that “prescription drugs sales will reach CNY 832.6BN (US$ 133.2.bn)
by 2018”.
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Figure A1.1 Chinese Health Expenditure Forecast
Source: BMI, 2014, p. 17
Urbanization is accelerating to bring development opportunities to the
pharmaceutical industry. In 2009, IMS Health predicted that China would
become the world’s third biggest pharmaceutical market by 2013, up from the
current number three ranking.
The aging population problem is also becoming increasingly serious in China.
The drug consumption of the elderly accounts for 50% of total drug production.
Public hospitals are the main end-users in the Chinese pharmaceutical industry
providing 90% of market share (Jiang, Lv and Zhao, 2014). Thus, the
prescription drug market has continued to expand at an increasing rate. In
particular, the Chinese Medical Reform started in 2009 has been boosting market
demand and growth. Regarding the current huge prescription drug market, a
series of policies and regulations have been promulgated since the Medical
Reform started.
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Appendix 2: China’s Medical Reform
The healthcare sector is very significant in any country and is related to public
and social policies. And the pharmaceutical industry is the important area in
healthcare. The evolution of China’s Medical Reform has been going through six
stages as set out below:
Phase 1 The preliminary stage, 1978-1984: The planned economy period
Phase 2 The second stage, 1985-1992: City economic system reform period
Phase 3 The third period,1992-2000: The reform exploration period
Phase 4 The fourth stage, 2000-2005: Health care reform
Phase 5 The fifth stage, 2006-2008: Emphasis on public welfare and medical
services;
The institutional framework of the medical system including: the public health
service system; medical service system; medical security system; the drug supply
system
Phase 6 The sixth stage, 2009-present: Adjustment and Transformation Period
164
Appendix 3: China’s Medical Reform for 2009
China’s Medical Reform for 2009 is a major reform regarding the people’s
livelihood in China. It was formulated under government macroeconomic
regulations for constructing a market mechanism. Based on the Chinese medical
administration system (see Figure 2.6), every department from central to
provincial governments involved in the supervision of Medical Reform and the
pharmaceutical industry has the power to formulate and supervise the
pharmaceutical industry chain. The hierarchical management system has been
rely on the guiding principles and directives for managing the industry, and many
important supervision policies were issued during this dynamic period of
adjustment (from 2009 to the present).
The Medical Reform includes four management systems:
Medical service system,
Drug supply assurance system,
Drug pricing theory system and
Medical supervision system.
Medical Reform for 2009 includes three stages (See Figure A3.1).
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Figure A3.1 China’s Medical Reform for 2009
(Source: Ministry of Health, P.R.C)
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Appendix 4: China’s Medical Organizations
China is huge and has different types of medical organizations. Based on the
definition from the Statistical Yearbook of China’s Health and Family Planning
(National Health and Family Planning Commission, 2014, p. 1-2), medical
organizations are defined as those which have been certificated with the license
of medical institutions in China. Hospitals include general hospitals, traditional
Chinese Medicines hospitals, hospitals of traditional Chinese and Western
medicine, national hospitals, special hospitals and nursing hospitals. Exceptions
are hospitals of specialized disease prevention, maternal and child-care service
centres and nursing homes. Special hospitals include stomatology hospitals, ear
nose and throat hospitals, tumor hospitals, maternity hospitals, childrens’
hospitals, dermatology hospitals, mental diseases hospitals, orthopaedic hospitals
and rehabilitation hospitals. Public hospitals mean hospitals which are
state-owned and under collective rule. Private hospitals mean hospitals except for
hospitals which are state-owned and under collective rule.
By the end of 2013, China’s medical organizations are of different types. China
has 974,398 medical organizations including 13,396 public hospitals, 11,313
private hospitals, 915,368 primary healthcare organizations, 31,155 specialized
public health organizations. The number of registered doctors is 2,285,794,
1,109,345 of whom work in public hospitals (Statistical Yearbook of China
Health and Family Planning, 2014) (See Figure A4.1 and Table A4.1).
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Figure A4.1 China’s Medical Organizations in 2014
Source: Statistical Yearbook of China Health and Family Planning, 2014
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Table A4.1 Chinese Medical Organizations in 2014
Total Percentage
974398
一、Hospital 24709 2.54%
Public Hospital 13396
#Class III Hospitals 1692
#Class II Hospitals 5944
#Class-I Hospitals 2784
#Ungraduated Hospital 2976
Private Hospital 11313
二、Primary Health Care Institution 915368 93.94%
Community Health Service Centre(Station) 33965
#Government-owned 18638
County Hospital （& Community Hospital） 37608
#Government-owned 37105
Clinic （Infirmary） 195176
Village Health Clinic 648619
三、Specialized Public Health Institutions 31155 3.20%
Centres for Disease Control and Prevention 3516
Specialized Disease Prevention & Treatment
Institution
1270
Maternity and Child health Care Institution 3144
Health Inspection Institute 2967
四、Other Institutions 3166 0.32%
(# indicates that the number is included in the total number shown for the particular sector.)
Source: Statistical Yearbook of China Health and Family Planning, 2014
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Appendix 5: The Classification of Small and Medium-sized Pharmaceutical
Companies in China
According to “small and medium-sized enterprises designated type
standard”(SMEs-DTS) (Chinese website, 2011), the term small and
medium-sized enterprise covers three types of enterprise – medium, small, and
micro – based on the enterprise’s number of employees, operating income, assets
and other indicators with the characteristics of the relevant industry. Although the
SMEs-DTS did not single out pharmaceutical and medicine enterprises, it
indicated the definition for small and medium-sized pharmaceutical companies
(SMPCs). It pointed out that the present DTS should be applicable to all types of
enterprises legally established within the territory of the People’s Republic of
China. Based on the author’s practical working experience in China, the author
considers that this standard is not suitable for the pharmaceutical industry.
Pharmaceutical companies are bigger than the standard of SMEs-DTS. The
European Commission defines the SME as having 10-250 staff and turnover of
between €2 million and €50 million (see Table A5.1). Thus, the author considers
the European Commission classification of SMEs is more suitable for SMPCs.
Table A5.1 shows the classification of SMCs in the EU converted from Euro to
Renminbi.
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Table A5.1 The Classification of SMEs in the EU
(Source: collocated by the author from European Commission, 2003, p. 36)
Enterprise
category
Headcount Turnover in EU Turnover in
China
medium-sized < 250 ≤ € 50 million ≤ RMB 400
million
Small < 50 ≤ € 10 million ≤ RMB 80
million
Micro < 10 ≤ € 2 million ≤ RMB 16
million
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Appendix 6: New Good Manufacturing Practice for 2010 (New GMP)
Based on the international GMP regulations, pharmaceutical manufacturers must
obtain the new version of GMP certification. The new version of GMP
certification has two significant stages: blood products, vaccines and injection of
sterile drug production should be qualified following the new drug GMP
standards before 31 December 2013. Other categories of drug production should
be qualified by 31 December 2015. All Chinese pharmaceutical companies must
adhere to the practice by 2015 (See Table A6.1).
The Chinese medicine economic structure is going through a process of
industrial upgrading and adjustment. The New GMP regulations, so far, have
been implemented over a period of three years. GMP certification is the most
essential basic condition for medicine producers. Compared to the GMP version
of 1998, the New Good Manufacturing Practice for 2010 highlights the
management of professionals, post-marketing observation of product usage and
dynamic full supervision of drug quality. The New GMP marks the standard of
drug production quality (Wang, 2011). Liang (2011) commented that the new
GMP is crucial to upgrade the country’s pharmaceutical sector, not only
improving drug quality but also assisting the pharmaceutical industry in its goal
of going international. For medicine producers, those without GMP certification
cannot be listed in the most important national and provincial medical insurance
schemes and are not allowed to participate in any market activities including
sales, tender bids and service.
172
Table A6.1 The Deadlines for Chinese GMP Certification
Source: Chinese Pharmaceuticals & Healthcare Report, Business Monitor
International, 2014, p. 90
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Appendix 7: The Drug Centralized Procurement Bidding
The centralized procurement bidding of drugs began in 1999 and now has over
14 year’s history by the end of 2014 in China. The Drug Centralized
Procurement Bidding is an important policy which is a drugs logistics reform.
The purpose is to standardize the processes of purchase, payments, and
behaviours (Li and Wang, 2014).
● 2001-2004: Every province had its own procurement system and operator for
every city and district with each starting at a difference stage and time in each
place. Usually, the procurement time was one year, and was automatically
restarted the following year.
● 2004-2009: The provincial level of procurement was implemented in 2009.
The new directives were organized by the provincial governments and resulted in
a unified distribution system and also achieved economy of scale. The process of
DCBP was complicated and different. Imperfect regulations and poor supervision
existed.
● 2009-Present: A series of directives of DCBP were issued by the departments
of Ministry of Health. Then, provincial DCBP is based on the provincial unit and
implemented by online drug purchase. The policy has been implemented
nationwide since 2009.
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Appendix 8: Guanxi Approaches
This appendix explores which approaches can be utilized to build, develop, and
use guanxi. Approaches to researching guanxi are described in a number of
references too. The main approaches are collected from literature, with some are
based on the outline in the Figure A8.1.
Figure A8.1 Guanxi Approaches
Source: Compiled by the author from Li and Wright, 2000; Fan, 2002, p. 544;
Millington, Eberhardt and Wilkinson, 2005; Qian, Razzaque and Keng, 2007;
Chen, 2011; Chen and Kim, 2013; Xu and Li, 2013, p. 834; Wang, Wang and
Zheng, 2014; Yang and Lau, 2015.
As shown in Figure 2.3, whatever the political or commercial intentions, building
and developing guanxi starts with emotional connections. Get-to-know-you gifts,
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such as souvenirs, small presents (Yang and Lau, 2015; Qian, Razzaque and
Keng, 2007) are like a key to open a gateway (Gao, Knight and Ballantyne, 2012)
for people. A gift shortens the distance between individuals, binds individuals
and reduces a sense of strangeness. At the same time, a gift economy (Chen,
2011) derives from the culture of guanxi. Even more, healthcare products, such
as over the counter (OTC) medicines, healthcare nursing products, or household
medical devices, can be adopted as gifts too. Prevalence in gifting has also
developed to add higher quality and value, such as luxury fashion articles (Chen
and Kim, 2013), top-grade cosmetics, famous perfumes. Thus, gift selection and
brand orientation enhance gift-giving value (Millington, Eberhardt and
Wilkinson, 2005; Qian, Razzaque and Keng, 2007). Various gifts seem good for
starting to build initial guanxi, such as Chinese tea, porcelain artworks and
alcohol. For instance, China’s famous alcohol, ‘Mao tao’ is often adopted as
expensive gifts to friends, customers, and government officials. It is often used in
banquets officially or unofficially. As well as practical gifts, more and more
collectibles (e.g. precious paintings, porcelain and antiques) have been utilized to
facilitate a big transaction or project. Exchange of favors positively impacts on
and facilitates personal trustworthiness (Jiang, Chen and Shi, 2013).
Another means of building and developing guanxi between two individuals or
organizations is the banquet (Yang, 1994; Yen, Barnes and Wang, 2011; Chen,
2011). Banquets, entertainments and sight-seeing (Gao, et al., 2014) are basic
social activities. Up to now, the banquet amount, selection, location and food
style and quality. have been changing based on the needs. Further, some
hospitality services, for instance, housekeeping services and 7/24 hours
designated drivers are provided to very important persons (VIPs). In addition,
accompanying participants to take exercise and engage in sports (Wang, Wang
and Zheng, 2014) is also intended to facilitate relationships and trust. Those
activities involve time and cost. Thus, identifying the process of quality guanxi is
the process of building trustworthiness guanxi. When guanxi reaches a high level,
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favors and commission (Yang, Meng and Lau, 2015) may need to be added to
maintain and solidify it. This guanxi alliance may be solid and maintain
long-term interests. Hence one can see that building, developing and using
guanxi is a complicated process that is involved in individual daily life, the
workplace and study.
This thesis cannot list all approaches from literature. There are“some tactics and
approaches secretly”(Yen, Wang and Kao, 2015, p10) that were not researched or
could not be discovered. Anyway, approaches are based on requirements and
needs. The greater the satisfaction of the other party, the greater the benefits to be
obtained.
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Appendix 9: Types of Guanxi
The implications of guanxi are very confusing (Fan, 2002). Consequently, the
types of guanxi are similarly complex. The author compiled the different types
from literature (See Table A9.1) in order to identify relevant types for this thesis.
Table A9.1 Types of Guanxi
Types of guanxi from Literature
● Two different types of guanxi: person-to-person and firm-to-firm (Li and
Wright, 2000, p. 369)
● Three types of family, helper and business (Fan, 2002, p. 543).
● Two types of guanxi: strong guanxi and cheap guanxi (King, Yu and Zhuang,
2009, p. 9)
● Two types of guanxi: with business partners and with government officials
(Chen and Wu, 2011)
● Guanxi types classified into four types: Inherent guanxi (e.g. parent, brothers
and sisters, family members); Embedded guanxi (e.g. classmate, colleagues,
superior-subordinate); Emerging guanxi (e.g. friends); Developed guanxi (e.g.
customers) (Zhuang, 2012, p. 25).
● Two types of guanxi: role-based hierarchical guanxi endorsed by
Confucianism and soil-rooted egocentric guanxi derived from daily practices of
Chinese people.
(Gong, He and Hsu, 2013, p. 362).
● Three streams of individual/interpersonal level and organizational level and
social and moral practice (Chen, Chen and Huang, 2013, p. 168).
● Reflecting two types: Vertical (e.g. external guanxi with government officials)
（Continued）
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and horizontal (e.g. intra-organizational guanxi; inter-organizational guanxi)
(Yen, Wang and Kao, 2015, p. 10).
● Dividing guanxi circles into core and peripheral members (Luo and Cheng,
2015, p. 1024).
● Four types of guanxi: family ties, business ties, community ties, government
ties (Chen, Chang, and Lee, 2015, p. 900).
Source: compiled by the author from references cited.
The types of guanxi in Table A9.1 are mainly categorized under politics,
economy and culture. It is obvious there is no criteria to categorize guanxi types.
In summary, those types are in relation to personal, business (e.g. organizational)
and government relations.
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Appendix 10: The Prescription Drug Distribution System in China
China’s prescription drug distribution system is complicated. In general, there are
four types of company in the Chinese pharmaceutical industry. They are:
medicine producers, medicine logistics companies, medicine distributors, and
medicine agents (see Figure A10.1). Medicine producers are to produce products
based on the Good Manufacturing Practice (GMP) standard. If the producers
have strength and capital, they establish their own professional sales team to
introduce and promote products to public hospitals. The Chinese market is huge
and wide. Medicine producers still need local medicine logistics companies to
distribute their products into public hospitals. The functions of medicine logistic
companies are to deliver products, provide services, and collect market
information from public hospitals based on the Good Supplier Practice (GSP)
standard. When SMPCs’ medicine goes into the market, it needs a company
which can provide market information and services to push up the total sales
volume. Thus, medicine distributors and agents were born. Large producers with
sufficient funds set up wholly-owned subsidiary companies to be in charge of the
market development and sales. Yet due to the insufficiency of funds, networks
and human resources, SMPCs have to transfer the risk to the agent in developing
the potential market. Hence, they need to develop the market and push up the
sales volume with an independent distributor and agents help. To sum up,
SMPCs are mainly in charge of the production process. They have to give much
attention to the production technology and standards, and leave the marketing
and sales to distributors and agency type companies.
Medicine agents are mainly agencies for producers at the national, provincial and
city level. The functions of agents are to be in charge of the contact, introduction,
promotion, marketing, and the professional product information service to public
hospitals. Medicine agents have professional sales teams which are in direct
contact with doctors. They are a core bridge between the medicine producers and
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the public hospitals. They have good relationship with local hospitals. However,
they still need the local logistics companies’ help to distribute products to the
public hospitals. Medicine agents control the product sales, market information
and act as the doctors’ contact resource. Thus, they are really in possession of an
important position in the value chain of China’s medicine industry. The sales
volume would be influenced if there were to be a subtle change in this
intermediate link. So usually, large foreign pharmaceutical companies, joint
ventures and large state-owned enterprises establish their own sales teams in
order to ensure the smooth circulation and direct control of distribution networks.
Medicine distributors take the dual roles of medicine logistics companies and
agents. On the one hand, they take the function of logistics companies to help
medicine producers deliver products to hospitals. On the other hand, they are also
in charge of delivering qualified products to public hospitals through marketing
coordination and promotion.
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Figure A10.1 Prescription Drugs Distribution System
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Appendix 11: The Pharmaceutical Regulatory System
Chinese pharmaceutical industry regulations rely largely on government
regulatory agencies, through rigorous regulations as well as certification and
censorship programmes, monitoring all facets of the industry. The central
government agencies provide industry development directions, promulgate
regulations, and serve the pharmaceutical industry. The regulations and policies
issued have far-reaching and significant impacts on the Chinese medical industry.
The following Chinese central government agencies relate to the pharmaceutical
industry.
● China Food and Drug Administration (CFDA)
● The National Development Reform Commission (NDRC)
● National Health and Family Planning Commission (NHFPC)
● Ministry of Industry and Information Technology (MIIT)
● The Ministry of Finance (MOF)
● Ministry of Human Resources and Social Security (MNRSS)
● Ministry of Commerce (MOC)
● State Administration of Traditional Chinese Medicine (SATCM)
Many central health policies are issued by those government departments shown
above; here these are called central policies. Chinese pharmaceutical policies are
formulated and implemented following the administrative structure system from
the top down (see Figure 2.6). For each province there are relevant departments
whose function is to implement the national policies. Policies made and issued
by local government are called provincial/local policies.
Policy dictates the direction and development of the pharmaceutical industry, and
influences pharmaceutical companies significantly. The medical administration
183
system has been impacting the uncertainty and complexity of domestic and
foreign companies conducting business in the Chinese market (Deng and Kaitin,
2004). The Chinese government has carried out a series of reforms related to the
pharmaceutical industry regulatory system, the public healthcare insurance
system, the drug pricing system, the drug tendering bidding system, and the drug
distribution system.
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Appendix 12: The National Basic Medical Insurance List
The National Basic Medical Insurance List (NBMIL) is an important policy
component of China’s Medical Reform. The goal is to ensure drug quality, safety
and efficacy. Its implementation regulates standards of medication behaviour,
ensures safety of drug usage and reduces medical expenses. It includes national
and provincial schemes. The provincial government can supplement the local
insurance list in order to develop the local pharmaceutical economy and
healthcare. The national and local basic medical insurance lists determine which
drugs can be reimbursed for people who have only participated in the basic
health insurance programme (see Figure A12.1). It is obvious that listed drugs
determine the market share. The sales of listed products can be exploited fully.
Thus, regarding this policy, every drug producer absolutely wants its products to
be listed in the schemes.
There is little literature on the schemes. Zhang (2010) comments that the medical
insurance scheme intends to balance medical insurance funding and control drug
expenditure based on drug quality, efficacy and price. Thus, the pharmaceutical
companies whose drugs are on the list have an opportunity to cover the potential
market.
Figure A12.1 Coverage Differences between NBMIL and NEDL
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Appendix 13: The National Essential Drug List (NEDL)
According to the WHO (World Health Organization), the definition of the
National Essential Drug List (NEDL) refers to a list of pharmaceuticals needed to
meet the public health care needs, at any time, with the qualifications that there is
sufficient quantity in the appropriate dosage forms, as well as with prices that the
individual and the community can afford. In China, this refers to drugs that have
the characteristics of medications that meet basic medical needs, prescription via
proper dosage forms and with reasonable prices, all to ensure an adequate supply
and demand so that the public can obtain them at a fair price.
NEDL is the generic/characteristic list of medications that the Chinese medical
health system has prescribed since 1990. The first edition of NEDL (only
chemical medicines) was published in 1982. The new NEDL was published in
August 2009, and the NEDL was first seen in the National Basic Medical
Insurance List (NBMIL) on this date. If SMPCs’ products can be listed in the
NEDL, the benefits are that listed products can be used by all primary-level
medical organizations in the Chinese market.
Based on the national catalogue lists, the different provincial governments can
add a specified number of drugs onto the list, named as the Provincial list, so as
to meet the medical and coverage requirements. Thus, the NEDL has sufficiently
wide and multi-level coverage (see Figure A13.1). For example, the Urban Basic
Medical Insurance System covered over 3.8 million persons in 2008 and the new
Rural Cooperative Medical System covered over 8.3 million persons by June of
2009.
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Figure A13.1 Provincial Supplemented Essential Drugs Lists
Source: Yang and Yang, 2013, p. 12
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Appendix 14: The Main Differences between the National Essential Drugs
List and the National Basic Medical Insurance List
The NEDL and NBMIL are main important parts of the Medical Reform for 2009.
Two lists has differentiation among drugs amount, structure, and forms (Wang
and Li, 2013; Yang and Yang, 2013). Follows are the main differences between
them (See Figure A14.1).
First, the purposes of the two lists are different. The National Basic Medical
Insurance List is mainly used to guide clinicians to choose drugs properly, to
guide the production direction of pharmaceutical production enterprises, and to
ensure sufficient market supply of essential drugs. The National Basic Medical
Insurance List, on the other hand, is mainly used for controlling the drugs cost
range for the national basic medical insurance. It is the reference for social
insurance agencies to pay the costs of the insured person. Its purpose is to protect
the basic medical needs of the insured people, and to ensure the balance of the
medical benefits fund.
Second, the basis is different. The National Essential Drugs List mainly considers
drugs’ rationality and safety issues in clinical use and the level of basic drug use
in the whole society. Apart from considering the drugs’ safety and effectiveness
for the insured person, based on the affordability of the Basic Medical Insurance
Fund, the National Basic Medical Insurance List mainly considers drug prices.
Third, the application and scope are different. The National Essential Drugs List
applies to all China’s people in society, while the National Basic Medical
Insurance List only applies to people who have only participated in the basic
health insurance programme.
Fourth, the execution effect is different. The National Essential Drugs List plays
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a guiding role for clinicians in drug use. It encourages conscious directory usage
mainly by social propaganda and doctor training. The National Basic Medical
Insurance List is used during payment by the social insurance institute.
Fifth, the administrative agency is different. The National Basic Medical
Insurance List is issued by the Ministry of Social Security, while the National
Essential Drugs List is issued by the State Food and Drug Administration.
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Figure A14.1 Comparative Drugs Amount Among the Provincial
Supplemented Essential Drugs Lists and the National Medical Insurance
List
(PSEDL: Provincial Supplemented Essential Drugs Lists; NBMIL: National
Basic Medical Insurance List )
Source: Wang and Li, 2013, p. 903
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Appendix 15: Background of Two Case Studies
(Continued)
Enterprise category Company A Company B
Company Nature Private company Private Company
Establishment 1989 2000
Location Guangdong Guizhou
Employee numbers 150 120
Turnover( RMB) 300 million 400 million
Variety of Products 50 36
Medicine
Categories
1. Chemical Medicine:
anti-cancer chemical
drugs of
osteocarcinoma, multiple
myeloma, lung cancer
and gastric cancer and so
on.
2. Other OTC products
1. Traditional Chinese
Medicine of
gynecology, urology, oncology
and cardiovascular.
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(National Basic Medical Insurance List (NBMIL); National Essential Drugs List
(NEDL))
Drug Form Prescription drugs are
injections and OTC
products are capsules and
tablets.
Tablet, capsule and granule
Product features Products are imitation
drugs. Many competitors
for every drug.
Exclusive production for
TCMs
Products listed in
the NBMIL or
NEDL
6 for NBMIL
2 for NEDL
6 for NBMIL
1 for NEDL
Market Coverage Whole Chinese market Whole Chinese market
Number of
Interviewees
First time: 5
Second time: 2
First time: 4
Second time: 2
Distributor Number 150 300
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Appendix 16: Background of Interviewees
(Continued)
Interviewee Company A Company B
Headcount 5 4
CEO
Gender: male
Age: 56
Work Experience: 30 years,
Education: Economics and
management
PhD in economics, post-doctoral in
management, professor,
Connection: Getting to know him
Gender: male
Age: 50; one of the owners
Work Experience: 30 in
Pharmaceutical manufacture;
Education: bachelor of
Traditional Chinese Medicine
(TCM)
Connection: Knowing him
Sales director Gender: male
Age: 44
Work Experience: 20 years; 7 years
as a doctor. 13 years in Company A
Education: bachelor of clinical
medicine
Connection: Knowing him
Gender: male
Age: 43
Work Experience: 20 years
7 years in Company B
Education: bachelor of
Chemistry：Analysis and
Testing of Food
Connection: Knowing him
well
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Sales manager Gender: female
Age: 38
Work Experience: 13 years in
Pharmaceutical manufacture
Working title: dual role of manager
of tender bidding
Education: bachelor of finance
Connection: Knowing her
Gender: male
Age: 41
Work Experience: 16 years
Education: bachelor of
Chinese Language
Connection: Knowing him
Marketing
director
Gender: male
Age: 35
Work Experience: 7 years in
Pharmaceutical manufacture
Education: Master of pharmacology
Connection: Knowing him well
Dual role by sales director
R&D manager/
factory director
Gender: female
Age: 38;
Work Experience: 8 years in
Pharmaceutical manufacture
Education: PhD in pharmaceutical
chemistry
Connection: Knowing her
Gender: male
Age: 35
Work Experience: 10 years in
pharmaceutical manufacture;
Education: Bachelor
in pharmaceutical
Connection: Getting to know
him
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Appendix 17: The Questions Asked in the Semi-structure Interviews
1. The Questions Asked in the First interview:
Q1: Could you please introduce yourself and your company? (Gender, Age,
Working Experience and Working title)
Q2: Are you involved in the strategy formulation and implementation in your
company?
Q3: What is the most important for developing a company strategy?
Q4: Why do you think the policy issue is important in Chinese pharmaceutical
industry?
Q5: Which current policies do you think influence your strategy formulation and
implementation? And Why and How?
Q6: What role does guanxi play under current business environment?
Q7: How do you identify opportunities and avoid the threat under current
environment of relevant policies?
2. The Questions Asked in the Follow-up Interview:
Q 1. What factors will you consider when strategy formulation?
Q 2. What do you mean by guanxi?
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Q 3. You mentioned the interrelationship between institutional system and guanxi,
what do you mean by that?
Q 4. What are the critical factors on policy making? And why?
Q 5. How to identify and maintain guanxi?
Q 6. What is the interaction between guanxi and product’s competitiveness?
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Appendix 18: The Letter for the Semi-structured Interview
Bo Xu
Unit 2402-2404, Chunhui Building
No. 16, Yueken Road, Tianhe District
Guangzhou Guangdong, P.C. China, 510610
August, 2014
Dear participant:
Thanks for your attending my face-to-face interview for doctoral research, which
is named “The Influence of Guanxi and Government Policies on Application of
Porter’s Strategy in Small Medium-sized Pharmaceutical Companies (SMPCs) in
China”. The semi-structured questions are about influencing factors of policy and
guanxi on SMPCs strategy application in China. The opinions you provide will
help me obtain better understanding.
The face-to-face interview is just between you and me. It will take one hour and I
will record under your permission and hold the digital record of our interview. I
shall immediately turn off the record anytime following your request. The
information you provide will be kept strictly confidential and is for academic
research purposes only.
For protection of your privacy, your name will not showed on the thesis. Just
your work title will be named. It is worthy mentioning that you can withdraw the
data without any reason any time before the thesis is submitted to the
Nottingham Business School.
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Thank you very much for your time and cooperation.
Best regards,
B o Xu
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Appendix 19: Quality Criteria for Case Study Research within the Realism Paradigm, and other Research Criteria
Source: Healy and Perry, 2000, p. 122
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Appendix 20: Tests and Techniques for Establishing Validity and Reliability in Case Study Research
Source: Riege, 2003, p. 78
(Continued)
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Tests and Techniques for Establishing Validity and Reliability in Case Study Research
Source: Riege, 2003, p. 79
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Appendix 21: Guanxi Patterns
Interviewees provided several patterns for developing and using guanxi at the
individual level (see Figure A21.1) and organizational level (See Figure A21.2).
So how to identify and maintain guanxi in practice? There were no detailed
approaches obtained but common patterns were provided by interviewees.
Identifying and maintaining guanxi can be cultivated from study, work and life,
such as natural relations (family links), common language (common-interest
topics) and background (study, working experiences).
In looking at the literature, the contribution of guanxi shows tangible and
intangible sides ( Xu and Li, 2013, p. 834). In practice, interviewees mentioned
that building guanxi can contribute a number of tangible benefits, such as
increased salary/commission, job promotions, directly improving business
performance; and intangible benefits, such as valuable connections with highly
positioned managers, medical experts, and government officials. For instance,
attending professional, academic, and commercial conferences contributes more
benefits for individuals. It is worth mentioning, individuals can obtain double
benefits not only by developing skills but also by cultivating guanxi through
high-quality study (e.g. industrial E-MBA programme).
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Figure A21.1 Guanxi’s Patterns and Benefits for Individuals
Source: Compiled by the author from quotations from the interviews
Organizational guanxi is based on individual activities. Individuals know what
patterns and approaches can be used to identify and maintain guanxi. And more
senior managers work on behalf of the organization to build, develop and
maintain relationships with government. Gu (2013, p. 232) suggests that
organizations should “build guanxi with relevant government departments to
develop a harmonious relationship” so as to “cope with regulatory uncertainty”.
Thus, there exist formal and informal channels to represent organizational voices.
Equally, informal connections are based on individuals. An organization attends
many formal meetings to link and build guanxi with local government. Senior
managers act on behalf of organizations to display personal talents during the
connection with government officials.
Because of limited participation mechanisms for the public, citizens, including
senior managers, can have some voice in the policy process (Truex, 2014, p. 25).
Successful senior managers contribute interests and taxes to local government.
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Thus, they could be elected as a municipal/provincial/national member of the
National People’s Congress (NPC) or the Chinese People’s Political Consultative
Congress (CPPCC). They can, on behalf of themselves, their own enterprises and
industry, propose suggestions so as to influence national and local policies. As
China’s formal participation channels, the two congresses of NPC and CPPC
provide a stage for senior managers who can make their voices heard and explore
their resources. At the same time, political connections help private enterprises to
obtain resources including market access and financial resources.
At an organizational level, working out the guanxi orientations (Zhuang, 2012) is
important. An organization can use different patterns from individuals to achieve
benefits. Basically, there are two dimensions of political and commercial
intentions for firms (see Figure A21.2).
Figure A21.2 Guanxi’s Patterns and Benefits for Organizations
Source: Compiled by the author, cited Gao and Tian, 2006, and based on
quotations from the interviewees
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Appendix 22: Comparison of Two Case Studies’ Strategies
Contents Company A Company B
Company
Strategy
Hybrid strategy: Relevant
diversification strategy
Focus on strategy: Focus on
prescription drugs market
Product strategy
(prescription
drugs)
Prescription drugs are focused
on providing anti-cancer drugs
and cardiovascular drugs
Focus on providing
gynecological products
Product system Chemical drugs including
anti-cancer drugs, generic
drugs and OTC
TCMs including patented
TCMs and generic TCMs
R&D 1. Generic first serial drugs
2. Treatment of drugs,
paramedicines and drugs
enhancing body immune
function
Focus on own unique and
patented TCMs
Marketing
strategy
1.Building own professional
sales teams based on product
system
2.Three professional teams
focus on professional products
3. Increasing investment in
product’s academic promotion
and professionalism
4. Building distributor system
1. Building professional
distributor system
2. Seeking for potential
distributors that have strength
and guanxi in regional market
(Continued)
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as supplementary channel in
2012
Policy influences 1. Medical Reform
2. New GMP
3. NBMIL & NEDL
4. DCBP
1.Medical Reform
2. New GMP
3. NBMIL & NEDL
4. DCBP
Strategy
implementation
1. Hard to do self-initiated
R&D chemical drugs
2. Fewer opportunities for
imitating generic first serial
chemical drugs
1. Hard to do self-initiated
R&D TCMs
2. Because of new drugs
registration policy, fewer
opportunities to imitate TCM
Strategic
adjustment and
transfer (since
2013)
1. Transfer one professional
team of prescription drugs to
distributors
2. Focus on building
professional distributors for
anti cancer drugs
3. Invest in reagent market
and health of the general
public sector
1. Invest in medical instrument
and pathologic diagnosis
sectors
(NBMIL: National Basic Medical Insurance List; NEDL: National Essential
Drugs List; TCM: Traditional Chinese Medicine)
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Appendix 23: Transcription of Follow-up Interview-CEO of Company B
XU BO:
Mr ***, thank you very much for the second interview. Let’s start with the first
question. In strategy formulation in the pharmaceutical industry, what factors will
you consider?
CEO:
In my opinion, for strategy formulation, the company should think in the long
term rather than the short-term perspective, with market factors as the main focus.
Because the market decides on your products, right? You build up a good product
structure according to the market. Only after the good product structure is built,
can you make a good product strategy. All strategies should be market oriented.
XU BO:
Could you be more specific about “market oriented”? What aspects are included
in market factors?
CEO:
For example, I offer a product in *** area. Why did I decide to offer this product?
Logically, it’s very risky as the technology is not mature yet, right? Besides, it’s
not been tested in the market. First of all, the *** market is not mature yet in our
country. Second, the market size remains unknown. Third, are there many
competing manufacturers? Fourth, will there be any difficulty in obtaining
approval? The *** diagnosis technology is still blank fields.
XU BO:
There are opportunities from government policy.
CEO:
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The product approval takes a very long time. You can’t get it approved in just a
few years. As a matter of fact, I would consider the market is just beginning, and
policy will follow. With the development of the market need, as the incidence of
the disease increases the market develops. I have done production and sales. I
think I have worked in production and sales and now I think I should establish a
pharmaceutical company and manufacture the product. According to my previous
experience, policy control was quite loose at the very beginning, usage rate of
such medicine was high, and I think this is an opportunity. At that time, we only
had one product. Then, we started thinking of selecting products in areas such as
gynecology, cardio-cerebral vascular disease and cancer. The competition for
cardio-cerebral vascular products is too strong, so I chose specialist products.
Obtaining production certificate and the quality control for Traditional Chinese
Medicine injections is very difficult. This is still controversial. At that time, we
were not strong enough, so we didn’t try in this field. When we were strong
enough and ready to develop products in this field, the Zheng Xiaoyu news
exploded and the state stopped approval for many products with “one knife-at a
stroke” all together.
(* Zheng Xiaoyu, former director general of China’s Food and Drugs
Administration was executed for the crime of accepting bribes in 2007.)
XU BO:
Then you use a “specialist product” strategy?
CEO:
Right, specialized and focused on strategy.
XU BO:
OK, apart from policy and product, do you consider other factors?
208
CEO:
We consider market factors first. We first need to identify the market, then we
choose which area to enter. That is, we need to decide which market area to enter.
After that, we decide on the product lines for our main and dedicated products.
XU BO:
OK, apart from these points, will you consider other factors, like guanxi?
CEO:
As a matter of fact, I don’t think too much about this question. Guanxi can only
facilitate your approvals and help your products to be listed in the national or
provincial health insurance list, in the basic medicine list to be specific. Do you
think guanxi helps formulate big strategies for pharmaceutical enterprises? I
don’t think so. That is to say, at the beginning of strategy formulation, guanxi is
not a core factor. Guanxi can be helpful in strategy implementation for achieving
strategy goals.
XU BO:
Do you think guanxi is important in strategy formulation? Why?
CEO:
It’s not a determining factor; it can help you decide how to do it, but it can’t
determine your strategy goals. For instance, if you have broad human resources
and connections in ***, you can consider making *** products.
XU BO:
When you say you have broad connections in a certain aspect, do you mean
individual, group, company or third party?
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CEO:
All of them. You need to consider the subject comprehensively.
XU BO:
Could I interpret it as choosing your products according to a guanxi network?
Following this logic, do you choose products according to guanxi, or do you
choose guanxi for your products?
CEO:
Based on strategy, you should consider products first. When you have two
products, you can think of other reasons. At that time, we have broad guanxi in
the cardio-cerebral vascular field, but there are too many products in this field.
It’s hard to maintain good prices. As such, we mainly focus on *** products. So
guanxi is not a pivotal factor for a pharmaceutical manufacturer. Guanxi is only
helpful.
XU BO:
Apart from policy, product and guanxi, what other factors will pharmaceutical
enterprises consider when formulating strategy?
CEO:
In fact, the market has decided your product structure.
XU BO:
That is to say, gather resources according to the product structure and market
needs. Will you adjust the strategy over a period of time?
CEO:
That is for sure.
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XU BO:
In that case, you will adjust your strategy? What factors are impacting your
strategy?
CEO:
Market factors and state policies. For example, if your products are not listed on
the national basic medical insurance list, and you promote them as main products,
this is not realistic. Since the products are not national medical insurance
products yet, you will need to adjust your strategy.
XU BO:
Will guanxi help in strategy implementation then?
CEO:
Ah…that is to say, guanxi can make you more confident. Or facilitate and help
you to achieve your strategic goal.
XU BO:
Let’s move on to the second question. What’s your understanding of guanxi?
Could you define it?
CEO:
I think it will be difficult for foreigners to understand our guanxi. Strictly
speaking, guanxi is “human resources”.
XU BO:
You mentioned in the first interview that guanxi is a traditional Chinese culture.
It is civic culture. Guanxi is everywhere and has something to do with the
“policy system”. Could you elaborate on the relationship between guanxi and
culture?
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CEO:
In China, if you want to achieve a goal, people normally think “what guanxi do I
have?”, “can it be faster?”, “can I take a short cut?” If I achieve my goal through
guanxi, you might say my guanxi is illegal and improper. This may be a natural
relationship, e.g. brothers, sisters, classmates and teachers. Maybe because of this
natural relationship, I gain more information to help me understand policy, right?
And, if I have good relationships with certain experts, communications are
smooth. Maybe he/she trusts our products and knows us well, so he/she supports
us more. As for the connection between guanxi and culture and policy systems,
this is difficult to elaborate on. For instance, if the product of one manufacturer
becomes a national basic medical insurance product just because they have
guanxi, do you think their product is good?
XU BO:
That’s right. Then let’s move onto the next question: how do you see the “policy
system” in the pharmaceutical industry? Does the policy system have anything to
do with guanxi? Why?
CEO:
China’s medical policy system is somewhat related to the state’s policy and
strategy. Now the state produces a “simplified policy”. The problem now is the
government intervenes too much. The government intervenes on price, pricing
and national health insurance. It’s only opening up now gradually. The current
policy system does not promote official and fair competition. So guanxi kicks in.
So if you have guanxi, you will have a competitive advantage. Thus guanxi is an
endowed condition. Guanxi is a way to avert fair competition. That is, you gain
an “exclusive” competitive advantage with guanxi. That’s why the state
simplifies policy, to stop such a situation from happening. When the state’s
policy and institutional system is not working well, guanxi kicks in.
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XU BO:
We were talking about the current policy system, the effect of guanxi. But in
more than five thousand years of Chinese history, guanxi has a profound history,
and has played an important role in imperial times.
CEO:
Yes, great effects. But in a short time, this is difficult to change. So sometimes
guanxi is going against the law, against regulation in people’s mind, even if it is
legal, it doesn’t behave according to regulation.
XU BO:
OK, in the pharmaceutical industry, what factors will be considered in the state’s
or in the local strategy’s formulation?
CEO:
In my opinion, first, the state’s institutional system for sure. Second, the state’s
finance, including local finance, human resources structure and the economic
status quo, and the effect on the whole industry.
XU BO:
What do you mean by effect on the industry?
CEO:
The effect on the industry means the issue of policy will have a great impact on
every medical manufacturer, hospital and user. So when making policy, the state
will consider these factors. For example, the health insurance in Guizhou will be
different from that in Zhejiang and Beijing, because Guizhou is relatively poor.
Of course, policy making will be influenced by interest groups. But I don’t think
the influence of the interest groups is determining factor. Because the policy
issued is not for one company or two. For example, Good Manufacturing
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Practice (GMP), national health insurance, basic essential drugs list policy. These
policies are issued for all companies, not just one or two.
For example, in the pharmaceutical industry, you can’t do original equipment
manufacturer (OEM), so enterprise has to invest a lot in fixed assets. This is one
kind of resource waste.
As for creativity, the state wants to encourage the creation of enterprises.
Because of the limitations resulting from policies, it is hard for enterprises to
earn profits. Enterprises have no money to do R&D. So most of the enterprises
are repeating low-level production. The homogeneous competition has to do with
state policy. For example, for an enterprise most of the expenses are taken by
intermediaries and the taxes are high. So from where does the money come for
R&D? However, the policy does not allow research enterprises to manufacture
and the manufacturing enterprises need a large amount of investment.
XU BO:
That is to say, there is contradiction in industry policies. They are not well built
yet, but the SMPCs’ resources are lacking. So it’s difficult to invest in research
CEO:
Even big enterprises have to face this situation. Few enterprises have high-tech
medicines. Enterprises would prefer to use the money in advertising rather than
R&D. Because, once it invests, it may not be able to get the approval, and the
approval process takes a long time. It’s too risky. So the contradiction of state
policy and mismatch creates a series of problems. That is for sure. So it creates
enterprise “myopia” (short sightedness) in our country.
XU BO:
So the reason that medicine manufacturing enterprises need adjustment from
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time to time is also because of such an environment.
CEO:
For example, the medical approval was with provincial medical supervision
bureaus at one time, then later it lay with the state bureau. We thought we
couldn’t implement policy in this way, so we adjusted our products from time to
time, for our future development. For example, if the state prohibits Chinese
medicine, what’s the point of researching it? When the state’s strategy and
directives are not issued yet, the local government has no standard. In this case,
the central policies will be different to local policies. For the poor and
mountain-locked areas, the state gives political support to Guizhou, especially to
Miao medicine. This is a regional advantage.
XU BO:
Let’s move onto the fifth question: how to establish and maintain guanxi?
CEO:
First, contact during work, foster relationships, develop relationships; second,
communicate through culture. As one with a Chinese medical academic
background, I may communicate easier with someone with the same background.
That’s “communicate with the same language and culture”. With the same
interests and academic background, it will be easier to establish and maintain
guanxi.
XU BO:
That is the same interest, right? As such, could I take it to mean lower expenses?
Haha....
CEO:
You can take it as such. Third, that’s communication. Mainly because we have
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the same hobbies and share the same ideas for our kids. For example,
entertainment and physical activities. This is emotional communication.
XU BO:
The establishment of guanxi has to do with people’s life, work. A person can
establish a network with himself or herself at the centre.
CEO:
Right. And the maintenance of guanxi. It’s difficult to maintain only with
emotion. Nobody accepts you. So you need to consider it from several aspects.
XU BO:
To maintain and establish guanxi. Guanxi has continuity and value. So what
factors will affect the establishment and maintenance of guanxi?
CEO:
What factors? For example, if one only talks about interest but nothing else, the
relationship can’t last long, there will be problems sometimes. Second, if there is
only work and no cultural and emotional communication, it won’t go well. If you
handle these things well, they will help you more.
XU BO:
During business activity in the pharmaceutical industry, will most SMPCs copy
the same methods?
CEO:
Yes, they will. For example, in the condition of product homogeneity, people will
be more willing to accept your product because of guanxi. Guanxi is the
productive force.
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Guanxi has nothing to do with product competition. But under the competition of
product homogeneity, guanxi is the productive force. So must guanxi be bribery?
Not necessarily. Customers know more about your products, contacts know more
about your way of handling things, so they will be more comfortable in helping
you. They appreciate your academic background, expertise and behaviour. So
small and medium sized pharmaceutical companies are using guanxi to form a
special and natural competitive advantage.
We need to view guanxi critically, via culture, work, emotional communication
and human resources. Everyone understands guanxi differently. We need to know
people, enterprise and enterprise culture, because there are many similar
products.
The entrepreneur plays different roles in strategy formulation. Many strategies
are set before looking for guanxi. Guanxi identifies additional opportunities.
For example, in the cooperation with the Swiss company, you are guanxi. In the
cooperation with American company, Ms *** is guanxi. If we try to look for the
client and communicate with them, then it takes longer. But through introduction,
we know each other. Since I know the introducer very well and I believe in him
or her, it will take a much shorter time. As such, guanxi is one kind of
productivity or multiplier.
XU BO:
Then let’s move onto the last question: what’s the relationship between guanxi
and product competitiveness?
CEO:
In my opinion, I don’t think they have an inevitable connection. When we face
the same challenges, guanxi is the power of competition. When products are
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homogeneous, especially when all are products on the national health insurance
list, ie., XXX and YYY, when the hospital considers the same medicines and
effects, which one will they choose? It will depend on their guanxi. For instance,
what kind of product is listed on the national medical insurance list? Listed or not
listed, that’s a fundamental difference! How to compete? Use guanxi! Then, must
guanxi be bribery? Not necessarily! Clients will be more confident when they
know more about your products, contact you more, know more about you and
your way of doing things, your professional background, expertise and behaviour.
If they don’t know you, they will be worried about whether your enterprise will
still exist in the future. If people don’t know the industry and still want to go
ahead, how long can they last? If they know you well, they join you at the same
starting line, through proper competition. They give the same products to the
government. If the experts for approval are the same, they will know you better
and accept you if you have guanxi.
XU BO:
In the pharmaceutical industry, most products are facing competition due to
product homogeneity. For SMEs (small and medium-sized enterprises), it will
take a very long time for registration, approval and marketing. Risk is very high
and investment is too much. Few enterprises invest in these, perhaps because
they don’t have the capability, finance and enough resources. In such situations,
how can the small and medium pharmaceutical enterprises win or gain a
competitive advantage in the competitive environment? Can we interpret guanxi
as some kind of advantage from special environmental circumstances? All small
and medium pharmaceutical enterprises use guanxi or other factors, such as
pushing their products to be included in the national health insurance list. It is
necessary to foster an environment that is good to yourself, or develop a
competitive advantage or monopoly in a certain market.
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CEO:
That’s right! Not necessarily a monopoly, but forming a natural competitive
advantage. That is for sure. Let’s take the quality of imported products. For
example, X and Y companies have the same product type, both of them want to
enter China or have entered China. Which product sells better? They will not
only need a strong team, but also better guanxi.
XUBO:
Right, guanxi helps.
CEO:
Right. As a matter of fact, guanxi helps, but the enterprise itself will also need to
be strong enough. Apart from that, some people understand guanxi very
superficially. Since everyone understands guanxi differently, guanxi has layers of
meanings. Some meanings have a dark side, some have a bright side, some are
positive, some are negative. Take face, for example. I have a good relationship
with one expert, but he can’t get the products accepted in the hospital just
because of my face. What if my products are fake products or poor-quality
products? He will surely check a series of things. For example, he will study me,
my enterprise, enterprise culture and products. If there is no problem in all of
these, it will be better if you have guanxi, because there are many homogeneous
products.
(* “Face” and renqing (sympathy) belong to Chinese cultural values (Qian,
Razzaque and Keng, 2007), and both have an interrelationship with guanxi. Face
shows complexity and comprehensive implications. Face indicates Chinese
socio-cultural phenomena, and the states of moral, pragmatic or utilitarian and
positional valuations (Qi, 2015, p.292).)
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XU BO:
Organizational strategy is product-oriented. Could you elaborate on whether
guanxi has any influence on the strategy formulation?
CEO:
Personally speaking, you look for guanxi after the company strategy is
formulated, rather than the other way around.
XU BO:
That’s right, for pharmaceutical manufacturing enterprises. But for the agents,
they might be the agent for the products just because of certain guanxi.
CEO: That’s because we are a manufacturing enterprise, in which guanxi shows
differently. The reason that we establish a pharmaceutical manufacturing
enterprise is not because of the guanxi we have!
XU BO:
Thank you very much for taking time from your busy schedule to attend our
interview. (Smile.....)
CEO:
Hope you find it helpful. (Smile.....)
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ABBREVIATIONS AND GLOSSARY
CEO Chief executive officer
CFDA China Food and Drug Administration
CPPCC Chinese People’s Political Consultative Congress
DCPB Drug Centralized Procurement Bidding
GMP Good manufacturing practice
GSP Good supply practice
MIIT Ministry of Industry and Information Technology
MNRSS Ministry of Human Resources and Social Security
MOC Ministry of Commerce
MOF Ministry of Finance
NBMIL National Basic Medical Insurance List
NDRC National Development Reform Commission
NEDL National Essential Drugs List
NHFPC National Health and Family Planning Commission
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NPC National People’s Congress
OTC Over-the-counter
R&D Research and development
SATCM State Administration of Traditional Chinese Medicine
SMEs Small and medium enterprises
SMPCs Small and medium-sized pharmaceutical companies
TCMs Traditional Chinese Medicines
Generic drug: a bioequivalent medicine that contains the same active ingredient
as an originator drug. The originator drug is an innovative medicine that no
longer has intellectual property protection due to patent expiry (BMI, 2014, p.
191)
Health expenditure: the sum of the funds mobilised by government and private
systems for the operation of a healthcare system, according to the World Health
Organization (WHO) (BMI, 2014, p. 191).
OTC drug: a medicine that does not require a prescription to be sold to patients.
Also known as non-prescription medicines (BMI, 2014, p. 191).
Patented drug: an innovative medicine granted intellectual property protection
by the patent and trademark office. The patent may encompass a wide range of
claims, such as active ingredient, formulation, mode of action, giving the patent
222
holder the sole right to sell the drug while the patent is in effect (BMI, 2014, p.
191)
Pharmaceutical, medicines, drugs: synonym terms used interchangeably
Prescription drugs: Patented and generic drugs regulated by legislation that
requires a physician’s prescription before they can be sold to a patient. (BMI,
2014, p. 191)
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